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1. Lipids and lipoprotein metabolism 
 
Triglycerides (TG) and cholesterol are the most common dietary lipids. TG 
serve as an important energy source for muscle tissue and can be stored in 
adipose tissue. Cholesterol is an important component of the cell membrane and 
the precursor of vitamin D, bile acids and steroid hormones. Since TG and 
cholesterol are hydrophobic molecules, they are transported in the blood in 
specialized particles called lipoproteins. Lipoproteins consist of a hydrophobic 
core containing cholesteryl esters (CE) and TG, which is surrounded by a polar 
surface of phospholipids, unesterified cholesterol and apolipoproteins. 
Apolipoproteins stabilize the lipid particle. In addition, they regulate the 
transport and redistribution of lipids by modulation of enzyme activities in 
plasma and by serving as ligands for cell surface receptors. Lipoproteins are 
divided in five main classes according to their density, namely (in order with 
increasing density): chylomicrons, very low density lipoproteins (VLDL), 
intermediate density lipoproteins (IDL), low density lipoproteins (LDL) and 
high density lipoproteins (HDL).
1,2
 A schematic representation of lipoprotein 
metabolism is depicted in Figure 1, and explained in sections 1.1-1.3. 
 
 
Figure 1. Schematic overview of lipoprotein metabolism. See text for explanation.  
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1.1 Chylomicrons 
 
TG are the major dietary lipids, and other dietary lipids include phospholipids 
and cholesterol. In the intestine, lipids are lipolyzed, the lipolysis products are 
taken up by the enterocyte, and lipids are re-synthesized.
3-6
 Enterocytes 
synthesize apoB48 which is lipidated in the endoplasmatic reticulum (ER) by 
the microsomal TG transfer protein (MTP), resulting in the formation of a small 
apoB48 containing particle which fuses with large apoB48-free lipid droplets to 
form a prechylomicron which moves to the Golgi, and is subsequently excreted 
via exocytosis.
3,5
 The chylomicron which than contains apoB48, apoAI and 
apoAIV enters the lymph and subsequently the blood where chylomicrons 
acquire exchangeable apolipoproteins apoCI, apoCII, apoCIII and apoE whereas 
apoAI and apoAIV can dissociate from the particle and stay in the plasma in a 
free form or become associated with HDL.
5,7
 Chylomicrons can exchange lipids 
with other lipoproteins. TG and CE are exchanged via the cholesteryl ester 
transfer protein (CETP), phospholipids via the phospholipid transfer protein 
(PLTP) and cholesterol via passive diffusion.
8,9,10,11
 Chylomicrons transport 
dietary TG and cholesterol to various parts of the body where TG are 
hydrolyzed by lipoprotein lipase (LPL), an enzyme attached to the endothelium. 
Since LPL expression is highest on adipose tissue in the postprandial state, fatty 
acids (FA) released by LPL are predominantly taken up by adipose tissue, 
where they are stored as TG, and the remainder is taken up by muscle (skeletal 
muscle and heart) for use as energy source.
12,13
 Chylomicron remnants which 
are relatively rich in cholesterol and apoE can then be taken up by the liver 
mainly via the apoE-recognizing receptors LDL receptor (LDLr) and LDLr-
related protein (LRP). In addition, uptake can occur via interaction of apoE with 
cell surface-bound heparin sulfate proteoglycans (HSPG) or scavenger receptor 
class B type I (SR-BI).
14-18
 During fasting, the intestine can produce smaller, 
less TG-rich, VLDL particles via a similar pathway.
5,6
 
 
1.2 VLDL and LDL 
 
The liver thus takes up chylomicron remnants, but can also synthesize new 
lipids as the liver contains several lipogenic enzymes including FA synthase 
(FAS) and stearoyl CoA desaturase (SCD1) for TG synthesis and HMG-CoA 
reductase for cholesterol synthesis. Hepatic lipids can be stored as TG and CE 
or can be excreted as VLDL particles. Assembly of VLDL involves a similar 
pathway as chylomicron synthesis including the transfer of lipids to apoB-100 
(or, in some animal species including mice also apoB-48) by MTP and 
subsequent fusion with protein-free lipid droplets formed in the ER to form 
mature VLDL which is secreted into the circulation and then is enriched with 
apoCI, apoCII, apoCIII and apoE.
17,19,20
 Similarly to chylomicrons, VLDL can 
exchange TG, CE and phospholipids via CETP and PLTP, and cholesterol via 
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passive diffusion.
8,9,10,11
 VLDL particles undergo similar LPL-mediated 
degradation as chylomicrons, resulting in the uptake of liberated FA by tissues. 
In contrast to chylomicrons which are synthesized in the postprandial state, 
VLDL ensures a supply of FA as energy source for muscle tissue in the fasted 
state as LPL is highest on muscle tissue during fasting.
12,13
 During lipolysis, 
VLDL becomes depleted of TG leading to conversion of VLDL via IDL to LDL 
and eventually to small dense LDL (sdLDL).
2,17
 Just like chylomicron remnants, 
VLDL remnants are taken up mainly via apoE by the LDLr and LRP, with 
additional roles for HSPG and SR-BI.
1,2,16-18,21,22
 The lipolytic end product LDL 
is virtually depleted of TG, has lost most of its apolipoproteins except for apoB-
100 and is taken up mainly via apoB-100 by the LDLr in the liver and by tissues 
involved in hormone synthesis such as the adrenals and gonads for cholesterol 
supply.  
 
1.3 HDL  
 
In contrast to apoB-containing lipoproteins, HDL is generally believed to be 
anti-atherogenic, mainly because of its involvement in the reverse cholesterol 
transport (RCT). This process describes the transport of cholesterol from the 
periphery back to the liver, after which cholesterol is secreted via the bile into 
the feces. The liver and intestine both synthesize the major HDL apolipoprotein, 
apoAI, and release it into the circulation. Subsequently, apoAI is lipidated via 
the ATP binding cassette transporter A1 (ABCA1), which is also mainly 
expressed in the liver and in the intestine. This is a crucial step in HDL 
formation as subjects with ABCA1 gene mutations as well as mice lacking 
ABCA1 have very low HDL levels.
23-26
 During this process nascent discoidal 
HDL (HDL-3) is formed, a small lipoprotein particle mainly consisting of 
apoAI and phospholipids. While the liver and intestine are essential for the 
initial lipidation of apoAI, nascent HDL can take up additional cholesterol and 
other lipids from the periphery via ABCAI or from other lipoproteins via 
PLTP.
8,9
 The acquired cholesterol is esterified by lecitin:cholesterol 
acyltransferase (LCAT), allowing the resulting CE to accumulate in the core. 
Esterification of cholesterol by LCAT is also essential in HDL metabolism, as 
patients or mice lacking LCAT have low HDL levels.
27,28
 Following cholesterol 
esterifcation by LCAT, HDL becomes a spherical HDL-2 particle which 
contains not only apoAI but can also acquire apoAII, apoAIV, apoAV, apoCI, 
apoCII, apoCIII and apoE. It has been suggested that more cholesterol from the 
periphery, including from macrophages in the vessel wall can be taken up in the 
mature particle via ABCG1.
29
 Cholesteryl esters can be transferred from HDL 
to TG-rich lipoprotein particles by CETP,
10,11
 or selectively taken up by the 
liver via SR-BI.
30,31
 TG and phospholipids in HDL can be lipolyzed by hepatic 
lipase (HL) and endothelial lipase (EL).
32-34
 Once taken up by the liver, HDL-
derived cholesterol can be stored, used for the assembly of new lipoproteins, or 
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converted into bile acids (initiated by Cyp7A1 or Cyp27A1) or neutral sterols. 
In the liver, ABCG5 and ABCG8 are involved in secretion of sterols into the 
bile, after which sterols enter the intestine and are reabsorbed (so-called 
enterohepatic circulation) or excreted into the feces.
33,35-38
 In addition to its role 
in reverse cholesterol transport, HDL has anti-oxidative, anti-inflammatory and 
anti-thrombotic properties. 
 
2. Atherosclerosis  
 
2.1 Dyslipidemia 
 
The apoB-containing lipoproteins (i.e. chylomicrons, VLDL, LDL) are 
considered to be atherogenic since these particles can enter the arterial wall, 
become modified by e.g. oxidation and aggregation, after which they can be 
taken up by arterial macrophages that subsequently turn into foam cells and 
initiate the atherosclerotic process (see section 2).
1,2,39,40
  
HDL is protective in atherosclerosis because of its role in RCT as described 
above. In addition HDL also has antioxidative, anti-inflammatory and anti-
thrombotic properties. HDL inhibits the oxidation of LDL by transition metal 
ions and 12/15-lipooxygenase-mediated formation of lipid hydroperoxides. 
HDL can scavenge oxygen-derived free radicals and carries antioxidative 
proteins including paraoxonase, platelet-activation factor acetylhydrolase (PAF-
AH) and glutathione peroxidase. In addition, apoAI may also have anti-
oxidative functions. HDL is anti-inflammatory as it can repress induction of cell 
adhesion molecules such as E-selectin, intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which reduces 
leukocyte attachment to the vessel wall. Other anti-inflammatory properties 
probably also result from its ability to remove cholesterol and oxysterols from 
the vessel wall and because of its anti-oxidative actions.
35,41,42
 HDL improves 
vasorelaxation via stimulation of nitric oxide (NO) and prostacyclin synthesis 
which are both stimulators of vasorelaxation. Its stimulatory effects on NO and 
the ability of HDL to inhibit tissue factors render HDL anti-thrombotic as 
well.
41,42
 
Dyslipidemia as characterized by high plasma levels of cholesterol and TG in 
VLDL and LDL particles and low plasma levels of HDL-C, is thus an important 
risk factor for the development of atherosclerosis. Dyslidemia can be caused by 
genetic disorders (i.e. primary dyslipidemia). Impaired lipoprotein clearance by 
defects in the LDLr or genes that interact with the LDLr, such as apoE and 
apoB, results in familial hypercholesterolemia (FH). Defects in LPL or genes 
interacting with LPL, for example deficiency of apoCII, the cofactor for LPL, 
are main causes of familial hypertriglyceridemia. Hypoalphalipoproteinemia 
(low HDL) can be caused by mutations in apoAI, ABCA1 and LCAT. 
Secondary dyslipidemias are not caused by a monogenetic disorder but by other 
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diseases, life style or medication. These include obesity, diabetes, 
hypothyroidism, exercise, diets rich in saturated fat, glucocorticoids, retinoic 
acid derivates, and HIV protease inhibitors.
43,44
 Dyslipidemia is a major risk 
factor for coronary heart disease (CHD) (see section 2.2). In addition to 
dyslipidema, other lipid-unrelated factors can also increase CHD risk. These 
lipid unrelated risk factors for CHD include homocysteinemia, hypertension and 
infection.
45
  
 
Figure 2. pathogenesis of atherosclerosis development. Adapted from de Winther et al.
46
 See 
text for explanation. 
 
2.2 Atherosclerosis 
 
Atherosclerosis is a complex disorder in which lipids and fibrous elements 
accumulate in the vessel wall (Fig. 2). The innermost layer of a healthy vessel is 
the thin intima, consisting of a monolayer of endothelial cells (EC) on the 
luminal side and the internal elastic lamina consisting of elastic fibers. The 
second layer, the media, consists of smooth muscle cells (SMC) and the third 
layer, adventitia, consists of connective tissue with fibroblasts and SMC.
39
  
Atherosclerosis starts with the infiltration of atherogenic lipoproteins such as 
LDL into the vessel wall where LDL-apoB can interact with proteoglycans 
which can lead to retention of LDL in the vessel wall. Once trapped, LDL can 
be modified (e.g. by oxidation or aggregation). Accumulation of oxidized LDL 
stimulates EC to produce inflammatory cytokines, such as chemoattractant 
Chapter 1 
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molecules (e.g. monocyte chemoattractant protein-1, MCP-1) and growth 
factors (e.g. macrophage colony-stimulation factor M-CSF) and they begin to 
express adhesion molecules such as VCAM-1, ICAM, E-selectin, P-selectin, ß2 
integrin, Very late antigen-4 (VLA-4) and platelet cell adhesion molecule 
(PCAM-1). Leukocytes such as monocytes and T cells are attracted and adhere 
to and migrate into the vessel wall via these adhesion molecules. Activation of 
leukocyte Toll-like receptors (TLRs) in the vessel wall leads to production of 
more pro-inflammatory molecules including cytokines and proteases. Within 
the plaque, monocytes become macrophages that take up LDL after extensive 
oxidation by reactive oxygen produced by EC and several enzymes including 
myeloperoxidase, sphingomyelinase and secretory phospholipase. The uptake of 
oxidized LDL occurs mainly via the scavenger receptors scavenger receptor-A 
(SR-A), cluster designation (CD)36 and CD68 which are upregulated by 
cytokines present in the plaque. Internalized cholesterol is esterified by acyl 
CoA:cholesterol acyltransferase-1 (ACAT-1) and is stored in lipid droplets, and 
the macrophage becomes a lipid-rich foam cell. In the macrophage foam cell, 
CE can be hydrolyzed again and the cell can dispose cholesterol via efflux via 
ABCA1 and ABCG1 to apoE produced by the macrophage and HDL. Early 
lesions consisting of macrophage foam cells and T cells are called fatty streaks 
and give no symptoms but are precursors of more advanced lesions.
39,40,45,47
 
When the lesion becomes more advanced, interactions between inflammatory 
cells, ECs and SMCs evoke a chronic inflammatory state, more cytokines are 
expressed and SMCs migrate into the plaque. SMCs and macrophage foam cells 
accumulate and die leaving their lipid content behind leading to accumulation of 
a lipid-rich necrotic debris which is usually covered by a fibrous cap consisting 
of SMCs and extracellular matrix excreted by these SMCs. The plaques can 
become more complex e.g. by calcification. The large plaque can lead to 
ischemic symptoms when it blocks blood flow. In addition, the plaque can lead 
to an acute block of blood flow when it ruptures. The stability of a plaque 
depends on its composition. Vunerable plaques have thin fibrous caps and a 
large number of leukocytes, mainly as macrophages produce proteases that 
degrade the extracellular matrix of the fibrous cap. Plaque rupture exposes pro-
thrombotic material which activates a coagulation cascade leading to 
thrombosis and an acute blockage of blood flow and infarction.
39,40,45,47
  
 
2.3 Animal models to study lipid metabolism and atherosclerosis 
 
To study atherosclerosis in vivo, several animal models have been used. Non-
human primates develop atherosclerosis very similar to humans but are a less 
suitable model because of ethical issues, high costs and because it takes very 
long to develop atherosclerosis.
48
 Therefore, in early atherosclerosis studies, 
birds, especially pigeons, chickens and quails
49-51
 were used, as they are 
relatively hypercholesterolemic and atherosclerosis prone.
49-52
 Another 
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atherosclerosis-susceptible model used in early studies is the swine,
48,53,54
 a 
major drawback is however the size of the animals leading to high costs and the 
need for large amounts of experimental agents.
48
 Dogs and rats are resistant to 
atherosclerosis and cats develop no human-like lesions and are, therefore, also 
not suitable models.
48,52,55
 The hamster is sensitive for cholesterol-enriched diets 
and develops mild fatty streak-like atherosclerotic lesions and is, therefore, used 
in some studies.
48,55
 Rabbits, a widely used animal model, have as herbivores 
naturally low cholesterol levels and no atherosclerosis development. On 
atherogenic diets, however, rabbits are atherosclerosis prone but lesions are 
macrophage-rich and have a fatty streak-like appearance.
52
 The Watanabe 
heritable hyperlipidemic (WHHL) rabbit has a defect in the LDLr and is 
therefore hyperlipidemic, susceptible to atherosclerosis and able to develop 
more advanced lesions.
56,57
 A drawback of rabbits is that atherosclerosis 
development is dependent on infections as pathogen-free rabbits develop no 
atherosclerosis.
48
 Another drawback is that they have no HL which is important 
in HDL metabolism.
58
 
The mouse is a widely used model for atherosclerosis studies because of low 
costs and availability of several strains and genetically modified mice. Wild-
type mice have a plasma cholesterol of approximately 2 mM, which is almost 
all confined to the HDL fraction, while VLDL and LDL are virtually absent. 
These animals require an extreme atherogenic diet to develop 
atherosclerosis.
59,60
 Since mice are exceptionally suitable for genetic 
modification, several atherosclerosis-prone mouse models have been generated, 
such as apoE-knockout (apoE
-/-
), LDLr-knockout (LDLr
-/-
) and APOE*3-Leiden 
transgenic (E3L) mice. Nowadays these mice are widely used as animal model 
in atherosclerosis research. 
The apoE-knockout mouse has highly impaired VLDL and LDL clearance, as 
apoE is important in the uptake of lipoprotein remnants by the liver. Therefore, 
plasma cholesterol is increased in these mice (approx. 8 mM on chow and up to 
70 mM on a high cholesterol-containing diet) and present mainly in VLDL and 
LDL. Therefore, these animals already develop atherosclerosis on a chow diet
61-
64
 and heterozygote apoE-knockout mice develop atherosclerosis on an 
atherogenic diet.
65
 Lack of macrophage apoE also contributes substantially to 
the atherosclerosis susceptibility of these mice as mice lacking apoE specifically 
in the macrophage have increased foam cell formation and atherosclerosis.
66
 
LDLr knockout mice have also highly impaired VLDL and LDL clearance and 
increased plasma cholesterol levels, as the LDLr is important in uptake of these 
lipoproteins by the liver. However, their phenotype is milder than that of apoE-
knockout mice and they therefore need an atherogenic diet to develop 
atherosclerosis.
67,68
 A drawback of both apoE
-/-
 and LDLr
-/-
 mice is that they do 
not respond in a human-like manner to pharmacotherapeutic interventions like 
statins and fibrates, with respect to their lipid-lowering properties.
69
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E3L mice carry a construct containing apoE*3-Leiden, a mutation of apoE 
characterized by a tandem duplication of codons 120-126 that causes 
hyperlipidemia in humans,
70,71
 together with apoCI that elevates plasma TG. As 
a result, E3L mice have somewhat increased levels of plasma cholesterol and 
TG on a chow diet,
70
 but their phenotype with respect to plasma lipids is milder 
than that of apoE-knockout and LDLr-knockout mice, and the mice need an 
atherogenic diet for inducing atherosclerosis development.
72,73
 A major 
advantage of E3L mice is that they respond in a human-like manner to 
pharmaceutical interventions including statins and fibrates with respect to lipid 
lowering.
69
 Probably because mice lack CETP, an important protein in HDL 
metabolism, E3L mice do not properly respond to HDL modulating therapy. 
Therefore, we have crossbred E3L mice with CETP transgenic mice.
74-77
 
 
3. Factors regulating lipid metabolism  
 
3.1 Apolipoproteins 
 
Apolipoproteins stabilize the lipoprotein particle and have functions in lipid and 
lipoprotein metabolism. Several apolipoproteins are known and they all have 
their own functions.  
ApoAI and apoAII are the two major HDL-associated apolipoproteins and are 
both required for normal HDL synthesis. ApoAI is present on most HDL 
particles and constitutes 70% of HDL protein. ApoAII is present on two third of 
the HDL particles and constitutes 20% of HDL protein content.
33,36
 ApoAI is 
synthesized in the liver and intestine and is lipidated to form HDL. In humans 
and mice, apoAI deficiency leads to a large decrease in HDL
78,79
 and increase in 
atherosclerosis.
80
 ApoAII is synthesized in the liver, and apoAII deficiency also 
reduces HDL levels,
81
 indicating that both apoAI and apoAII are needed for 
HDL synthesis. ApoAIV is expressed in the intestine, increases HDL levels and 
protects against atherosclerosis in mice.
82,83
 It may also be involved in 
chylomicron synthesis
84,85
 and is important in regulation of food intake.
86
 
ApoAV is a more recently discovered apolipoprotein that reduces TG levels.
87
 
ApoAV stimulates LPL-mediated TG lipolysis and inhibits VLDL production 
which may explain the effect of apoAV on TG levels.
88
 
ApoB is present on chylomicrons, VLDL, IDL and LDL. ApoB consists in two 
forms: apoB48 is expressed by the intestine and is present on chylomicrons, 
whereas apoB100 is expressed in the liver and present on VLDL. In several 
species including mice both apoB forms are expressed by the liver. ApoB is 
required in the assembly of chylomicrons and VLDL and serves as ligand for 
lipoprotein clearance by the LDLr in liver and other tissues.
89
 Mutations in the 
apoB gene can lead to hypolipidemia or, when the LDLr binding domain is 
affected, to hyperlipidemia.
90
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ApoE is present on chylomicrons, VLDL, IDL and HDL. ApoE is crucial for 
the efficient uptake of lipoprotein remnants by the liver.
91
 However, at high 
concentrations, apoE inhibits LPL that may lead to hypertriglyceridemia.
92
 Lack 
of apoE in mice severely increases atherosclerosis development
61-64
 and apoE 
deletion in macrophage increases foam cell formation and atherosclerosis.
66
 
An interesting apolipoprotein which, despite its small size, has many functions 
in lipid metabolism but also in inflammation is apoCI. ApoCI is mainly 
synthesized in the liver but also in macrophages. ApoCI is released into the 
circulation, is present on chylomicrons, VLDL, LDL and HDL and is highly 
exchangeable between these lipoproteins. ApoCI is the smallest of the 
apolipoproteins (57 amino acids, 6.6 kDa) and highly positively charged. The 
apoCI peptide forms 2 α-helices which are separated by a flexible linker. ApoCI 
has many functions in lipoprotein metabolism. Overexpression of apoCI leads 
to highly increased TG levels and mildly elevated total cholesterol levels in 
mice,
93
 while apoCI knockout mice have decreased TG levels and decreased 
HDL levels at least on an apoE-knockout background. The elevated TG and 
cholesterol levels in apoCI-overexpressing mice are mainly confined to VLDL 
and were initially explained by an inhibitory effect of apoCI on lipoprotein 
clearance via the LDLr and other classical apoE-recognizing receptors.
94-98
 
Later, apoCI was found to be an inhibitor of LPL
93
 which explains the relative 
large elevation in TG as compared to cholesterol in apoCI overexpressing mice. 
In addition, apoCI affects HDL metabolism by stimulation of LCAT,
99,100
 
inhibition of HL,
101,102
 and inhibition of CETP.
103
 These effects on HDL thus 
suggest that apoCI may causally increase HDL levels. Overall, apoCI 
expression is atherogenic, at least in absence of CETP, probably because of the 
induction of hyperlipidemia.
104
 In addition to affecting plasma cholesterol and 
TG levels, apoCI has also a role in endodermal lipid metabolism as mice 
overexpressing high levels of apoCI have skin abnormalities.
105
 In addition, 
apoCI is involved in regulation of inflammation as it enhances the early 
response to LPS.
106
  
Other members of the apoC family are also involved in regulating TG lipolysis. 
ApoCII is the cofactor for LPL, is essential for lipolysis of TG, and apoCII 
deficiency thus leads to severe hyperlipidemia.
107,108
 ApoCIII, on the other hand, 
is the main endogenous LPL inhibitor. Overexpression of apoCIII thus leads to 
elevated TG levels and apoCIII-deficiency to decreased TG levels.
109,110
 
ApoCIII may also increase intestinal lipid uptake and VLDL production.
111
 
 
3.2 Cholesteryl ester transfer protein 
 
The human CETP gene is located on the long arm of chromosome 16 (16q12-
16q21).
112
 The gene is 25 kb and consist of 16 exons between 32 to 250 bp 
which account for 8% of the total gene sequence.
113,114
 CETP gene expression is 
regulated by several factors, including the zinc finger proteins SP1 and 
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SP3,
115,116
 ARP-1,
117
 C/EBP,
118
 and lipids, directly, or indirectly via 
SREBP
119,120
 and LXR.
11,121-124
 In addition to the normal full-length mRNA, an 
alternatively spliced mRNA can be expressed in which exon 9 is removed. The 
exon 9-deleted protein is inactive and inhibits secretion of the normal CETP 
protein
125,126
 and may also be involved in the regulation of plasma CETP 
activity. CETP is expressed mainly in the liver, adipose tissue and in 
macrophage-rich tissues and is a 74 kDa (476 aa) glycoprotein.
114
 CETP is 
highly hydrophobic as it consists of 45% hydrophobic amino acids which form 
a hydrophobic pocket for the binding of neutral lipids.
127
 CETP circulates in the 
plasma at a concentration of approx. 1-3 µg/mL and is mainly bound to HDL 
(74%).
11,128
 CETP transfers neutral lipids (i.e. TG and CE) between plasma 
lipoproteins leading to a net transfer of CE from HDL to VLDL and a reciprocal 
transfer of TG from VLDL to HDL.
11
 
As CETP transfers CE out of HDL, CETP activity leads to decreased HDL-C 
levels. Since HDL-C is associated with reduced cardiovascular disease (CVD) 
risk, CETP has been suggested to be atherogenic. Albeit that CETP-deficiency 
thus was expected to be atheroprotective, studies involving CETP-deficient 
subjects showed controversial results. In Japanese subjects a CETP mutation 
has been identified that leads to complete CETP deficiency (Intron14+1 
G>A)
129
 and another mutation that leads to a marked reduction of CETP 
(D442G).
130
 Both mutations indeed increase HDL levels, especially those of 
large HDL. The HDL of CETP-deficient subjects is enriched in CE and poor in 
TG. TG and LDL-C levels are not or only mildly affected and LDL particles are 
smaller and more heterogeneous compared to LDL of normal subjects.
130-133
 
Although their high HDL levels suggest protection from atherosclerosis, CETP 
deficient subjects are susceptible to atherosclerosis development.
134
 
Remarkably, prevalence of CETP-deficiency in people over 80 years is reduced 
indicating that CETP deficiency does not reduce overall mortality.
135
 Zong et 
al.
136
 showed even an increase of CHD in carriers of a CETP mutation with 
HDL-C levels between 1-1.5 mM. However, CHD prevalence was similar in 
patients with higher HDL levels with and without CETP mutations. Another 
study showed that high HDL (>2 mM) protects against CHD independent of 
CETP mutations.
137
 The relation between CETP deficiency and atherosclerosis 
thus remains controversial. However, these mutations are often linked to HL 
deficiency.
134
 Together with the low number of subjects, this makes it difficult 
to study the effect of CETP on atherosclerosis.
133,138
 
Besides the Intron14+1 G>A and D442G mutations, some other CETP gene 
polymorphisms have been identified. These polymorphisms affect plasma 
CETP activity to a milder extent, but these mutations are more common and, 
therefore, easier to study in large patient groups. The TaqIB polymorphism 
which is in strong linkage disequilibrium with -C629A
139
 is the most widely 
studied CETP polymorphism. The B2 allele is clearly associated with reduced 
CETP levels and higher HDL levels. However, again literature is inconsistent 
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about effect of the TaqIB phenotype on CHD risk. The B2 allele has either been 
associated with reduced CHD risk,
140-143
 no effect on CHD risk,
144-146
 or even an 
increased CHD risk.
147,148
  A recent review showed that the odds ratio for CVD 
risk was 1.45 in B2B2 carriers versus B1B1 carriers in population based studies, 
while the odds ratio in high risk populations was 0.84 for B2B2 carriers versus 
B1B1. This difference could possibly be explained by selection for a lower 
frequency of B2B2 carriers in high risk populations. However the effect of this 
common CETP gene variant on CVD was only modest.
149
 Mutations in the 
CETP gene that cause low CETP mass thus clearly cause higher HDL-C levels, 
but the effect of CETP mutations on atherosclerosis is controversial.  
In addition to human studies, animal models have been used to experimentally 
address the effect of CETP on atherosclerosis further. Since wild-type mice are 
naturally deficient for CETP, CETP transgenic mice have been created.
121,150,151
 
These mice have reduced HDL-C levels in plasma.
150,151
 Simian CETP 
expression in wild-type mice increases atherosclerosis.
151
 Since LDLr
-/-
 and 
apoE
-/-
 mice are hyperlipidemic and have a more human like lipoprotein profile, 
they have been considered as relevant mouse models to study atherosclerosis. 
Similarly to wild-type mice, CETP expression in both hyperlipidemic mice 
increases atherosclerosis.
152
 Also, in E3L mice, CETP expression leads to a 
higher VLDL, lower HDL and increases atherosclerosis by 7-fold.
75
  
CETP thus increases atherosclerosis in wild-type mice and in hyperlipidemic 
mice in which VLDL clearance is impaired to some extent. However, CETP has 
been shown to be anti-atherogenic in other mouse models. LCAT 
overexpressing mice have a high increase of plasma levels of large HDL, CETP 
expression in these mice reduces HDL levels and atherosclerosis.
153
 Similarly, 
SR-BI-deficient mice accumulate large HDL. In this model, CETP expression 
reduces atherosclerosis
154
 as explained by normalization of dysfunctional HDL. 
However, CETP expression did not reduce atherosclerosis in SR-BI mice in 
another study despite of HDL normalization (Van Eck et al. unpublished 
results). The latter may be related to the finding that SR-BI-deficiency not only 
results in dysfunctional HDL, but also increases oxidative stress,
155
 which is not 
relieved upon CETP expression. In mice with hypertriglyceridemia due to 
apoCIII overexpression and in diabetic mice, CETP expression protects against 
atherosclerosis development, probably by reduction of total cholesterol 
levels.
156-158
 
CETP is thus protective in mouse models of diabetes and hypertriglyceridemia, 
possibly related to a plasma cholesterol lowering effect of CETP in these 
models. Also when HDL accumulates CETP is protective by reducing HDL via 
an alternative route. In animal models with a more humanized lipoprotein 
profile however, CETP is atherogenic.  
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3.3 Nuclear receptors 
 
Since several nuclear receptors are important in regulating expression of genes 
in lipid metabolism, they are potential targets in drug development. 
Peroxisome proliferator-activated receptors (PPARs) are important regulators of 
expression of genes involved in lipid and glucose metabolism. PPARs are 
activated by FA and ecosanoids and heterodimerize with RXR to affect gene 
expression by binding to DR-1 responsive elements. PPARα is expressed in 
several metabolically active tissues including liver and muscle where it is 
important for regulation of genes involved in lipid metabolism such as apoCIII, 
LPL and apoAI (the latter in humans, but not in mice). PPARγ is expressed in 
adipose tissue, macrophages, colon and placenta and is important in regulation 
of lipid and glucose metabolism and adipocyte differentiation. PPARγ 
activation makes tissues more insulin sensitive and agonists are therefore 
applied in diabetes. PPARδ is expressed at low levels in a variety of tissues, is 
involved in lipid and glucose metabolism
159-162
 and is regarded as novel target in 
the treatment of dyslipidemia and insulin resistance.
163
   
Sterol Regulatory Element Binding Proteins (SREBPs) are other important 
regulators in lipid metabolism. SREBPs are activated when cells are depleted of 
cholesterol. Three SREBP isoforms exist, namely SREBP1a, SREBP1c and 
SREBP2. SREBP1a and SEBP1c are derived from the same gene by use of 
alternative transcription start sites. SREBP1a is a potent activator of all SREBP 
responsive genes, these genes are involved in cholesterol, FA and TG synthesis 
and include HMG-CoA reductase, FAS and SCD. SREBP1c mainly activates 
genes for FA synthesis and SREBP2 activates genes in cholesterol synthesis.
164
 
SREBP1c and SREBP2 also induce genes important for the synthesis of 
NADPH which is used in lipid biosynthesis. 
Another group of receptors important in regulation of lipid metabolism include 
LXR, FXR, PXR and RXR. LXR consists in 2 forms, LXRα and LXRß which 
are both activated by oxysterols (i.e. cholesterol derivates). LXRα is mainly 
expressed in liver and macrophages while LXRß is more ubiquitously 
expressed. Upon activation, LXR forms a heterodimer with RXR which binds to 
LXR-responsive elements to affect expression of genes in lipid metabolism such 
as apoE, CETP, ABCA1 and SREBP1c.
165,166
 In mouse models, LXR agonism 
shows protection against atherosclerosis, but leads also to hypertriglyceridemia 
due to increased VLDL production.
167,168
 FXR and PXR also form heterodimers 
with RXR to regulate gene expression. FXR is activated by bile acids and target 
genes include Cyp7a1 and PLTP. FXR plays an important role in the regulation 
of synthesis, excretion and reuptake of bile acids from the intestine but also 
reduces plasma lipid levels.
166
 PXR is activated by xenobiotics and increases 
expression of the Cyp3a enzymes to increase removal of xenobiotics by the 
body. PXR increases hepatic TG synthesis and may affect HDL metabolism but 
the effect of PXR on overall lipid metabolism is unknown.
162,166,169
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4. Pharmacological interventions in dyslipidemia 
 
High LDL-C and low HDL-C are associated with increased CVD risk. Several 
anti-atherogenic drugs have been developed that mainly aim at reducing 
(V)LDL levels, including statins, fibrates, bile acid binding resins and 
cholesterol uptake inhibitors.  
 
4.1 Statins 
 
Statins are the most widely used drugs to reduce plasma (V)LDL-C levels. The 
first statins were fungal derivatives (e.g. pravastatin and simvastatin) but later 
more potent fully synthetic statins including atorvastatin and rosuvastatin were 
developed. Statins show structural similarities to the cholesterol precursor 
hydroxymethylglutaryl-coenzyme A (HMG-CoA) and, therefore, they block 
entry of HMG-CoA to HMG-CoA reductase, an enzyme important in 
cholesterol synthesis.
170,171
 Via this action, statins inhibit cholesterol synthesis in 
the liver and its subsequent release in the plasma within VLDL particles.
172
 In 
addition, to compensate for hepatic cholesterol depletion, the LDLr is 
upregulated and uptake of lipoproteins from the plasma is increased, which 
contributes to the reduction in plasma cholesterol levels.
173
 Statins reduce not 
only cholesterol levels but also TG which may contribute to their anti-
atherogenic effects.
174
 In addition, statins mildly increase HDL-C levels (up to 
+10%).
175
 Atorvastatin treatment has been associated with a decrease in CETP 
mass
176-178
 and activity.
177-180
 however whether a reduction in CETP is the causal 
factor for the observed HDL increase has not been established yet. In addition to 
lipid lowering, statins improve endothelial function, are anti-oxidative and are 
anti-inflammatory contributing to its atheroprotective actions. Statins also 
inhibit cell proliferation and are, therefore, anticarcinogenic and statins may 
inhibit kidney graft rejection.
181
 Statins decrease plasma (V)LDL-C efficiently 
up to -40%
182
 and the combined actions of statins lead to a reduction of 
cardiovascular events of about -20% per mM cholesterol reduction.
183
 
 
4.2 Fibrates 
 
Fibrates are PPARα agonists, and therefore affect transcription of many genes 
in lipid metabolism leading to a net reduction of mainly plasma TG (up to -
50%) and a mild reduction in plasma cholesterol.
160,184,185
 The reduction in 
plasma TG may be a consequence of increased TG lipolysis caused by 
upregulation of LPL
186
 and downregulation of the LPL inhibitor apoCIII.
187-189
 
TG may also be reduced by increased hepatic ß-oxidation and reduced FA 
synthesis.
189-192
 In addition, fibrates mildly increase HDL-C (up to +20%).
175,193
 
Fibrates induce apoAI expression in humans but not in mice which may 
contribute to the observed HDL increase in humans.
194
 Another difference 
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between humans and mice is that mice do not express CETP. CETP activity in 
humans is reduced upon treatment with fibrates
195
 but if this contributes to the 
HDL increase in humans is still unknown. The clinical benefit of fibrates is 
uncertain.
184,185
 A recent meta analysis shows a reduction of non fatal MI (-
22%) but not of other cardiovascular events including cardiovascular 
mortality.
184
 
 
4.3 Bile acid binding resins and cholesterol uptake inhibitors 
 
Other cholesterol lowering drugs available are bile acid binding resins and 
cholesterol uptake inhibitors. Resins bind bile acids in the intestine, which 
interrupts the enterohepatic circulation of bile acids and results in an increased 
excretion of bile acids via the feces. This results in an increased production of 
new bile acids from cholesterol in the liver and therefore lowers plasma 
cholesterol levels. Resins reduce plasma cholesterol levels up to -25%.
196-198
 
Cholesterol uptake inhibitors such as ezetimibe reduce intestinal cholesterol 
absorption via Niemann-Pick C1 Like 1 (NPC1L1), a protein essential in 
cholesterol uptake from the intestine.
199
 On top of statin treatment, ezetimibe 
reduces cholesterol by an additional -16%, but does not affect IMT, possibly 
related to a low baseline IMT of the study subjects. The effect of ezetimibe on 
clinical endpoints is still uncertain.
200
 
 
Via effective plasma cholesterol lowering, statins, fibrates, bile acid binding 
resins and cholesterol uptake inhibitors prevent up to 40% of cardiovascular 
events, a significant residual risk thus remains. Therefore several new drugs to 
prevent CVD further are under development. As HDL has been suggested to be 
a more important predictor of CVD development,
201
 one group of these new 
drugs are aimed to increase HDL and include niacin and CETP inhibitors.  
 
4.4 Niacin 
 
Niacin (nicotinic acid, vitamin B3) is the most potent HDL-raising drug used in 
the clinic. In addition to raising HDL-C (up to +35%),
196,202-204
 niacin decreases 
plasma LDL-C and TG levels (up to -25 and -50% respectively). The reduction 
in TG and cholesterol may be explained as niacin decreases hormone sensitive 
lipase activity via the GRP109A. This rapidly decreases plasma FA. Therefore, 
less FA are available for TG synthesis in the liver and subsequent VLDL 
production.
204
 Niacin may also decrease TG synthesis via a direct effect on TG 
production in hepatocytes.
205,206
 The underlying mechanism of the HDL 
increase is also not fully understood but is possibly related to CETP.
207
 Niacin 
reduces IMT progression
38
 and overall mortality (-11%)
208
 but is not well 
tolerated because it causes severe flushing via increasing plasma prostaglandins. 
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Addition of the prostaglandin D2 receptor 1 blocker laropiprant reduces niacin 
mediated flushing and makes niacin therefore a better tolerated drug.
203
  
 
4.5 CETP inhibitors 
 
As CETP decreases HDL, various strategies have been developed to inhibit 
CETP activity to increase HDL levels. Two natural CETP inhibitors are known. 
The lipid transfer inhibitory protein (LTIP), also called apoF, has been detected 
in LDL and inhibits the involvement of LDL in the actions of CETP.
209,210
 In 
addition, apoCI has been discovered as the main endogenous inhibitor of CETP 
activity on HDL.
103
  
The first experiments to evaluate the effect of inhibition of CETP were 
performed with antibodies against CETP. These antibodies were indeed able to 
increase HDL in hamsters and rabbits.
211-213
 Antisense oligodeoxynucleotides 
(ODNs) against CETP also reduced CETP mRNA and increased HDL in 
rabbits,
214
 and were also able to reduce the aortic cholesterol content and lesion 
area.
215
 Atherosclerosis could also be reduced in rabbits by vaccination to 
generate auto-antibodies against CETP.
216
 The first chemical compound 
designed to inhibit CETP tested in rabbits was JTT-705. JTT-705 inhibits CETP 
by the formation of a disulphide bond with CETP. In rabbits, JTT-705 indeed 
increased HDL, decreased non HDL-C and reduced atherosclerosis.
217
 In a 
second study in which rabbits were fed a high cholesterol diet, JTT-705 failed to 
reduce atherosclerosis despite of an increase in HDL.
218
 A second CETP 
inhibitor is torcetrapib, which inhibits CETP via the formation of an inactive 
complex with CETP and HDL.
219
 Torcetrapib increases HDL and reduces 
atherosclerosis in rabbits.
220
 In humans, both JTT-705 and torcetrapib are well 
tolerated in short term studies, despite of a small increase in blood pressure in 
torcetrapib treated subjects. Both compounds raise HDL-C in humans.
221-224
 
JTT-705 is only tested in short term studies in humans, and therefore its effect 
on atherosclerosis and cardiovascular events in humans is still unknown. 
Torcetrapib is tested in long term studies in combination with atorvastatin. 
Despite of a HDL increase of about 60% however, torcetrapib in combination 
with atorvastatin treatment failed to reduce atherosclerosis, as assessed by 
Intima Media Thickness (IMT) an Intravascular Ultrasound (IVUS), compared 
to atorvastatin alone.
225-227
 Moreover, more people died in the torcetrapib treated 
group as compared to the atorvastatin alone group and cardiovascular event 
rates were increased rather than decreased by torcetrapib.
228
 These adverse 
effects may well be compound-specific, but further studies into the mechanism 
of the adverse effects are necessary to evaluate if CETP inhibition is still a 
promising strategy in the search for new anti-atherogenic drugs. In addition, it is 
still unknown if the combination with atorvastatin extinguished a protective 
effect of torcetrapib. Therefore further studies are needed to evaluate if 
torcetrapib or other CETP inhibitors alone are able to reduce atherosclerosis. A 
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new CETP inhibitor is anacetrapib, a torcetrapib-like compound that increases 
HDL in humans without affecting blood pressure.
229
 If anacetrapib will decrease 
atherosclerosis is however still unknown.  
 
5. Outline of this thesis 
 
Statins, fibrates and cholesterol absorption inhibitors lower plasma cholesterol 
very efficiently (up to 40%). However, efficient cholesterol lowering only 
prevents a fraction of cardiovascular events. Therefore new therapeutic 
strategies to further reduce cardiovascular events are necessary. HDL-raising 
therapy may be such a new strategy, and CETP is an important factor in 
regulating HDL levels. In this thesis we evaluate the mechanism underlying the 
effects of pharmaceutical intervention on HDL metabolism in E3L.CETP mice. 
In humans statins and fibrates mildly increase HDL. This effect is not observed 
in E3L mice, despite a human-like cholesterol lowering effect. To evaluate 
whether the HDL increase as seen in humans depends on CETP expression, we 
treated E3L.CETP and E3L mice with a diet rich in fat and cholesterol, and 
added fenofibrate (chapter 2) or atorvastatin (chapter 3). The most potent HDL 
raising drug available is niacin, but the mechanism underlying the HDL increase 
is still unknown. In chapter 4 we treated E3L.CETP mice with niacin to 
evaluate the involvement of CETP in niacin’s HDL raising properties. 
Torcetrapib has been the first CETP inhibitor tested in large clinical trials, and 
is able to increase HDL by about 60%. However, despite the large increase in 
HDL, humans treated with atorvastatin and torcetrapib showed no reduction in 
atherosclerosis (measured by IMT and IVUS) as compared to patients treated 
with atorvastatin only. Moreover, torcetrapib treatment led to adverse effects 
including an increase in cardiovascular events and increased death rate. To 
study the effects of torcetrapib with and without atorvastatin and to study the 
adverse effects of torcetrapib, in chapter 5 we treated E3L.CETP mice with 
torcetrapib and atorvastatin.  
In chapter 6 we studied another mechanism to interfere with HDL metabolism. 
In literature, PXR agonists are shown to increase HDL levels in wild type mice. 
However, other studies suggest that PXR activation decreases rather than 
increases HDL. In addition, the effect of PXR on HDL in the presence of CETP 
is not known. To evaluate the effect of PXR in a model with a human like 
lipoprotein profile, we treated E3L and E3L.CETP mice with a high 
fat/cholesterol diet with and without the PXR agonist pregnenolone-16α-
carbonitrile (PCN). 
ApoCI has several functions in HDL metabolism. ApoCI is the main 
endogenous HDL associated CETP inhibitor, the second LCAT activator, and 
apoCI inhibits HL. The effect of apoCI on HDL clearance and overall HDL 
levels is however not known. Therefore, we studied the effect of apoCI on SR-
BI in vitro and overall effect of apoCI in HDL metabolism in vivo in chapter 7. 
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In chapter 8 we focused on the CETP-inhibitory effect of apoCI. As full length 
apoCI increases VLDL levels by LPL reduction, full length apoCI is not a good 
agent to increase HDL by CETP inhibition. Therefore we used an array of 
apoCI peptides to identify a peptide that inhibits CETP but does not inhibit LPL 
efficiently. 
Chapter 9 gives an overview of animal models that are used to study HDL 
metabolism. The results of the studies described in this thesis and the future 
perspectives are discussed in chapter 10. 
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Abstract 
 
In addition to efficiently decreasing VLDL-triglycerides (TG), fenofibrate 
increases HDL-cholesterol levels in humans. We investigated whether the 
fenofibrate-induced increase in HDL-cholesterol is dependent on the expression 
of the cholesteryl ester transfer protein (CETP). To this end, APOE*3-Leiden 
(E3L) transgenic mice without and with the human CETP transgene, under 
control of its natural regulatory flanking regions, were fed a Western-type diet 
with or without fenofibrate. Fenofibrate (0.04% in the diet) decreased plasma 
TG in E3L and E3L.CETP mice (-59% and -60%; P<0.001), caused by a strong 
reduction in VLDL. Whereas fenofibrate did not affect HDL-cholesterol in E3L 
mice, fenofibrate dose-dependently increased HDL-cholesterol in E3L.CETP 
mice (up to +91%). Fenofibrate did not affect the turnover of HDL-cholesteryl 
esters (CE), indicating that fenofibrate causes a higher steady-state HDL-
cholesterol level without altering the HDL-cholesterol flux through plasma. 
Analysis of the hepatic gene expression profile showed that fenofibrate did not 
differentially affect the main players in HDL metabolism in E3L.CETP mice 
compared with E3L mice. However, in E3L.CETP mice, fenofibrate reduced 
hepatic CETP mRNA (-72%; P<0.01) as well as the CE transfer activity in 
plasma (-73%; P<0.01). We conclude that fenofibrate increases HDL-
cholesterol by reducing the CETP-dependent transfer of cholesterol from HDL 
to (V)LDL, as related to lower hepatic CETP expression and a reduced plasma 
(V)LDL pool. 
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Introduction 
 
High plasma TG levels are correlated with an increased risk for cardiovascular 
disease.
1
 Fibrates are widely used to reduce hypertriglyceridemia, thereby 
generating a less atherogenic lipid phenotype. Fibrates perform their actions 
through activation of peroxisome proliferator-activated receptor alpha 
(PPARα).
2,3
 Activated PPARα heterodimerizes with retinoid X receptor (RXR) 
and subsequently binds to specific peroxisome proliferator response elements 
(PPREs) in target genes to alter their transcription.
2,4
 Fibrates thus decrease TG 
levels by inhibiting hepatic TG production through increased hepatic ß-
oxidation and inhibition of de novo fatty acid synthesis, increasing LPL-
mediated lipolysis, and providing a higher affinity of remnants for the LDL 
receptor (LDLr).
3
 
A meta-analysis of 53 clinical studies using fibrates enrolling 16,802 subjects 
indicated that apart from a 36% reduction in plasma TG, fibrates increase HDL-
cholesterol levels by ~10% in humans.
5
 Studies in vitro and in (transgenic) mice 
showed that fibrates increase the hepatic transcription of human APOA1
6
 and 
APOA2,
7
 decrease hepatic receptor B type I (SR-BI) protein,
8
 increase the SR-
BI-mediated
9
 and ABCA1-mediated
10
 cholesterol efflux from human 
macrophages, and increase plasma phospholipid transfer protein (PLTP) 
activity.
11,12
 All of these effects may thus potentially contribute to the increase 
in HDL-cholesterol as observed in humans. 
In contrast to humans, fibrates decrease HDL-cholesterol levels in 
apolipoprotein E (apoE)-deficient mice
13
 and do not affect HDL-cholesterol 
levels but increase the HDL particle size in wild-type mice and human APOA1 
transgenic mice by downregulation of SR-BI
8
 and/ or induction of PLTP.
11
 The 
fact that fibrates do not increase the level of regularly sized HDLs in mice may 
be attributed to the fact that, in contrast to the human APOA1 promoter, which 
contains a functional positive PPRE leading to increased APOA1 transcription, 
the murine apoa1 promoter contains a nonfunctional PPRE.
6
 However, another 
major difference between both species is that, in contrast to humans,
14
 mice do 
not express the cholesteryl ester transfer protein (CETP).
15
 CETP is a 
hydrophobic plasma glycoprotein that is involved in the exchange of cholesteryl 
esters (CE) and TG between HDL and apoB-containing lipoproteins (e.g. VLDL 
and LDL), resulting in the net transfer of CE from HDL to apoB-containing 
lipoproteins.
16
 CETP deficiency in humans is associated with increased HDL-
cholesterol levels
17
 and inhibition of CETP activity by small-molecule inhibitors 
increases HDL-cholesterol levels.
18-21
 Interestingly, bezafibrate,
22,23
 
fenofibrate,
24
 and ciprofibrate
25
 increase HDL-cholesterol in subjects with 
hyperlipidemia with a concomitant reduction in plasma CETP activity. In the 
latter study, plasma apoAI levels were not affected, which indicates that fibrates 
may increase HDL-cholesterol levels via apoAI-independent mechanisms, 
including a potential effect of fibrates on CETP expression.  
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Therefore, our aim was to investigate whether the fibrate-induced increase in 
HDL-cholesterol depends on CETP expression. To this end, we used, APOE*3-
Leiden (E3L) mice that express a natural mutation of the human APOE3 gene 
(i.e., tandem repeat of codons 120-126, yieling a protein of 306 amino acids) in 
addition to the human APOC1 gene. Introdution of these genes results in an 
attenuated clearance of apoB-containing lipoproteins via the LDL receptor 
pathway. Therefore these mice show modlerately increased cholesterol and TG 
levels on a chow diet and a human-like lipoprotein profile an a cholesterol rich 
diet.
26,27
 E3L mice were crossbred with mice expressing human CETP under 
control of its natural flanking regions,
28
 resulting in E3L.CETP mice.
29
 
E3L.CETP and E3L littermates were fed a cholesterol-rich (0.25%, w/w) diet 
with or without fenofibrate. After 2 weeks of administration, fenofibrate dose-
dependently increased HDL-cholesterol in E3L.CETP mice, but did not affect 
HDL levels in E3L mice. In addition, in E3L.CETP mice fenofibrate reduced 
hepatic CETP mRNA expression, as well as CE transfer activity in plasma. 
From these studies, we conclude that fenofibrate increases HDL-cholesterol by 
reducing CETP-dependent transfer of CE from HDL to apoB-containing 
lipoproteins.  
 
Materials and Methods 
 
Animals 
Hemizygous human CETP transgenic (CETP) mice, expressing a human CETP 
minigene under the control of its natural flanking sequences
28
 were purchased 
from the Jackson Laboratory (Bar Harbor, ME) and cross-bred with hemizygous 
E3L mice
30
 at our Institutional Animal Facility to obtain E3L
 
and E3L.CETP 
littermates.
29
 In this study, male mice were used, housed under standard 
conditions in conventional cages with free access to food and water. At the age 
of 8 weeks, mice were fed a semi-synthetic cholesterol-rich diet, containing 
0.25% (w/w) cholesterol and 15% (w/w) fat (Western-type diet) (Hope Farms, 
Woerden, The Netherlands) for 3 weeks. Upon randomization according to total 
plasma cholesterol (TC) levels, mice received Western-type diet without or with 
0.004%, 0.012%, or 0.04% (w/w) fenofibrate (Sigma, St. Louis, MO). 
Experiments were performed after 4 h of fasting at 12:00 PM with food 
withdrawn at 8:00 AM, unless indicated otherwise. The institutional Ethical 
Committee on Animal Care and Experimentation approved all experiments.  
 
Plasma lipid and lipoprotein analysis 
Plasma was obtained via tail vein bleeding as described
31
 and assayed for TC 
and TG, using the commercially available enzymatic kits 236691 and 11488872 
(Roche Molecular Biochemicals, Indianapolis, IN), respectively. The 
distribution of lipids over plasma lipoproteins was determined by fast-
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performance liquid chromatography using a Superose 6 column as described 
previously.
31
 
 
Cholesteryl ester transfer activity in plasma 
The transfer of newly synthesized CE in plasma was assayed by a radioisotope 
method as described previously.
32
 In short, [
3
H]cholesterol was complexed with 
BSA and incubated overnight at 4°C with mouse plasma to equilibrate with 
plasma free cholesterol. Subsequently, the plasma samples were incubated for 3 
h at 37°C. VLDL and LDL were then precipitated by addition of sodium 
phophotungstate/MgCl2. Lipids were extracted from the precipitate by 
methanol-hexane (1:2, v/v) and [
3
H]CE was separated from [
3
H]cholesterol on 
silica columns, followed by counting of radioactivity. 
 
Plasma apoAI concentration 
Plasma apoAI concentrations were determined using a sandwich ELISA. Rabbit 
anti-mouse apoAI polyclonal antibody (ab20453; Abcam plc, Cambridge, UK) 
was coated overnight onto Costar strips (Costar, Inc., New York, NY) (3 µg/ml) 
at 4°C and incubated with diluted mouse plasma (dilution 1:400,000) for 90 min 
at 37°C. Subsequently, goat anti-mouse apoAI antibody (600-101-196; 
Rockland Immunochemicals, Inc., Gilbertsville, PA; dilution 1:3000) was added 
and incubated for 90 min at 37°C. Finally, HRP-conjugated rabbit anti-goat IgG 
antibody (605-4313; Rockland Immunochemicals; dilution 1:15,000) was added 
and incubated for 90 min at 37°C. HRP was detected by incubation with 
tetramethylbenzidine (Organon Teknika, Boxtel, The Netherlands) for 15 min at 
room temperature. Purified mouse apoAI (A23100m; Biodesign International, 
Saco, ME) was used as a standard. 
 
Radiolabeling of autologous HDL 
One mouse from each experimental group was euthanized by cervical 
dislocation, and blood was drawn from the retro-orbital vein. Sera were 
collected and HDL was isolated after density ultracentrifugation in a SW 40 Ti 
rotor (Beckman Instruments, Geneva, Switzerland) (4°C; 40,000 rpm; 
overnight).
33
 HDL (0.4 µmol HDL-cholesterol) was radiolabeled by incubation 
(37°C; 24 h) with [
3
H]cholesteryl oleyl ether ([
3
H]COEth)-labeled egg yolk 
phosphatidylcholine vesicles (40 µCi; 0.5 mg phospholipid) in the presence of 
lipoprotein deficient serum (1 ml) from E3L.CETP mice. Subsequently, HDL 
was reisolated after density ultracentrifugation (12°C; 40,000 rpm; 24 h).  
 
In vivo clearance of autologous HDL 
After 6 weeks of diet, mice were injected via the tail vein with a trace of 
autologous [
3
H]COEth-labeled HDL (0.2x10
6
 cpm in PBS) at 8:00 am. At the 
indicated time points after injection, blood was collected to determine the 
plasma decay of [
3
H]COEth by scintillation counting (Packard Instruments, 
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Dowers Grove, IL). The total plasma volumes of the mice were calculated from 
the equation V (ml) = 0.04706 x body weight (g), as determined from previous 
125
I-BSA clearance studies.
34
 The fractional catabolic rate (FCR) was calculated 
as pools of HDL-CE cleared per h from the plasma decay curves as described 
previously.
35
 Briefly, curves were fitted using GraphPad Prism software, giving 
the best fit for one-phase exponential decay curves, described by the formula 
Y=span*exp(-k*x)+plateau. Subsequently the FCR was calculated as span/(area 
under the curve). Taking into account the fact that the plasma level of HDL was 
altered by the expression of CETP and fenofibrate treatment, the FCR was also 
calculated from these data as millimolar HDL-CE cleared per hour, based on the 
actual level of HDL-CE in the various mouse groups.  
 
Hepatic mRNA expression, SR-BI protein analysis, and lipid analysis 
Livers were isolated after cervical dislocation. Total RNA was isolated using 
the NucleoSpin
®
 RNA II kit (Macherey-Nagel, Düren, Germany) as 
recommended by the manufacturer. RNA expression was determined in 
duplicate by real-time PCR on a MyiQ Single-Color real-time PCR detection 
system (Bio-Rad Laboratories, Hercules, CA). Primers for CETP
36
 and sr-b1
37
 
have been described previously. Primers for abca1, apoa1, cyp7A1, and pltp are 
listed in Table 1. Expression levels were normalized using hypoxanthine-
guanine phosphoribosyl transferase (HPRT) and cyclophilin as housekeeping 
genes.
37,38
 Hepatic SR-BI protein was determined by immunoblot analysis as 
described previously.
39
 Liver lipids were determined by homogenizing liver 
samples in water (~10% wet w/v) using a mini-bead beater (Biospec Products, 
Inc., Bartlesville, OK; 20 sec; 5,000 rpm), followed by lipid extraction as 
described by Bligh and Dyer.
40
 Extracts were assayed for TC as described 
above. Protein was determined according to the method of Lowry et al.
41
 
 
Table 1. Primers for quantitative real-time PCR analysis 
Gene Forward primer (5'-3') Reverse primer (5'-3') 
abca1 CCCAGAGCAAAAAGCGACTC GGTCATCATCACTTTGGTCCTTG 
apoa1 GGAGCTGCAAGGGAGACTGT TGCGCAGAGAGTCTACGTGTGT 
cyp7a1 CAGGGAGATGCTCTGTGTTCA AGGCATACATCCCTTCCGTGA 
pltp TCAGTCTGCGCTGGAGTCTCT AAGGCATCACTCCGATTTGC 
 
Abca1, ATP-binding cassette transporter a1; apoa1, apolipoprotein a1; cyp7a1, cholesterol 
7α-hydroxylase; pltp, phospholipid transfer protein. 
 
Statistical analysis 
All data are presented as means ± SD unless indicated otherwise. Data were 
analyzed using the unpaired Student’s t test. P < 0.05 was considered 
statistically significant. 
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Results 
 
Fenofibrate increases HDL-cholesterol in E3L.CETP mice 
To study the dose-dependent effect of fenofibrate on plasma lipid levels on a 
hyperlipidemic background, E3L.CETP mice were fed a cholesterol-rich diet 
with increasing doses of fenofibrate in the diet (0%, 0.004%, 0.012%, and 
0.04%) for 2 weeks each (Fig. 1). Fenofibrate caused a dose-dependent decrease 
in plasma TG levels (up to -62% at the highest dose; P<0.05) (Fig. 1A), and 
only tended to reduce plasma cholesterol levels (up to -35%; NS) (Fig. 1B). 
However, fenofibrate had a great impact on the distribution of cholesterol over 
the various lipoproteins. Whereas on a cholesterol-rich diet, most cholesterol in 
E3L.CETP mice is carried in (V)LDL, fenofibrate resulted in a dose-dependent 
shift of cholesterol from (V)LDL to HDL (Fig. 1C). 
Subsequently, we compared the effect of fenofibrate on plasma lipid levels in 
E3L.CETP mice with those in E3L mice by using the highest dose of fenofibrate 
(0.04%) (Fig. 2). In E3L mice, fenofibrate decreased plasma TG levels (-59%; 
P<0.001) (Fig. 2A) to a similar extent as in E3L.CETP mice (-60%; P<0.01) 
Figure 1. Dose-dependent effect of 
fenofibrate on plasma TG and cholesterol 
in E3L.CETP mice. Mice received a 
Western-type diet with increasing doses 
of fenofibrate in the diet (0%, 0.004%, 
0.012%, and 0.04%) for two weeks each. 
At the end of the 2-week periods, plasma 
TG (A), plasma cholesterol (B), and the 
distribution of cholesterol over 
lipoproteins (C) were determined. Values 
are means ± SD (n=7 per group). 
**P<0.01 compared to control. 
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(Fig. 2B). In both E3L mice and E3L.CETP mice, these effects of fenofibrate on 
plasma TG levels were reflected by a strong reduction in VLDL-TG (not 
shown). Fenofibrate also caused small trends towards lower plasma cholesterol 
levels in both E3L and E3L.CETP mice (Fig. 2C,D). Fenofibrate similarly 
decreased (V)LDL-cholesterol in both E3L mice (-91%) and E3L.CETP mice (-
93%). However, whereas fenofibrate did not affect HDL-cholesterol levels in 
E3L mice, fenofibrate increased HDL-cholesterol in E3L.CETP mice (+91%) 
(Fig. 3), consistent with the dose-escalating study (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of fenofibrate on the distribution of cholesterol over lipoproteins in E3L and 
E3L.CETP mice. E3L mice (A) and E3L.CETP mice (B) received a Western-type diet 
without (white circles) or with (black circles) fenofibrate. Plasmas of the various mouse 
groups were pooled (n=6 per group). Lipoproteins were separated by FPLC, and fractions 
were analyzed for cholesterol. 
 
 
 
Figure 2. Effect of fenofibrate on 
plasma TG and cholesterol in E3L 
and E3L.CETP mice. E3L mice 
(A, C) and E3L.CETP mice (B, 
D) received a Western-type diet 
without (white bars) or with 
(black bars) fenofibrate for 2 
weeks, and plasma TG (A, B) and 
cholesterol (C, D) were 
determined. Values are means ± 
SD (n=6 per group). **P<0.01 
compared with controls. 
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Fenofibrate increases the steady-state plasma HDL level without affecting net 
HDL-CE output in E3L.CETP mice  
To examine the mechanism underlying the fenofibrate-induced increased HDL-
cholesterol in E3L.CETP mice, E3L and E3L.CETP mice were injected with 
autologous [
3
H]COEth-labeled HDL and the plasma decay was determined (Fig. 
4). The expression of CETP per se appeared to accelerate the plasma decay, 
reflected by an increased fractional catabolic rate (FCR) as calculated pools of 
HDL-CE cleared per hour (+65%; P<0.01; Table 2). In E3L mice, fenofibrate 
administration did not affect the clearance of HDL-CE (Fig. 4A; Table 1). In 
contrast, fenofibrate decreased the FCR of HDL in E3L.CETP mice (-27%; 
P<0.01). However, taking into account the fact that CETP expression and 
fenofibrate treatment influence plasma HDL levels (Fig. 3), the FCR was also 
calculated as millimolar HDL-CE cleared per hour. In fact, CETP expression in 
E3L mice, or fenofibrate feeding of either E3L or E3L.CETP mice, did not 
affect the amount (mM) of HDL-CE cleared per hour (Table 2). This indicates 
Figure 4. Effect of fenofibrate 
on the plasma clearance of HDL 
in E3L and E3L.CETP mice. 
E3L mice (A) and E3L.CETP 
mice (B) received a Western-
type diet without (white circles) 
or with (black circles) 
fenofibrate. Mice were injected 
with autologous [
3
H]COEth-
labeled HDL and plasma 
3
H-
activity was determined at the 
indicated time points. Values 
are means ± SD (n=5 per 
group). **P<0.01 compared 
with controls. 
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Table 2. Effect of fenofibrate on the FCR of HDL-CE in E3L and E3L.CETP mice  
  Control Fenofibrate 
FCR (pools HDL-CE per h) 
 E3L 0.067±0.003 0.057±0.004 
 E3L.CETP 0.111±0.006 0.081±0.003* 
FCR (mM HDL-CE per h) 
 E3L 0.166±0.008 0.162±0.011 
 
E3L.CETP 
 
0.142±0.008 
 
0.162±0.007 
 
 
E3L and E3L.CETP mice were fed a Western-type diet with or without fenofibrate, and mice 
were injected with autologous [
3
H]COEth-labeled HDL. The data from Figure 4 were used to 
calculate the FCR as pools of HDL-CE cleared per hour or millimolar HDL-CE cleared per 
hour. Values are expressed as means ± SEM relative to control mice (n=5 mice per group). 
*P<0.01 compared with controls.  
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that CETP expression and fenofibrate feeding alter the steady-state plasma 
HDL-cholesterol level without affecting the net HDL-cholesterol flux through 
plasma. These data indicate that the residual CETP activity in E3L.CETP mice 
on fenofibrate is sufficient to maintain net HDL-CE output. 
 
Fenofibrate does not differentially affect hepatic mRNA expression of genes 
involved in plasma HDL metabolism 
Because differences in genes encoding proteins that are crucially involved in 
HDL metabolism may account for the increase in HDL-cholesterol in 
E3L.CETP mice upon fenofibrate treatment, we examined the effect of 
fenofibrate on their hepatic expression (Fig. 5). The expression of these genes 
was not substantially different in E3L.CETP mice compared with E3L mice. 
Fenofibrate increased Pltp in E3L (3.5-fold; P<0.01) and E3L.CETP mice (2.7-
fold; P<0.05), consistent with previously reported effects of fenofibrate.
11,12
 The 
expression of abca1, which is involved in HDL formation, was similarly 
decreased in E3L (-50%; P<0.05) and E3L.CETP (-33%; P<0.05) mice. 
Likewise, sr-b1 was decreased in E3L (-48%; P<0.05) and E3L.CETP (-42%; 
P<0.05) mice to a similar extent, as reflected by similar reductions in hepatic 
SR-BI protein levels (~-25%) for E3L (P=0.06) and E3L.CETP mice (P<0.05) 
(data not shown). Apoa1 expression was decreased in E3L (-49%; P<0.05) and 
E3L.CETP (-41%; P<0.05) mice, without substantially affecting the plasma 
apoAI level (~80 mg/dL in all groups). The expression of cyp7a1, pltp, abca1, 
sr-b1, and apoa1 is thus similarly affected by fenofibrate in E3L and E3L.CETP 
mice, and cannot explain the differentially raised HDL in E3L.CETP mice as 
compared to E3L mice. 
 
Figure 5. Effect of fenofibrate on hepatic mRNA expression in E3L and E3L.CETP mice. 
E3L mice (A) and E3L.CETP mice (B) were fed a Western-type diet with or without 
fenofibrate. Mice were euthanized, and livers were collected to determine mRNA expression. 
Values are expressed as means ± S.E. relative to control mice (n=4 per group). *P<0.05; 
**P<0.01 compared with controls. 
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Fig. 6. Effect of fenofibrate on 
hepatic CETP mRNA 
expression and cholesteryl ester 
transfer activity in plasma of 
E3L.CETP mice. E3L.CETP 
mice received a Western-type 
diet with or without fenofibrate, 
and mice were euthanized. 
Livers were collected to 
determine CETP mRNA 
expression (A), and plasma was 
assayed for CE transfer activity 
(B). Values are means ± SD 
(n=4-6 per group). **P<0.01 
compared with controls. 
 
 
 
 
 
 
 
 
 
 
 
Fenofibrate decreases hepatic CETP mRNA expression and CE transfer activity 
in plasma 
To investigate whether the effect of fenofibrate on increasing HDL-cholesterol 
in E3L.CETP mice is caused by reduction of CETP activity, we determined the 
hepatic CETP expression and CE transfer activity in plasma (Fig. 6). Indeed, 
fenofibrate markedly decreased CETP expression in E3L.CETP mice (-72%; 
P<0.01) (Fig. 6A). Because the liver X receptor (LXR) strongly regulates the 
expression of CETP,
42
 we determined whether fenofibrate feeding would 
decrease the cholesterol content in the liver. Indeed, fenofibrate reduced the 
hepatic cholesterol content in E3L mice (4.9±2.6 vs 9.6±3.7 µg TC/mg protein) 
and E3L.CETP mice (3.6±1.0 vs 13.0±3.7 µg TC/mg protein; P<0.05). The 
fenofibrate-induced reduction in hepatic CETP expression was accompanied by 
a similar reduction in the CE transfer activity in plasma of E3L.CETP mice (-
73%; P<0.01) (Fig. 6B). Therefore, the HDL-raising effect of fenofibrate in 
E3L.CETP mice is thus likely to be a direct consequence of lower CETP 
expression. 
 
Discussion 
 
In this study, we investigated whether CETP might play a role in the 
fenofibrate-induced increase in HDL-cholesterol. Here we show that fenofibrate 
increases HDL-cholesterol in E3L.CETP mice, as paralleled by a reduction in 
hepatic CETP mRNA and plasma CE transfer activity, whereas fenofibrate does 
not increase HDL in E3L mice.  
We showed previously that E3L mice are highly susceptible to dietary 
interventions with respect to modulating plasma lipid levels, and that these mice 
show a human-like response to drug interventions aimed at reducing plasma 
levels of apoB-containing lipoproteins, including statins (atorvastatin
43
 and 
rosuvastatin)
44
 and fibrates (gemfibrozil).
45
 This is in sheer contrast with wild-
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type mice
6,13
 and more conventional hyperlipidemic mice such as apoE-
deficient
13,46
 or LDL receptor-deficient
47
 mice, which show either an adverse or 
no response to such interventions. In particular, administration of fenofibrate to 
wild-type
13
 and apoE-deficient
13,48
 mice showed an unexpected increase in 
plasma TG and TC levels caused by elevated levels of lipoprotein remnants, 
with a concomitant reduction in HDL-cholesterol. Here we demonstrate that 
E3L mice also show a human-like response to fenofibrate with respect to 
decreasing TG and cholesterol in apoB-containing particles, although HDL-
cholesterol was not increased after 2 weeks of intervention (Fig. 3A). We 
reasoned that introduction of human CETP in these E3L mice, which permits 
CE exchange between HDL and apoB-containing lipoproteins, would result in 
an excellent mouse model to study the effects of fenofibrate on HDL 
metabolism. 
Indeed, we demonstrate that although E3L.CETP mice retain their ability to 
respond to fenofibrate with respect to a similar reduction of VLDL-TG and 
VLDL-cholesterol as compared with E3L mice, they also respond with an 
increase in HDL-cholesterol level. Apparently, the fact that mice normally do 
not express CETP prevents a human-like response to HDL-modulating drug 
interventions, such as fibrate treatment. In agreement with this hypothesis, we 
observed previously that treatment of E3L mice with statins also did not 
increase HDL-cholesterol even though VLDL reductions of as much as 60% 
were achieved.
43,45,49
  
HDL-cholesterol levels can theoretically be modulated by several key proteins 
involved in HDL metabolism, including ABCA1,
10
 SR-BI,
9
 PLTP,
11,23
 
apoAI,
3,6,48,50,51
 and CETP.
22,24,25
 Therefore, we examined the potential 
contribution of each of these factors in the fenofibrate-induced increase of 
HDL-cholesterol in E3L.CETP mice. The HDL-cholesterol level in mice is 
largely determined by the hepatic expression of ABCA1, which plays an 
important role in HDL formation by mediating hepatic cholesterol efflux to 
apoAI.
52
 In fact, it has been reported that treatment of chow-fed rats with 
ciprofibrate increased their hepatic abca1 expression, concomitant with an 
increase in plasma HDL-cholesterol levels.
53
 However, fenofibrate did not 
increase hepatic abca1 expression in either E3L or E3L.CETP mice. On the 
contrary, fenofibrate decreased abca1 mRNA in both genotypes and thus can 
not explain the selective increase of HDL-cholesterol in E3L.CETP mice. 
Whereas bezafibrate did not increase the plasma PLTP mass and activity levels 
in humans,
23
 fenofibrate has been shown to increase the hepatic pltp expression 
in mice, which was associated with increased plasma PLTP activity and HDL 
size, at least in human apoAI transgenic mice.
11
 Accordingly, we found that 
fenofibrate induced the hepatic pltp expression both in E3L and E3L.CETP 
mice. However, the relative increase was even more pronounced in E3L mice as 
compared to E3L.CETP mice, whereas HDL-cholesterol was not affected in 
E3L mice. It is also of note that adenovirus-mediated hepatic expression of 
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PLTP results in a dose-dependent reduction of HDL-cholesterol levels, instead 
of increasing HDL-cholesterol, in both wild-type and human apoAI-transgenic 
mice.
54
 It is thus unlikely that the induction of PLTP is the cause of the increase 
in HDL-cholesterol as observed in E3L.CETP mice.  
In mice, hepatic SR-BI represents the most important pathway for the selective 
clearance of HDL-associated cholesteryl ester from plasma.
55
 It has been shown 
that fenofibrate can downregulate hepatic SR-BI protein in wild-type mice, 
independent of sr-b1 expression, via a posttranscriptional mechanism. This was 
correlated with a substantially increased HDL size, based on fast-performance 
liquid chromatography profiling.
8
 We found that fenofibrate treatment did result 
in a similar reduction of sr-b1 expression in E3L mice (-48%) and E3L.CETP 
mice (-42%), with a concomitant reduction in hepatic SR-BI protein levels (~-
25%). Although fenofibrate did not increase in large HDL-1 in E3L mice after 
only 2 weeks of fenofibrate intervention (Fig 3A), cholesterol within large 
HDL-1 was indeed increased (+69%) after prolonged treatment of E3L mice 
(i.e., 6 weeks), as has also been shown for wild-type mice,
8
 In E3L.CETP mice 
fenofibrate treatment for 2 weeks increased the levels of cholesterol in regularly 
sized HDLs but also increased the levels of HDL-1 to some extent (Figs. 1C, 
3B). Therefore, the reduction in hepatic SR-BI levels may contribute to the 
appearance of HDL-1 in both E3L and E3L.CETP mice but does not explain the 
increase of regularly sized HDL in E3L.CETP mice. 
In APOA1 transgenic mice, human apoAI hepatic mRNA and plasma protein 
levels were increased after fenofibrate treatment,
6
 probably by the binding of 
PPARα to a positive PPRE in the human apoAI gene promoter.
51
 Given the tight 
relation between HDL-cholesterol and apoAI levels in humans, it could be 
expected that upregulation of apoAI expression would be the main causal factor 
for increasing HDL-cholesterol levels in humans. Fenofibrate treatment has an 
opposite effect on murine apoAI (i.e., reduction of expression and plasma 
levels),
6
 which theoretically could easily explain why fenofibrate does not 
increase HDL-cholesterol in mice. However, although we do observe a 
reduction in hepatic apoa1 expression upon fenofibrate treatment of E3L (-49%) 
and E3L.CETP (-41%) mice, HDL-cholesterol was nevertheless markedly 
increased in E3L.CETP mice. The fact that plasma apoAI was not affected by 
fenofibrate treatment may thus be explained by increased lipidation of apoAI, 
thereby preventing the clearance of apoAI. 
Collectively, these data thus suggest that downregulation of CETP expression is 
the predominant cause of the fenofibrate-induced elevation of HDL-cholesterol. 
Expression of CETP in E3L mice decreased the HDL-cholesterol level (~-35%) 
but did not affect the HDL turnover, calculated as millimolar HDL-CE cleared 
per hour. Likewise CETP inhibition in rabbits, although increasing HDL-
cholesterol, does not compromise the HDL-CE clearance from plasma.
56
  
Treatment of E3L.CETP mice with fenofibrate resulted in an increased HDL-
cholesterol level, strongly decreased hepatic CETP expression levels, and 
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reduced cholesteryl ester transfer activity in plasma. Thus the increase in HDL-
cholesterol may be caused by the combination of reduced hepatic CETP 
expression and reduced levels of apoB-containing lipoproteins as CE acceptors, 
thereby inhibiting the CETP-mediated transfer of CE from HDL to (V)LDL. 
It is tempting to speculate about the mechanism(s) underlying the effect of 
fenofibrate on hepatic CETP expression. Dietary cholesterol has been shown to 
increase CETP mRNA expression in CETP transgenic mice,
28,29
 presumably via 
an LXR responsive element in the CETP promoter.
42
 Conversely, a decrease in 
hepatic CETP mRNA expression might thus be the consequence of a reduction 
in LXR signaling. Fenofibrate treatment indeed decreased hepatic cholesterol, 
which is likely to reduce the level of oxysterols, the natural ligands of LXRα. 
Down-regulation of LXRα is supported by a concomitant decrease in the 
expression of cyp7a1, another LXR-target gene.
57
 This is in accordance with the 
observation that administration of ciprofibrate to wild-type mice caused a  65% 
reduction in hepatic cyp7a1 mRNA.
58
 Nevertheless it should be mentioned that 
cyp7a1 is also regulated directly by fibrates via a negative PPRE in its promoter 
sequence.
59
 A reduction in LXRα might also explain the reduction of abca1 
expression.
60
 In addition to these mechanisms explaining reduced CETP 
expression by fenofibrate, a potential PPRE in the promoter region of CETP 
was recently identified,
61
 which provides the possibility for direct regulation of 
CETP by PPARα agonists, although it is unclear whether this potential PPRE is 
functional.  
Our finding that fenofibrate reduced CETP activity in E3L.CETP mice 
corroborates the outcome of two human studies. Although one study failed to 
detect an effect of fenofibrate on plasma CETP activity,
62
 fenofibrate treatment 
did decrease CETP activity by 26% in subjects with combined hyperlipidemia
24
 
and by 18% in subjects with the metabolic syndrome.
63
 Based on our 
experimental study, the fenofibrate-induced decrease in CETP activity in 
humans is likely also a causal factor for the generally observed increase in 
HDL-cholesterol. 
Fibrate treatment has been associated with a reduction of cardiovascular 
disease.
5
 The recent FIELD study, which assessed the effects of fenofibrate on 
cardiovascular risk in subjects with type 2 diabetes mellitus in a long-term, 
controlled trial, showed a reduction in total cardiovascular events, but did not 
reveal a reduced risk of the primary outcome of coronary events.
64
 Nevertheless, 
the authors suggested that a more beneficial outcome might have been masked 
by a larger portion of statin treatment in the placebo group as compared with the 
fenofibrate group. Even though the benefit of an increase in HDL-cholesterol by 
CETP inhibition is still under debate,
65-68
 and despite the recent failure of the 
CETP inhibitor torcetrapib in the ILLUMINATE study,
69
 increasing HDL-
cholesterol levels is still generally considered anti-atherogenic. Besides the 
ability of fibrates to potently reduce plasma TG, their concomitant effect on 
increasing HDL by reducing CETP expression may thus be an additional 
Fenofibrate increases HDL by reducing CETP expression 
 57 
advantageous anti-atherogenic property. We speculate that combination 
therapies of fibrates (i.e., reducing CETP expression) with small molecule 
CETP inhibitors (i.e., reducing plasma CETP activity) may help to further 
reduce cardiovascular risk. 
Together, our data show that fenofibrate increases HDL-cholesterol by reducing 
CETP expression and plasma CE transfer activity in E3L.CETP mice. 
Therefore, we postulate that reduction of CETP expression also contributes to 
the increase in HDL that is found in human subjects treated with fibrates. 
Furthermore, we anticipate that the E3L.CETP mouse is a valuable model in 
which to test the effect of combination therapies (i.e., fibrates and CETP 
inhibitors) on plasma lipid metabolism and atherosclerosis.  
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Abstract 
 
Objective: In addition to lowering low-density lipoprotein (LDL)-cholesterol, 
statins modestly increase high-density lipoprotein (HDL)-cholesterol in humans 
and decrease cholesteryl ester transfer protein (CETP) mass and activity. Our 
aim was to determine whether the increase in HDL depends on CETP 
expression. 
 
Methods and results: APOE*3-Leiden (E3L) mice, with a human-like 
lipoprotein profile and a human-like responsiveness to statin treatment, were 
crossbred with mice expressing human CETP under control of its natural 
flanking regions resulting in E3L.CETP mice. E3L and E3L.CETP mice were 
fed a Western-type diet with or without atorvastatin. Atorvastatin (0.01% in the 
diet) reduced plasma cholesterol in both E3L and E3L.CETP mice (-26% and -
33%, P<0.05), mainly in VLDL, but increased HDL-cholesterol only in 
E3L.CETP mice (+52%). Hepatic mRNA expression levels of genes involved in 
HDL metabolism, such as phospholipid transfer protein (Pltp), ATP-binding 
cassette transporter A1 (Abca1), scavenger receptor class B type I (Sr-b1), and 
apolipoprotein AI (Apoa1), were not differently affected by atorvastatin in 
E3L.CETP mice as compared to E3L mice. However, in E3L.CETP mice, 
atorvastatin down-regulated the hepatic CETP mRNA expression (-57%; 
P<0.01) as well as the total CETP level (-29%) and CE transfer activity (-36%; 
P<0.05) in plasma. 
 
Conclusions: Atorvastatin increases HDL-cholesterol in E3L.CETP mice by 
reducing the CETP-dependent transfer of cholesterol from HDL to (V)LDL, as 
related to lower hepatic CETP expression and a reduced plasma (V)LDL pool. 
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Introduction 
 
Epidemiological studies have established that a high level of low-density 
lipoprotein (LDL)-cholesterol is a major cardiovascular risk factor. In the past 
decades, statins have been successfully used to reduce LDL-cholesterol. Statins 
inhibit the rate-limiting enzyme of cholesterol synthesis, i.e. 3-hydroxy-3-
methylglutaryl coenzyme A (HMGCoA) reductase, resulting in hepatic 
depletion of cholesterol. As a consequence, VLDL production is reduced and 
the hepatic expression of the LDL receptor (LDLr) is upregulated, leading to 
decreased plasma cholesterol levels in apoB-containing lipoproteins (i.e., VLDL 
and LDL).
1
 Indeed, a meta-analysis of 25 studies indicated that statins reduce 
LDL-cholesterol levels by 20-40%.
2
 In addition, statins elevate high-density 
lipoprotein (HDL)-cholesterol levels by typically 5-15%.
3-5
 This effect is 
already observed at a low dose (20 mg/day) while higher doses (40 and 80 
mg/day) have no additional elevating effects on HDL levels.
3-5
 
Low HDL-cholesterol has been confirmed as a strong and independent risk 
factor for cardiovascular disease. An increase in HDL-cholesterol of 1 mg/dL 
results in a 2-3% decrease in cardiovascular risk.
6
 One of the key players in 
HDL-metabolism is cholesteryl ester transfer protein (CETP). CETP is involved 
in the exchange of triglycerides (TG) and cholesteryl esters (CE) between 
lipoproteins, resulting in the net flux of CE from HDL towards apoB-containing 
lipoproteins (e.g. VLDL and LDL) in exchange for TG.
7
 Treatment of patients 
with combined hyperlipidemia with atorvastatin resulted in increased levels of 
relatively CE-rich large HDL2a with a concomitant decrease in CE-poor small 
HDL3c,
8
 as associated with a reduction in CETP mass.
8
 Likewise, in type 2 
diabetic subjects carrying the CETP TaqIB polymorphism, the increase in HDL-
cholesterol (+7.2%) after atorvastatin treatment was correlated with a reduction 
in CETP mass (-32%).
9
 These data suggest that the effects of statin treatment on 
HDL-cholesterol levels may actually be caused by a reduction in the CETP-
mediated transfer of CE.  
Therefore, the aim of this study was to evaluate whether the statin-induced 
increase in HDL-cholesterol would depend on CETP expression. Previously, we 
demonstrated that APOE*3-Leiden (E3L) mice, with a human-like lipoprotein 
profile
10
 show a human-like response to atorvastatin with reduced (V)LDL-
cholesterol levels accompanied by reduced VLDL production.
11
 In the current 
study, these mice were crossbred with mice expressing human CETP under 
control of the natural flanking regions, resulting in E3L.CETP mice.
12
 We 
treated E3L and E3L.CETP mice with atorvastatin to investigate whether CETP 
expression contributes to the HDL-raising effect of atorvastatin.  
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Methods 
 
Animals 
Hemizygous human CETP transgenic (CETP) mice, expressing a human CETP 
minigene under the control of natural flanking sequences were crossbred with 
hemizygous E3L mice
10
 at our Institutional Animal Facility to obtain E3L
 
and 
E3L.CETP littermates (C57Bl/6J background).
12
 In this study, mice were 
housed under standard conditions in conventional cages with free access to food 
and water. Male mice were fed a semi-synthetic diet containing 15% (w/w) fat 
(Hope Farms, Woerden, The Netherlands), supplemented with 0.25% (w/w) 
cholesterol (Sigma, St. Louis, MO) for two weeks. Subsequently, the mice 
received the same diet without or with 0.01% (w/w) atorvastatin (Lipitor
®
20, 
Pfizer B.V., Capelle a/d IJssel, The Netherlands) for 6 weeks (i.e. approx. 10 
mg/kg/day, which corresponds to a dose of 70 mg/day for an average 70 kg 
person, assuming a 10-fold higher metabolic rate in mice as compared to 
humans). To study whether atorvastatin sorts similar effects in female mice, and 
to evaluate the dose-response relationship, female E3L.CETP mice were fed a 
diet containing 15% (w/w) fat, supplemented with 0.1% (w/w) cholesterol and 
0.001% or 0.01% of atorvastatin for two weeks successively. Experiments were 
performed after 4 h of fasting at 12:00 pm with food withdrawn at 8:00 am, 
unless indicated otherwise. The institutional Ethical Committee on Animal Care 
and Experimentation has approved all experiments.  
  
Plasma lipid and lipoprotein analysis 
Plasma was obtained via tail vein bleeding and assayed for total cholesterol 
(TC) using the enzymatic kit 236691 (Roche Molecular Biochemicals, 
Indianapolis, IN, U.S.A.). The distribution of lipids over plasma lipoproteins 
was determined by fast-performance liquid chromatography (FPLC) as 
described previously.
12
 
 
Hepatic liver lipid levels  
Livers were isolated from control-treated and atorvastatin-treated mice after 
cervical dislocation. A small piece of liver was homogenated in 400 µL PBS 
and 1.5 mL CH3OH:CHCl3 (2:1, v/v) was added. After centrifugation, lipids 
were extracted from the supernatant with CHCl3 and H2O (1:1, v/v) and the 
CHCl3 phase was dried. Lipids were dissolved in H2O with 2% Triton-X100. 
TC levels were assayed as described above. Free cholesterol (FC) was analyzed 
with the Free Cholesterol C kit (WAKO, Neuss, Germany), and cholesteryl 
esters (CE) were determined as the difference between TC and FC. 
Phospholipids (PL) and TG were analyzed with the, phospholipids B kits 
(Wako, Neuss Germany) and the enzymatic kit 1488872 (Roche Molecular 
Biochemicals, Indianapolis, IN, U.S.A.), respectively. 
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Plasma CETP level 
The total CETP level in plasma was measured as the transfer of [
3
H]cholesteryl 
oleate from exogenous human LDL to HDL as described.
12
  
 
Plasma cholesteryl ester transfer activity 
The transfer of newly synthesized CE in plasma was assayed by a radioisotope 
method as previously described.
13
 In short, [
3
H]cholesterol was complexed with 
BSA and incubated overnight at 4°C with mouse plasma to equilibrate with 
plasma free cholesterol. Subsequently, the plasma samples were incubated for 3 
h at 37°C. VLDL and LDL were then precipitated by addition of sodium 
phophotungstate/MgCl2. Lipids were extracted from the precipitate by 
methanol: hexane (1:2, v/v) and [
3
H]CE was separated from [
3
H]cholesterol on 
silica columns, followed by counting of radioactivity. 
 
Plasma apoAI concentration 
Plasma apoAI concentrations were determined using a sandwich ELISA. 
Hereto, rabbit anti-mouse apoAI polyclonal antibody (ab20453; Abcam plc, 
Cambridge, UK) was coated overnight onto Costar strips (Costar, Inc., New 
York, NY) (3 µg/ml) at 4°C and incubated with diluted mouse plasma (dilution 
1:400,000) for 90 min at 37°C. Subsequently, goat anti-mouse apoAI antibody 
(600-101-196; Rockland Immunochemicals, Inc., Gilbertsville, PA; dilution 
1:3000) was added and incubated for 90 min at 37°C. Finally, horse radish 
peroxidase (HRP)-conjugated rabbit anti-goat IgG antibody (605-4313; 
Rockland; dilution 1:15000) was added and incubated for 90 min at 37°C, and 
HRP was detected by incubation with tetramethylbenzidine (Organon Teknika, 
Table 1. Primers for quantitative real-time PCR analysis. 
Gene Forward primer (5'-3') Reverse primer (5'-3') 
Hmgcoa red. CCGGCAACAACAAGATCTGTG ATGTACAGGATGGCGATGCA 
Pltp TCAGTCTGCGCTGGAGTCTCT AAGGCATCACTCCGATTTGC 
Abca1 CCCAGAGCAAAAAGCGACTC GGTCATCATCACTTTGGTCCTTG 
Sr-b1 GTTGGTCACCATGGGCCA CGTAGCCCCACAGGATCTCA 
Apoa1 GGAGCTGCAAGGGAGACTGT TGCGCAGAGAGTCTACGTGTGT 
CETP CAGATCAGCCACTTGTCCAT CAGCTGTGTGTTGATCTGGA 
Abcg5 TGTCCTACAGCGTCAGCAACC GGCCACTCTCGATGTACAAGG 
Abcg8 GACAGCTTCACAGCCCACAA GCCTGAAGATGTCAGAGCGA 
Lpl GTGGCCGAGAGCGAGAAC TCCACCTCCGTGTAAATCAAGA 
Srebp-1c GGAGCCATGGATTGCACATT CCTGTCTCACCCCCAGCATA 
Ldlr GCATCAGCTTGGACAAGGTGT GGGAACAGCCACCATTGTTG 
 
Abca1, ATP-binding cassette transporter A1; Abcg5/8, ATP-binding cassette transporter 
G5/G8, Apoa1, apolipoprotein AI; CETP, cholesteryl ester transfer protein; Hmgcoa 
reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase; Ldlr, low density lipoprotein 
receptor; Lpl, lipoprotein lipase; Pltp, phospholipid transfer protein; Sr-b1, scavenger 
receptor class B type I; Srepb-1c, sterol regulatory element-binding protein-1c. 
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Boxtel, The Netherlands) for 15 min at room temperature. Purified mouse 
apoAI (A23100m; Biodesign International, Saco, Maine, USA) was used as a 
standard. 
 
Hepatic mRNA expression and SR-BI protein analysis 
Livers were isolated after cervical dislocation. Total RNA was isolated using 
the NucleoSpin
®
 RNA II kit (Macherey-Nagel, Düren, Germany) as 
recommended by the manufacturer. RNA expression was determined in 
duplicate by real-time PCR on a MyiQ Single-Color real-time PCR detection 
system (Bio-Rad Laboratories, Hercules, CA, U.S.A.). Primers are listed in 
online Table 1. Expression levels were normalized, using hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) and cyclophilin as housekeeping genes.
14
 
Hepatic SR-BI protein was determined by immunoblot analysis exactly as 
described previously.
15
  
 
Statistical analysis 
All data are presented as means ± SD unless indicated otherwise. Data were 
analyzed using the unpaired Student’s t test unless indicated otherwise. P-values 
less than 0.05 were considered statistically significant. SPSS 12.0.01 was used 
for statistical analysis. 
 
Results 
 
Atorvastatin increases HDL-cholesterol in E3L.CETP mice 
On a diet containing 0.25% (w/w) cholesterol, atorvastatin (0.01%, w/w) 
reduced plasma total cholesterol in both E3L mice from 5.1 ± 0.9 mM to 3.8 ± 
1.2 mM (-26%; P<0.05) and E3L.CETP mice from 4.3 ± 0.8 mM to 2.9 ± 1.0 
mM (-33%; P<0.05) (Fig. 1), without substantially affecting TG levels (not 
shown). These effects were reflected by a strong decrease in (V)LDL-
cholesterol in E3L mice (-86%) and E3L.CETP mice (-88%) (Fig. 2). However, 
whereas atorvastatin did not affect HDL-cholesterol E3L mice (3.2 mM vs 2.9 
mM) (Fig. 2A), it did raise HDL-cholesterol (+52%) in E3L.CETP mice (2.1 
mM vs 1.4 mM) (Fig. 2B).  
Figure 1. Effect of atorvastatin on 
plasma total cholesterol levels. E3L 
(A) and E3L.CETP (B) mice 
received a diet containing 0.25% 
(w/w) cholesterol without (white 
bars) or with (black bars) 0.01% 
(w/w) atorvastatin for 6 weeks. 
Plasma was obtained, and assayed 
for total cholesterol. Values are 
means ± SD (n=6 per group). 
*P<0.05 compared to control. 
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Figure 2. Effect of atorvastatin on the distribution of cholesterol over lipoproteins. E3L (A) 
and E3L.CETP (B) mice received a cholesterol-containing diet without (white circles) or with 
(black circles) atorvastatin for 6 weeks. Plasmas of the various mouse groups were pooled 
(n=6 per group). Lipoproteins were separated by FPLC, and fractions were analyzed for 
cholesterol. 
 
 
 
 
 
Atorvastatin also reduced cholesterol levels in the liver of E3L mice (-24%) and 
E3L.CETP mice (-32%) (P<0.05). This decrease in hepatic cholesterol was 
mainly confined to the cholesteryl ester content in E3L mice (-38%) and 
E3L.CETP mice (-60%) (P<0.05)(Fig. 3).  
  
Atorvastatin does not differentially affect hepatic mRNA expression of genes 
involved in HDL metabolism in E3L versus E3L.CETP mice 
Atorvastatin increased the hepatic expression of Hmgcoa reductase both in E3L 
mice (2.5-fold; P<0.05) and in E3L.CETP mice (2.8-fold; P<0.05) (Fig. 4). 
Concomitantly, Ldlr expression was increased in E3L mice (+22%) and 
E3L.CETP mice (+24%) (not shown). These effects are in line with previous 
observations in E3L mice,
16
 and likely reflect an attempt of the liver to maintain 
its cholesterol balance. 
Since atorvastatin may affect PLTP, ABCA1, SR-BI, and apoAI, which are 
crucially involved in HDL metabolism, and may account for the increase in 
HDL-cholesterol in E3L.CETP mice upon atorvastatin treatment, we examined 
the effect of atorvastatin on their hepatic mRNA expression (Fig. 4). The 
expression of these genes was not substantially different in E3L.CETP mice as 
compared to E3L mice (<16%, not significant). Atorvastatin tended to increase 
the expression of Pltp, involved in remodeling of HDL by mediating transfer of 
phospholipids between lipoproteins, in E3L mice (+34%) and E3L.CETP mice 
(+69%), which did not reach statistical significance. The expression of Abca1, 
which is an important determinant for HDL formation, was decreased by  
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atorvastatin in E3L mice (-59%; P<0.05) and E3L.CETP mice (-45%; P<0.05) 
to a similar extent. The expression of Sr-b1, which is largely involved in the 
selective uptake of HDL-CE in mice, tended to be decreased in E3L (-30%) and 
E3L.CETP (-27%) mice, but hepatic SR-BI protein levels were unaffected in 
both mouse groups (not shown). Also, in both types of mice, atorvastatin did not 
increase hepatic Apoa1 expression or the plasma apoAI levels (not shown). 
Atorvastatin thus affects the mRNA expression of Pltp, Abca1, Sr-b1, and 
Apoa1 to a similar extent in E3L and E3L.CETP mice, and is thus unlikely to 
explain the differentially raised HDL in E3L.CETP mice as compared to E3L 
mice.  
In general, atorvastatin tended to decrease the expression of LXR target genes, 
including Abcg5 (-2% and -38%), Abcg8 (-26% and -46%), Lpl (-85% and -
77%) and Srebp-1c (-31% and -32%) in E3L and E3L.CETP mice, respectively. 
 
Atorvastatin decreases hepatic CETP mRNA expression and cholesteryl ester 
transfer activity in plasma of E3L.CETP mice 
To investigate whether atorvastatin increases HDL-cholesterol in E3L.CETP 
mice by reduction of CETP activity, we determined the hepatic CETP mRNA 
expression, the total plasma CETP level, and the CE transfer activity in plasma 
(Fig. 5). Indeed, atorvastatin markedly decreased CETP expression in 
E3L.CETP mice (-57%; P<0.01) (Fig. 5A). This effect was accompanied by a 
trend towards a reduction in the total plasma CETP level (-29%), which did not 
reach statistical significance, probably related to the relatively high variation in 
combination with the limited group size (Fig. 5B). Additionally, the CE transfer 
activity in plasma of E3L.CETP mice was reduced (-36%; P<0.05) (Fig. 5C). 
Taken together, the HDL-raising effect of atorvastatin in E3L.CETP mice 
appears a direct consequence of reduced CETP expression. 
Figure 3. Effect of atorvastatin on hepatic lipid levels. E3L (A) and E3L.CETP (B) mice 
were fed a cholesterol-containing diet without (white bars) or with (black bars) atorvastatin. 
After 6 weeks, livers were collected and lipids were extracted. Total cholesterol (TC), free 
cholesterol (FC), cholesteryl esters (CE), triglycerides (TG) and phospholipids (PL) were 
quantified. Values are means ± SD (n=3-5 per group). *P<0.05 compared to control. 
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Atorvastatin dose-dependently decreases CETP and increases HDL  
To determine whether atorvastatin also reduces CETP and increases HDL-
cholesterol in female mice, and to evaluate whether these effects would be dose-
dependent, female E3L.CETP mice were fed a cholesterol-containing diet that 
successively contained 0.001% and 0.01% of atorvastatin (w/w) for two weeks 
each. Atorvastatin dose-dependently decreased plasma cholesterol (-34% and -
71%, P<0.01). This was accompanied by a dose-dependent increase in HDL-
cholesterol levels (+118% and +176%) and reductions in total plasma CETP 
activity (-31% and -61%; P<0.01) (not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effect of atorvastatin on hepatic mRNA expression of genes. E3L (A) and 
E3L.CETP (B) mice were fed a cholesterol-containing diet without (white bars) or with 
(black bars) atorvastatin. After 6 weeks, livers were collected to determine mRNA 
expression. Values are expressed as means ± S.E. relative to control mice (n=4 per group). 
*P<0.05 compared to control. 
Figure 5. Effect of atorvastatin on hepatic CETP mRNA expression and cholesteryl ester 
transfer activity in plasma. E3L.CETP mice were fed a cholesterol-containing diet without 
(white bars) or with (black bars) atorvastatin. After 6 weeks, livers were collected to 
determine CETP mRNA expression (A), and plasma was assayed for total CETP level (B) 
and CE transfer activity (C). Values are means ± SD (n=4-6 per group). *P<0.05; **P<0.01. 
C
E
T
P
 m
R
N
A
 e
x
p
re
ss
io
n
 (
%
 o
f 
co
n
tr
o
l)
0
20
40
60
80
100
120
C
on
tro
l
A
to
rv
a
0
50
100
150
200
C
h
o
le
st
er
y
l 
es
te
r 
tr
an
sf
er
 a
ct
iv
it
y
In
 p
la
sm
a 
(n
m
o
l/
m
L
/h
)
BA
**
0
200
400
600
800
T
o
ta
l 
p
la
sm
a 
C
E
T
P
 l
ev
el
 (
n
m
o
l/
m
L
/h
)
*
C
C
on
tro
l
A
to
rv
a
C
on
tro
l
A
to
rv
a
C
E
T
P
 m
R
N
A
 e
x
p
re
ss
io
n
 (
%
 o
f 
co
n
tr
o
l)
C
h
o
le
st
er
y
l 
es
te
r 
tr
an
sf
er
 a
ct
iv
it
y
In
 p
la
sm
a 
(n
m
o
l/
m
L
/h
)
T
o
ta
l 
p
la
sm
a 
C
E
T
P
 l
ev
el
 (
n
m
o
l/
m
L
/h
)
0
100
200
300
400
H
m
gc
oa
re
d
Pl
tp
A
bc
a1
Sr
-b
1
A
po
a1
m
R
N
A
 e
x
p
re
ss
io
n
 (
%
 o
f 
co
n
tr
o
l)
0
100
200
300
400
H
m
gc
oa
re
d
Pl
tp
A
bc
a1
Sr
-b
1
A
po
a1
*
*
*
B E3L.CETPA E3L
*
m
R
N
A
 e
x
p
re
ss
io
n
 (
%
 o
f 
co
n
tr
o
l)
Chapter 3 
   72
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 6. Proposed mechanism underlying the HDL-raising effect of statins. See text for 
explanation. CE, cholesteryl ester; TG, triglyceride. 
 
Discussion 
 
E3L mice respond to statin treatment with respect to lowering of apoB-
containing lipoproteins and reduced atherosclerosis development similarly as 
humans,
11,16,17
 whereas statins do not affect or even increase plasma cholesterol 
levels in apoE-deficient mice
18,19
 and LDL receptor-deficient mice.
20
 However, 
whereas statins increase HDL in humans, atorvastatin and rosuvastatin did not 
increase HDL levels in E3L mice.
11,16,17
 
To investigate whether the statin-induced elevation of HDL-cholesterol in 
humans depends on CETP expression, we crossbred E3L mice with human 
CETP transgenic mice. We found that atorvastatin decreased (V)LDL in both 
E3L and E3L.CETP mice but increased the steady-state HDL-cholesterol level 
only in E3L.CETP mice, which was not observed in E3L littermates. We 
previously showed that atorvastatin reduces plasma cholesterol in E3L mice by 
reducing VLDL production.
11
 Since atorvastatin similarly reduces (V)LDL 
cholesterol in E3L.CETP mice as compared to E3L mice, and CETP expression 
per se does not affect VLDL production,
21
 it is likely that the mechanisms by 
which atorvastatin reduces (V)LDL-cholesterol are similar in E3L.CETP mice 
and E3L mice. In addition, the mild increase in LDLr expression in both E3L 
and E3L.CETP mice may contribute to lower plasma cholesterol levels. The 
increase in HDL was accompanied by decreased hepatic CETP mRNA 
expression levels with a concomitant reduction in plasma CE transfer activity. 
Apparently, the fact that mice naturally lack CETP expression prevents the 
atorvastatin-induced increase in HDL-cholesterol in mice. 
Since several additional key players in HDL metabolism might have been 
affected differently by atorvastatin treatment in E3L.CETP as compared to E3L 
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mice, and thus participate in the HDL-cholesterol raising effect, we have also 
evaluated the effect of atorvastatin on the hepatic expression of Apoa1, Abca1, 
Pltp, and Sr-b1. ApoAI is involved in the generation formation nascent HDL 
particles,
22
 which acquire cholesterol via ABCA1. In fact, the HDL-cholesterol 
level in mice is largely determined by the hepatic expression of ABCA1.
23
 
PLTP plays an important role in the remodeling of HDL, by facilitating 
phospholipid transfer to HDL during its maturation from discoidal HDL into 
spherical HDL.
24
 Finally, at least in mice, hepatic SR-BI is crucially involved in 
the selective uptake of HDL-CE.
25
 We found that atorvastatin did not affect the 
hepatic expression of Pltp, Sr-b1, and Apoa1. Atorvastatin did decrease Abca1 
expression in E3L and E3L.CETP mice. However, since a decreased Abca1 
expression would be expected to lower HDL levels, it also cannot be a causal 
factor for the selective elevation of HDL in E3L.CETP mice. Previous 
experiments in mice in which hepatic ABCA1 expression levels were 
modulated specifically, have shown a causal relationship between hepatic 
ABCA1 expression and plasma HDL-cholesterol. In our study, atorvastatin 
primarily decreases CETP expression as related to a reduced hepatic cholesterol 
content. We speculate that, as a consequence rather than as a cause, the liver 
attempts to maintain its cholesterol balance by an upregulation of LDL 
receptors to enhance cholesterol influx and a down-regulation of ABCA1 to 
decrease cholesterol efflux. 
Taken together, the selective raise in HDL-cholesterol in E3L.CETP mice 
cannot be explained by atorvastatin-mediated effects on apoAI, ABCAI, PLTP, 
or SR-BI, but is primarily caused by the reduction in CETP expression. Both a 
decrease in plasma CETP activity and a reduction in (V)LDL (i.e. acceptor of 
HDL-CE) can account for a reduction in CE transfer activity, which in its turn 
causes the increase in HDL-cholesterol. In addition to its transfer activity, 
CETP has also been implicated in the direct
26
 and in the SR-BI-mediated
27
 
HDL-CE uptake by hepatocytes. Inhibition of these uptake pathways by 
atorvastatin via reducing cellular CETP may thus potentially also contribute to 
the increase in HDL-cholesterol. 
The atorvastatin-induced down-regulation of CETP expression is presumably 
caused by a reduction in plasma and hepatic cholesterol levels. Cholesterol 
feeding of CETP transgenic mice increases hepatic CETP mRNA expression via 
an LXR responsive element in the CETP promoter.
28
 Conversely, atorvastatin 
may down-regulate CETP expression by reducing LXR signaling, as 
atorvastatin reduced plasma and hepatic cholesterol levels
16
 and consequently 
probably also hepatic oxysterols, the natural ligands of LXRα. In line with this 
hypothesis, the expression of other LXR target genes such as ABCG5, ABCG8, 
LPL and SREBP-1c were also reduced upon atorvastatin treatment. In addition, 
the CETP promoter activity is affected by several other regulatory transcription 
factors,
7
 which alone or in combination could also be responsible for decreased 
transcription. The fact that atorvastatin treatment of humans also decreases 
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plasma CETP
8,9
 may well be explained by similar regulation of CETP 
expression. 
Based on our collective data, we thus propose the following mechanism by 
which statins raise HDL-cholesterol, as summarized in Fig. 6. By inhibiting 
HMGCoA reductase activity, statins decrease the hepatic lipid content. This 
results in decreased (V)LDL levels by a lower VLDL production and a higher 
(V)LDL clearance. In addition, reduction in hepatic cholesterol results in 
reduced levels of hepatic oxysterols (i.e. the natural ligands of LXRα) and, 
consequently, decreased LXRα-induced hepatic expression of CETP. Therefore, 
the HDL-cholesterol levels are raised by lower (V)LDL levels and lower CETP 
expression, resulting in decreased CE transfer activity from HDL to (V)LDL. 
Clinical studies have established that statins improve the survival rate of 
patients with hypercholesterolemia and coronary artery disease by lowering 
LDL-cholesterol and by their pleiotropic anti-inflammatory effects.
29
 However, 
a high residual cardiovascular risk still remains.
3
 Even with aggressive 
atorvastatin treatment in the PROVE-IT study, the risk remained 60-70% 
despite greater protection against death or major cardiovascular events.
30
 
Therefore, concomitant raising of HDL-cholesterol is generally considered to 
enhance the anti-atherogenic potential of statins. Since our novel E3L.CETP 
mouse model is responsive to modulation of apoB-containing lipoproteins as 
well as HDL levels, we anticipate that our mouse model will be valuable to 
study the effect of such HDL-raising therapeutic strategies, alone or in 
combination with (V)LDL-lowering strategies, on plasma lipid metabolism and 
atherosclerosis development, and to study the underlying mechanisms. 
In conclusion, our results show that atorvastatin increases HDL-cholesterol by 
reducing the hepatic CETP expression and plasma CE transfer activity in 
E3L.CETP mice. Therefore, we postulate that reduction of CETP expression 
contributes to the increase in HDL that is found in human subjects treated with 
statins. 
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Abstract 
 
Objective: Niacin potently decreases plasma triglycerides and LDL-cholesterol. 
In addition, niacin is also the most potent HDL-cholesterol increasing drug used 
in the clinic. In the present study, we aimed at elucidation of the mechanism 
underlying its HDL-raising effect. 
 
Methods and Results: In APOE*3Leiden transgenic mice expressing the human 
CETP transgene, niacin dose-dependently decreased plasma triglycerides (up to 
-77%, P<0.001) and total cholesterol (up to -66%, P<0.001). Concomitantly, 
niacin dose-dependently increased HDL-cholesterol (up to +87%, P<0.001), 
plasma apoAI (up to +72%, P<0.001), as well as the HDL particle size. In 
contrast, in APOE*3Leiden mice not expressing CETP, niacin also decreased 
total cholesterol and triglycerides but did not increase HDL-cholesterol. In fact, 
in APOE*3Leiden.CETP mice, niacin dose-dependently decreased the hepatic 
expression of CETP (up to -88%; P<0.01) as well as plasma CETP mass (up to -
45%, P<0.001) and CETP activity (up to -52%, P<0.001). Additionally, niacin 
dose-dependently decreased the clearance of apoAI from plasma and reduced 
the uptake of apoAI by the kidneys (up to -90%, P<0.01).  
 
Conclusion: Niacin markedly increases HDL-cholesterol in 
APOE*3Leiden.CETP mice by reducing the CETP activity, as related to lower 
hepatic CETP expression and a reduced plasma (V)LDL pool, and increases 
HDL-apoAI by decreasing the clearance of apoAI from plasma.  
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Introduction 
 
Dyslipidemia is an important risk factor for the development of cardiovascular 
disease (CVD). Although lowering of LDL-cholesterol (C) by e.g. statins 
reduces CVD risk by approximately 30%, substantial residual cardiovascular
 
risk remains, even with very aggressive reductions in levels
 
of LDL-C.
1-3
 
Because of clinical studies, which have shown that HDL-C, independently of 
LDL-C, is inversely correlated with the risk of CVD,
4,5
 attention has shifted 
toward strategies for targeting HDL composition as adjunctive therapy to 
prevent
 
and treat CVD. Current strategies to mildly increase HDL-C levels 
include aggressive overall lifestyle modification (i.e. exercise, diet, weight loss, 
and smoking cessation), and modest increases in HDL-C levels are achieved 
with statins
6
 and fibrates (5-10%).
7
 
Niacin (nicotinic acid, vitamin B3) has been described to exhibit lipid-
modifying capacities already since the 1950s. Since then various (clinical) 
studies have shown the beneficial effects of niacin on plasma lipid levels. 
Treatment with niacin alone was associated with a 27% reduction in non-fatal 
myocardial infarction and it reduced all cause mortality by 11%.
8,9
 In 
combination with colestipol (FATS trial) or simvastatin (HATS trial), niacin 
reduced cardiac events by as much as 80-90%.
10,11
 These potent atherogenic 
properties of niacin are thought to be attributable to its marked HDL-elevating 
effect (+20% to +30%), besides it potent effect on reducing plasma TG (-40% to 
-50%) and LDL-C (-20%).
7,12
 In fact, niacin is currently the most effective 
therapy for elevating HDL-C. 
The mechanism underlying the ability of niacin to reduce the plasma (V)LDL 
level has been well-studied. By selective binding to GPR109A on adipocytes, 
niacin suppresses hormone sensitive triglyceride lipase (HSL) activity, resulting 
in a decreased release of free fatty acids (FFA) from adipose tissue and 
decreased plasma FFA levels.
13
 The resulting reduced supply of FFA towards 
the liver is believed to bring about a decreased hepatic VLDL-TG production, 
resulting in reduced VLDL-TG and (V)LDL-C levels.
13,14
 In contrast, the 
mechanism underlying the HDL-C raising effect of niacin has not been 
elucidated as yet. This is probably related to the lack of suitable animal models 
that respond in a human-like manner to HDL-raising drug interventions. In 
wild-type mice and apoE-knockout mice (the classical animal model for 
hyperlipidemia and atherosclerosis), rats and dogs, niacin only transiently 
reduced plasma levels of TG but failed to failed to raise HDL-C.
15,16
 An HDL-
C-elevating effect of niacin has been reported in rabbits, but with 30% ethanol 
as dosing vehicle and only after 12 weeks of treatment.
17
 
Therefore, the aim of this study was to elucidate the mechanism underlying the 
HDL-C raising effect of niacin. To this end, we used our recently developed 
APOE*3Leiden (E3L).CETP transgenic mouse model. We have previously 
demonstrated that E3L mice have a human-like lipoprotein profile in which the 
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elevated plasma cholesterol and TG levels are mainly confined to the (V)LDL-
sized lipoprotein fractions.
18,19
 These mice develop atherosclerosis upon dietary 
cholesterol feeding and respond in a human-like manner to drugs used in the 
treatment of CVD (e.g. statins, fibrates, cholesterol uptake inhibitors, calcium 
channel blockers and angiotensin II receptor antagonists),
20-23
 but they did not 
yet respond to HDL-modulating interventions. By cross-breeding E3L mice 
with mice expressing human CETP under control of its natural flanking regions, 
E3L.CETP were obtained
24
 that respond to the HDL-raising effects of 
fenofibrate,
25
 atorvastatin
26
 and torcetrapib.
27
 We now fed these mice a 
Western-type diet without or with increasing doses of niacin to reveal the 
mechanism underlying its HDL-C raising effect. 
 
Methods 
 
Animals 
Hemizygous human CETP transgenic (CETP) mice, expressing a human CETP 
minigene under the control of its natural flanking sequences
28
 were purchased 
from the Jackson Laboratory (Bar Harbor, ME) and crossbred with hemizygous 
E3L mice
18
 at our Institutional Animal Facility to obtain E3L
 
and E3L.CETP 
littermates.
24
 In this study, female mice were used, housed under standard 
conditions in conventional cages with free access to food and water. At the age 
of 12 weeks, E3L and E3L.CETP mice were fed a semi-synthetic cholesterol-
rich diet, containing 15% (w/w) fat and 0.25% (E3L) or 0.1% (E3L.CETP) 
(w/w) cholesterol (Western-type diet; Hope Farms, Woerden, The Netherlands) 
for three weeks to obtain similar total cholesterol levels in both strains (about 
12-14 mmol/L). After matching based on total plasma cholesterol (TC), 
triglyceride (TG) levels, and age, mice (n=8 per group) received a Western-type 
diet without or with 0.03% (~36 mg/kg/day), 0.1% (~118 mg/kg/day), 0.3% 
(~360 mg/kg/day) or 1% (~1180 mg/kg/day) niacin (Sigma, St. Louis, MO, 
USA) for at least 3 weeks. These doses correspond well to the doses used in 
humans, if the 10 times faster metabolism of mice as compared to humans is 
taken into account. Experiments were performed after 4 h of fasting at 12:00 pm 
with food withdrawn at 8:00 am, unless indicated otherwise. The institutional 
Ethical Committee on Animal Care and Experimentation has approved all 
experiments.  
 
Plasma lipid and lipoprotein analysis 
Plasma was obtained via tail vein bleeding as described
24
 and assayed for TC, 
TG and phospholipids (PL), using the commercially available enzymatic kits 
236691 and 11488872 (Roche Molecular Biochemicals, Indianapolis, IN, USA) 
and ‘Phospholipids B’ (Instruchemie, The Netherlands), respectively. The 
distribution of lipids over plasma lipoproteins was determined by fast-
performance liquid chromatography (FPLC) using a Superose 6 column as 
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described previously.
24
 HDL-C was isolated by precipitating the apoB-
containing lipoproteins from 20 µL EDTA plasma by adding 10 µL heparin 
(LEO Pharma, The Netherlands; 500 U/mL) and 10 µL 0.2 M MnCl2. Mixtures 
were incubated for 20 min at room temperature and centrifuged for 15 min at 
13,000 rpm at 4°C. In the supernatant HDL-C was measured using enzymatic 
kit 236691 (Roche Molecular Biochemicals, Indianapolis, IN, USA). 
 
Plasma apoAI concentration 
Plasma apoAI concentrations were determined using a sandwich ELISA. 
Hereto, rabbit anti-mouse apoAI polyclonal antibody (ab20453; Abcam plc, 
Cambridge, UK) was coated overnight onto Costar strips (Costar, Inc., New 
York, NY) (at 3 µg/mL) at 4°C and incubated with diluted mouse plasma 
(dilution 1:400,000) for 90 min at 37°C. Subsequently, goat anti-mouse apoAI 
antibody (600-101-196; Rockland Immunochemicals, Inc., Gilbertsville, PA; 
dilution 1:3000) was added and incubated for 90 min at 37°C. Finally, horse 
radish peroxidase (HRP)-conjugated rabbit anti-goat IgG antibody (605-4313; 
Rockland; dilution 1:15000) was added and incubated for 90 min at 37°C. HRP 
was detected by incubation with tetramethylbenzidine (Organon Teknika, 
Boxtel, The Netherlands) for 15 min at room temperature. Purified mouse 
apoAI (A23100m; Biodesign International, Saco, ME, USA) was used as a 
standard. 
 
HDL size by native PAGE 
The HDL size was determined essentially as described.
29
 Total lipoproteins 
were isolated from plasma by ultracentrifugation (5 h at 541,000 g) as the d < 
1.21 g/mL plasma fraction in a TLA 100.3 rotor (Beckman). Lipoproteins (7.5 
µg protein) were loaded onto a 4-20% polyacrylamide Tris.HCl gel (BioRad, 
Hercules, CA, USA) and electrophoresis was performed according to the 
manufacturer’s protocol. Gels were stained with Coomassie Brilliant Blue 
(Merck) and HDL size was compared with globular protein standards (HMW 
native marker kit, GE Healthcare). 
 
Plasma lipolysis 
Post-heparin plasma from overnight fasted mice was collected from the tail vein 
at 20 minutes after intraperitoneal injection of heparin (1.0 U/g body weight). 
Post-heparin plasma triacylglycerol hydrolase activity was determined in the 
presence or absence of 1 mol/L NaCl to estimate the hepatic lipase (HL) 
activity, which was calculated as the portion of total triacylglycerol hydrolase 
activity not inhibited by 1 mol/L NaCl.
30
 
 
Preparation of  
125
I-apoAI-labeled autologous HDL 
ApoAI was radiolabeled at pH 10 with carrier-free 
125
I according to the ICl 
method
31
, and separated from unbound 
125
I by Sephadex G50 gel filtration. 
125
I-
Chapter 4 
 84
apoAI (~75 µg) was incubated with 1.4 mL of plasma from E3L.CETP mice (3 
h at 37°C), and 
125
I-apoAI-HDL was isolated after density gradient 
ultracentrifugation. The specific activity was ~15 cpm /ng HDL protein. 
 
In vivo kinetics of 
125
I-apoAI-labeled HDL 
E3L.CETP mice were injected via the tail vein with 
125
I-apoAI-HDL (40 µg 
protein) in a total volume of 200 µL PBS. At the indicated time points after 
injection, blood was collected from the tail vein to determine the plasma decay 
of 
125
I-apoAI. The total plasma volumes of the mice were calculated from the 
equation V (mL) = 0.04706 x body weight (g), as determined from previous 
125
I-BSA clearance studies.
32
 At 6 h after injection, the mice were sacrificed and 
organs were taken and counted for 
125
I-activity. Values were corrected for serum 
radioactivity present in the liver (84.7 µL/g wet weight), kidneys (135.2 µL/g 
wet weight), skeletal muscle (13.7 µL/g wet weight) and white adipose tissue 
(16.1 µL/g wet weight).
33
 
 
Hepatic lipid analysis 
Liver tissue samples were homogenized in phosphate-buffered saline (approx. 
10% wet w/v), and the protein content was measured according to the method of 
Lowry et al. Lipids were extracted, separated by high-performance thin-layer 
chromatography on silica gel plates and analyzed with TINA2.09 software 
(Raytest Isotopen Messgeräte, Straubenhardt, Germany), as described before.
34
 
 
Hepatic mRNA expression 
Total RNA extraction from liver tissue samples was performed using RNA-Bee 
(Amsbio, Oxon, UK) according to the manufacturer’s instructions. RNA was 
converted to single-stranded cDNA by a reverse transcription procedure 
(Promega) according to the manufacturer’s protocol using random primers. 
cDNA levels were measured by real-time polymerase chain reaction (PCR) 
using the ABI Prism 7700 Sequence Detection System (Applied Biosystems, 
Foster City, CA, USA), according to the manufacturer’s instructions. PCR 
master mix from Eurogentec was used. Primers and probes were obtained from 
Biosource (Nivelles, Belgium). The probes were labelled with 3-BHQ1 and 5-
FAM or 5-TET. The mRNA levels were normalized to mRNA levels of three 
housekeeping genes (i.e., cyclophilin, HPRT and GAPDH). Primers and probes 
used for this study were described previously.
25
 The level of mRNA expression 
for each gene of interest was calculated according to the manufacturer’s 
instructions (Applied Biosystems) as described previously.
35
  
 
CETP mass and activity in plasma
 
Plasma CETP mass was analyzed by ELISA using kit ’CETP ELISA Daiichi’ 
(Daiichi Pure Chemicals Co, Ltd, Tokyo, Japan). Plasma CETP activity was 
measured as the transfer of [
3
H]cholesteryl oleate ([
3
H]CO) from exogenous 
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LDL to HDL as described.
36
 CETP activity was calculated as µmol CE transfer 
per mL plasma per hour.  
 
Biliary lipid secretion 
The common bile duct of anesthetized mice was ligated, the gall bladder was 
cannulated, and bile was collected during 90 minutes.
30
 Cholesterol, PL and 
total bile acids in bile were determined using kits ‘236691’ (Roche Molecular 
Biochemicals, Indianapolis, IN, USA), ‘Phospholipids B’ (Instruchemie, The 
Netherlands) and ‘Total bile acids assay’ (Bio-Stat, UK), respectively. 
 
Fecal excretion of bile acids and neutral sterols 
The mice were housed at 3 mice per cage. Feces produced during 2 subsequent 
periods (48 h each) were separated from the wood shavings by sieving. Aliquots 
of lyophilized feces were used for determination of neutral and acidic sterol 
content by gas-liquid-chromatography procedures as described.
30
 
 
Statistical analysis 
All data are presented as means ± SD unless indicated otherwise. Data were 
analyzed parametrically by 1-way ANOVA followed by Dunnett to correct for 
multiple testing. Probability values less than 0.05 were considered statistically 
significant. SPSS 14.0 was used for statistical analysis. 
 
Results 
 
Niacin decreases plasma lipids in both E3L and E3L.CETP mice, but increases 
HDL only in E3L.CETP mice 
No adverse clinical signs were observed with increasing dosages of niacin as 
indicated by absence of differences in weight gain and plasma ALT levels 
Figure 1. Effect of niacin on lipoprotein profiles. E3L (A) and E3L.CETP (B) mice received 
a Western-type diet without (open circles) or with (closed circles) niacin (118 mg/kg/day) for 
3 weeks. Plasma was pooled per group and the distribution of cholesterol over the individual 
lipoproteins was determined after separation by FPLC.  
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between treatment groups and the control. Treatment of E3L mice with niacin 
(118 mg/kg/day) caused a sustained reduction in plasma TG by -26% (1.4±0.6 
mM vs 1.9±0.6 mM; P<0.05) and in plasma TC by -35% (9.2±3.4 mM vs 
14.2±4.5 mM; P<0.05). Lipoprotein fractionation by FPLC showed that the 
reduction in cholesterol was confined to the apoB-containing lipoproteins 
(V)LDL, whereas HDL-C was not affected (Fig. 1A). An equal dose of niacin 
even more potently reduced plasma TG (-57%, P<0.05) and TC (-44%, 
P<0.01) in E3L.CETP mice. As in E3L mice, the TC-decreasing effect of 
niacin in E3L.CETP mice was caused by a reduction of (V)LDL-C. However, 
whereas niacin did not affect HDL levels in E3L mice, it increased HDL-C in 
E3L.CETP mice (Fig. 1B). In E3L.CETP mice, the effects of niacin on plasma 
TG and TC levels were dose-dependent as shown in figure 2. At the highest 
dose of 1180 mg/kg/day, niacin reduced TG levels by -77% (P<0.001) (Fig. 
2A) and TC levels by -66% (P<0.001) (Fig. 2B). 
 
The HDL-increasing effect of niacin in E3L.CETP mice is dose-dependent 
To investigate whether the HDL-increasing effect of niacin in E3L.CETP mice 
was also dose-dependent, we determined HDL-C concentrations in whole 
plasma after precipitation of apoB-containing lipoproteins by heparin/ MnCl2. 
Indeed, niacin appeared to decrease (V)LDL-C levels up to -79% (P<0.001) 
(Fig. 3A), and to increase HDL-C up to +87% (P<0.001) (Fig. 3B), both in a 
dose-dependent fashion. We next evaluated whether niacin also affects apoAI, 
the main apolipoprotein constituent of HDL. Indeed, niacin dose-dependently 
increased apoAI up to +72% (P<0.001) (Fig. 3C). Whereas niacin thus increases 
both HDL-C and apoAI, the effects on HDL-C at the various doses are 
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Figure 2. Dose-dependent effect of niacin on plasma triglycerides and total cholesterol. 
E3L.CETP mice received a Western-type diet without or supplemented with incremental 
doses of niacin for 3 weeks. Plasma triglycerides (A) and total cholesterol (B) were 
determined. Values are means ± SD (n=8 per group). *P<0.05, **P<0.01, ***P<0.001. 
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somewhat more pronounced than on apoAI,  suggesting that niacin increases the 
lipidation of apoAI. This was reflected by a modest increase of the HDL particle 
size as determined by native PAGE (Fig. 4). Further analyses of the pooled 
HDL fractions showed a decrease in triglycerides (-45%) and an increase in 
cholesteryl ester (+56%) and phospholipids (+66%) (data not shown). Niacin 
did not seem to affect the hepatic synthesis or clearance of HDL, at least judged 
from unchanged hepatic mRNA expression of genes involved in HDL synthesis 
(apoa1, abca1) or clearance (sr-b1; data not shown). Hepatic pltp mRNA 
Figure 3. Dose-dependent effect of niacin 
on (V)LDL-cholesterol, HDL-cholesterol 
and apoAI levels. E3L.CETP mice 
received a Western-type diet without or 
supplemented with incremental doses of 
niacin for 3 weeks. Plasma (V)LDL-C (A), 
HDL-C (B) and apoAI (C) were 
determined. n=8 per group. *P<0.05, 
**P<0.01, ***P<0.001. 
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expression was slightly increased upon niacin treatment (data not shown). In 
plasma niacin did decrease the HL activity, albeit that the effect was not dose-
dependent (maximal reduction of -47% at 118 mg/kg/day; P<0.05). 
 
Niacin increases the residence time of apoAI in plasma  
To evaluate whether the dose- dependently increased plasma apoAI level as 
induced by niacin-treatment was caused by decreased clearance of apoAI from 
plasma, we determined the effect of niacin on the plasma kinetics of 
intravenously injected 
125
I-apoAI-labeled HDL (Fig. 5). Indeed, niacin dose-
dependently increased the residence of 
125
I-apoAI in plasma (Fig. 5A). From the 
mono-exponential decay curves it was calculated that the plasma half-life of 
125
I-apoAI (3.5±0.1 h) was increased by niacin at 118 mg/kg/day (5.5±1.3 h; 
P<0.01) and 1180 mg/kg/day (6.6±1.3 h; P<0.01). This was accompanied by a 
dose-dependent reduction in the uptake of 
125
I-activity by the liver (up to -50%; 
P<0.05) and the kidneys (up to -90%; P<0.01) (Fig. 5B). For comparison, the 
uptake of [
3
H]cholesteryl oleoyl ether-labeled HDL by the liver was much 
larger (approx. 40% of dose/g wet weight), whereas the uptake by the kidneys 
was undetectable (data not shown). 
 
Niacin reduces the hepatic lipid content  
The effects of niacin on plasma lipid metabolism in E3L.CETP mice are 
consistent with a niacin-induced reduction in CETP activity. Because CETP 
expression is regulated by the hepatic cholesterol content,
28
 we first examined 
effects of niacin on liver lipids (Fig. 6A). Niacin decreased the hepatic TG 
content (-38%, P<0.05). This is consistent with the inhibitory effects of niacin 
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Figure 5. Dose-dependent effect of niacin on plasma apoAI kinetics. Mice were injected with 
125
I-apoAI-HDL, and plasma 
125
I activity was determined at the indicated time points (A). 
Thereafter the mice were euthanized and 
125
I activity was determined in the liver, kidneys, 
skeletal (hindlimb) muscle and white adipose tissue (WAT) (B). n=5 per group. *P<0.05, 
**P<0.01. 
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on HSL in adipose tissue,
13
 thereby reducing the trafficking of FFA to the liver 
for TG synthesis. Niacin also decreased the hepatic TC content (-21%, P<0.01), 
which was mainly attributed to a reduction in hepatic cholesteryl esters (-22%, 
P<0.05). This effect was in line with a compensatory increase in hepatic 
Hmgcoared mRNA expression (+232%, P<0.05; not shown). 
 
Niacin decreases hepatic CETP mRNA expression and plasma CETP levels 
The decrease in hepatic cholesterol was indeed accompanied by a dose-
dependent reduction in hepatic CETP mRNA up to -88% (P<0.01) at 1180 
mg/kg/day (Fig. 6B). To evaluate whether the niacin-induced decreased hepatic 
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Figure 7. Dose-dependent effect of niacin on plasma CETP mass and activity. E3L.CETP 
mice received a Western-type diet without or supplemented with incremental doses of niacin 
for 3 weeks. Plasma CETP mass (A) and CETP activity (B) were determined. Values are 
means ± SD (n=8 per group). *P<0.05, ***P<0.001. 
Figure 6. Effect of niacin on hepatic lipid content and CETP mRNA expression. E3L.CETP 
mice received a Western-type diet without (open bars) or with (closed bars) niacin. Hepatic 
triglycerides (TG), total cholesterol (TC), free cholesterol (FC) and cholesteryl esters (CE) 
quantified (A) and CETP mRNA expression was measured (B). *P<0.05, **P<0.01.  
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CETP mRNA expression was reflected by reduced CETP levels in plasma, we 
determined both CETP mass (Fig. 7A) and activity (Fig. 7B). Indeed, niacin 
dose-dependently decreased plasma CETP mass and CETP activity to a similar 
extent (up to -45% and -52%; P<0.001).  
 
Table 1. Effect of niacin on biliary and fecal lipid output.  
 Control Niacin 118 
mg/kg/d 
Niacin 1180 
mg/kg/d 
 
Bile 
   
Bile flow (µL/min/100g bw) 2.0 ± 0.5 2.0 ± 0.4 2.3 ± 0.7 
Bile acid output (nmol/min/100g bw)   50 ± 14 67 ± 18 65 ± 25 
Cholesterol output (nmol/min/100g bw) 1.1 ± 0.3 1.1 ± 0.2 1.1 ± 0.2 
Phospholipid output (nmol/min/100g bw) 14 ± 3 14 ± 3 16 ± 5 
    
Feces    
Neutral sterols (Fmol/100g bw/d 32.7 ± 2.2 34.8 ± 4.6 36.1 ± 4.5 
Bile acids (Fmol/100g bw/d) 8.6 ± 1.5 8.4 ± 1.6 6.7 ± 0.9* 
Total sterols (Fmol/100g bw/d) 
 
41.3 ± 3.1 43.2 ± 5.1 42.7 ± 4.7 
 
E3L.CETP mice received a western-type diet without or supplemented with niacin for 3 
weeks. The bile bladder was cannulated, and bile flow and composition were measured 
during 90 minutes (n=6-7). Feces were collected per cage (3 mice per cage) in two 
subsequent periods of 48 h each (n=8). Fecal composition was measured by gas-liquid-
chromatography and fecal sterol output was calculated. Data are presented as mean ± SD, 
*P<0.05. 
 
Niacin does not affect biliary and fecal cholesterol output 
To evaluate the consequences of the niacin-induced alterations in lipid 
metabolism on lipid excretion into bile and feces, we determined bile flow, 
biliary lipids and sterols in stool. Niacin did not affect bile flow or the bile 
composition (cholesterol, phospholipids and bile acids). The highest dose of 
niacin (1180 mg/kg/day) did affect the composition of the fecal sterols to some 
extent, as reflected by a slight non-significant increase in neutral sterols and a 
decrease in bile acids (-22%; P<0.05). However, like the dietary input, total 
fecal sterol output was not affected by niacin (Table 1).  
 
Discussion 
 
In this study, we investigated the mechanism(s) underlying the HDL-raising 
effect of niacin. We demonstrated that CETP plays a crucial role in the niacin-
induced increase in plasma HDL-C and apoAI levels in E3L.CETP mice. Niacin 
reduced CETP dependent transfer of cholesterol from HDL to (V)LDL as 
related to lower hepatic CETP expression and a reduced plasma (V)LDL pool. 
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This resulted in an increased lipidation of apoAI, as reflected by an increased 
HDL particle size, and a reduced uptake of apoAI by the kidneys. 
We previously showed that E3L mice are highly susceptible to dietary 
interventions with respect to modulating plasma lipid levels and that these mice 
show a human-like response to drug interventions aimed at treatment of CVD 
(e.g. statins, fibrates, cholesterol uptake inhibitors, calcium channel blockers 
and angiotensin II receptor antagonists)
20-23
 with respect to alterations in the 
lipoprotein profile and/or atherosclerosis development. This is in sheer contrast 
with wild-type C57Bl/6 mice and conventional hyperlipidemic mice, such as 
apoE-deficient or LDL receptor-deficient mice, which show either an adverse 
response or no response to such interventions.
37
 In particular, administration of 
niacin to wild-type mice or apoE-deficient mice did show a transient decrease in 
plasma TG and FFA levels, but failed to increase plasma HDL-C in these 
mice.
13,16
 Likewise, we now showed that niacin lowered TG and cholesterol 
Figure 8. Proposed mechanism underlying the HDL-raising effect of niacin. For explanation 
see text. CE, cholesteryl ester; FA, fatty acids; HSL, hormone sensitive lipase; TC, total 
cholesterol; TG, triglycerides. 
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within apoB-containing lipoproteins in E3L mice, but did not affect HDL-C 
levels. 
Recently, we showed that introduction of the human CETP gene in E3L mice 
results in a mouse model which also shows a human-like response with regard 
to raising HDL-C after treatment with fenofibrate,
25
 atorvastatin
26
 and 
torcetrapib.
27
 Since the introduction of CETP permits cross-talk between 
(V)LDL and HDL metabolism via the exchange of neutral lipids, we reasoned 
that the E3L.CETP mouse would also be an excellent mouse model to study the 
effects of niacin on HDL metabolism. 
First, we observed that niacin dose-dependently reduced VLDL-TG and 
(V)LDL-C levels. The primary action of niacin is inhibition of HSL activity in 
adipose tissue after binding to the GPR109A receptor that is selectively 
expressed by adipocytes. This results in a decreased liberation of FFA from 
adipose tissue, and a decreased flux of albumin-bound FA to the liver, which is 
required for substrate-driven hepatic TG synthesis and VLDL production.
13
 As a 
consequence we thus observed a concentration-dependent drop in VLDL-TG 
and (V)LDL-C levels. In addition, we observed that niacin reduced the hepatic 
cholesterol content. This may be caused by reduced input of cholesterol from 
plasma into the liver, since plasma (V)LDL-C concentrations are reduced and 
cholesterol-enriched HDL is formed from which cholesteryl esters are 
presumably not being delivered efficiently to the liver. The decreased hepatic 
cholesterol content cannot be explained by differences in biliary sterol output, 
since the excretion of bile acids and cholesterol remained unchanged. 
Alternatively, niacin may reduce the endogenous hepatic synthesis of 
cholesterol.  
Second, we showed that niacin dose-dependently raised HDL-C levels in 
E3L.CETP mice, but not in E3L mice, as paralleled by a less pronounced raise 
in apoAI. The presence of CETP thus plays a crucial role in the HDL-raising 
effect of niacin, and we reasoned that niacin may dose-dependently inhibit 
CETP activity. It is well-known that VLDL-TG is a driving force for CETP 
activity, and the relative proportions of VLDL and
 
HDL have been shown to 
play
 
a determinant role in CETP activity. It has been demonstrated that the 
capacity of apoB-containing
 
lipoproteins to accept CE from HDL is closely 
correlated with
 
the relative TG content of the lipoprotein acceptor particles.
38-41
 
By decreasing VLDL levels, niacin may thus reduce CETP activity simply by 
decreasing the availability of VLDL-TG as substrate for CETP.  
Our data corroborate recent observations from Hernandez et al.
15,42
 who showed 
that niacin increased HDL-C levels in CETP mice and APOB.CETP mice, but 
not their CETP-deficient wild-type littermates. In fact, they speculated the 
reduced VLDL levels to be the main mechanism underlying the HDL-raising 
effect of niacin. However, we observed that niacin not only reduced plasma 
CETP activity, but also dose-dependently reduced plasma CETP mass to a 
similar extent, suggesting that niacin reduces the synthesis of CETP leading to 
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less CETP  protein being released in plasma as reflected by similar reductions in 
CETP mass and activity. Indeed, niacin dose-dependently reduced hepatic 
CETP mRNA expression. It has been reported that hepatic cholesterol 
determines the hepatic CETP mRNA expression in CETP transgenic mice,
28
 
presumably via an LXR responsive element in the CETP promoter.
43 
Therefore, 
it is likely that niacin decreases the hepatic CETP mRNA expression as a result 
of the observed decreased cholesterol content of the liver upon niacin treatment. 
Besides increasing HDL-C, niacin also dose-dependently increased plasma 
apoAI levels. Niacin has been shown to inhibit the uptake of HDL-apoAI (but 
not HDL-CE) by cultured hepatocytes,
44
 which we now confirmed in vivo. This 
may partly contribute to the increased apoAI levels. Such a potential effect of 
niacin should be independent of GPR109A, since expression of this receptor has 
not been detected in hepatocytes.
13,45,46
 Together with our observations that 
hepatic mRNA expression of genes involved in HDL synthesis (apoa1, acba1) 
and clearance (sr-b1) were not affected by niacin, and an increase of PLTP 
would rather lead to a decrease in HDL-C levels,
30,47
 it is most likely that the 
raise in apoAI is explained directly by the niacin-induced decreased CETP 
activity, which prevents cholesteryl ester transfer from HDL to (V)LDL. This 
leads to increased lipidation of apoAI, resulting in larger and cholesteryl ester-
enriched HDL particles, and thus decreased glomerular filtration and excretion 
of lipid-poor apoAI via the cubulin/megalin receptor complex.
48
 Indeed, we 
demonstrated a clear dose-dependent reduction in the uptake of 
125
I-apoAI by 
the kidney. 
Based on our collective data, we thus propose the following mechanism by 
which niacin reduces TG and (V)LDL-C and concomitantly raises HDL-C, as 
summarized in figure 8. By inhibiting HSL in adipose tissue upon binding of the 
niacin receptor GPR109A, niacin decreases TG lipolysis and thereby the supply 
of FFA to the liver, required for lipid synthesis. The consequently reduced 
hepatic lipid content results in a lower VLDL production and thus lower 
(V)LDL levels. In addition, reduction in hepatic cholesterol results in reduced 
hepatic expression of CETP, as well as diminished release of CETP into the 
plasma. Additionally, HL activity is reduced which may contribute to reduced 
remodelling of HDL in plasma, resulting in decreased clearance of HDL. The 
HDL particles become CE enriched, and less lipid-poor apoAI is cleared by the 
kidney. Niacin thus increases HDL-C and apoAI levels by 1) reducing levels of 
(V)LDL, the acceptor of CETP-mediated HDL-CE transfer, 2) decreasing CETP 
expression, 3) decreasing HL activity, and 4) decreasing the clearance of apoAI.  
As concluded from a many clinical trials using statins, lowering LDL-C alone is 
not longer regarded to be sufficient to treat CVD. Therefore, comprehensive 
lipid management, in which raising HDL-C is an important target, is becoming 
a new standard.
4,7
 Niacin (at dosages of 2-4 g/day) is unsurpassed in raising 
HDL-C. We show that niacin (in a clinical relevant range if we take into 
account the 5-10 times faster metabolism of mice) significantly improves the 
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plasma lipid levels in E3L.CETP mice, e.g. reduces TG and (V)LDL-C and 
increases HDL-C, albeit that total fecal sterol output is unaffected. Whether this 
will lead to improved HDL function and HDL-related reductions in CVD in the 
clinic still remains to be investigated. 
Niacin has not been a very successful drug thus far because of its side-effect: 
severe flushing. Niacin is nowadays produced as an extended release (ER) 
compound, which enhances the tolerability. Clinical trails AIM-HIGH
49
 and 
ARBITER-6 (HALTS)
50
 evaluating the secondary prevention of CVD by ER 
niacin treatment are currently running. Post-hoc analysis of a subgroup of 
ARBITER-2, a randomized, placebo-controlled trial, showed increases in HDL-
C upon daily intake of ER niacin (+20%), which were related to reduced 
progression of carotid intima-media thickness in the setting of both normal 
glycemic status and diabetes mellitus.
51,52
 Because the flushing effects of niacin 
appeared to be prostaglandin D2 (PGD2) receptor mediated,
53
 a combination 
therapy is currently being evaluated combining ER niacin and PGD2 receptor 
antagonist laropiprant, which is better tolerated than ER niacin alone.
54
 
Currently one trail evaluating effects of this combination drug on hard clinical 
endpoints, as myocardial infarction, stroke or revascularisation (HPS2-
THRIVE) is underway. 
In conclusion, our results show that niacin increases HDL-C by reducing the 
hepatic CETP expression and plasma CETP protein and CE transfer activity in 
E3L.CETP mice. Therefore, we postulate that reduction of CETP expression 
contributes to the increase in HDL that is found in human subjects treated with 
niacin, which should be subject of further investigation. 
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Abstract 
 
Background: Although CETP inhibition is regarded as a promising strategy to 
reduce atherosclerosis by increasing HDL-cholesterol, the CETP inhibitor 
torcetrapib given on top of atorvastatin had no effect on atherosclerosis and 
even increased cardiovascular death in the recent ILLUMINATE trial. 
Therefore, we evaluated the anti-atherogenic potential and adverse effects of 
torcetrapib in humanized APOE*3-Leiden.CETP (E3L.CETP) mice. 
 
Methods and Results: E3L.CETP mice were fed a cholesterol-rich without drugs 
or with torcetrapib (12 mg/kg/day), atorvastatin (2.8 mg/kg/day) or both for 14 
weeks. Torcetrapib decreased CETP activity both in the absence and presence 
of atorvastatin (-74% and -73% respectively, P<0.001). Torcetrapib decreased 
plasma cholesterol (-20%, P<0.01), albeit to a lesser extent than atorvastatin (-
42%, P<0.001) or the combination of torcetrapib and atorvastatin (-40%, 
P<0.001). Torcetrapib increased HDL-cholesterol in the absence (+30%) and in 
the presence (+34%) of atorvastatin. Torcetrapib and atorvastatin alone both 
reduced atherosclerotic lesion size (-43% and -46%, P<0.05), but combination 
therapy did not reduce atherosclerosis as compared to atorvastatin alone. 
Remarkably, as compared to atorvastatin, torcetrapib induced enhanced 
monocyte recruitment and expression of monocyte chemoattractant protein-1 
and resulted in lesions of a more inflammatory phenotype, as reflected by an 
increased macrophage content and reduced collagen content.   
 
Conclusions: CETP inhibition by torcetrapib per se reduces atherosclerotic 
lesion size but does not enhance the anti-atherogenic potential of atorvastatin. 
However, as compared to atorvastatin, torcetrapib introduces lesions of a less 
stable phenotype. 
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Introduction 
 
The cholesteryl ester transfer protein (CETP) is an important regulator of the 
HDL-C level. CETP is secreted predominantly by the liver and mainly 
associates with HDL in plasma, where it transports cholesteryl esters (CE) from 
HDL to (V)LDL in exchange for triglycerides,1,2 and thus lowers HDL-C. HDL 
is atheroprotective as it mediates reverse cholesterol transport (i.e. transport of 
cholesterol from the vessel wall to the liver) and it has anti-inflammatory, anti-
thrombotic and anti-oxidative properties.3,4 Therefore, CETP inhibition is 
regarded as a promising strategy to increase HDL-C levels and to reduce 
atherosclerosis.2 However, the effect of CETP activity on atherosclerosis in 
humans has not been unequivocally determined. Mutations in the CETP gene 
that reduce CETP mass and activity (e.g. D442G and Int14 G(+1)>A) lead to 
elevated HDL-C levels,5,6 but the effects of these mutations on atherosclerosis 
are still in dispute.7-10 
Torcetrapib, which forms an inactive complex between CETP and HDL2 has 
been the first CETP inhibitor tested in large human trials, in which it was shown 
to increase HDL-C levels by approx. 60%.11-13 The resulting HDL particles 
were able to mediate cellular cholesterol efflux more efficiently.14 However, the 
large scale ILLUMINATE trial was stopped prematurely because of an excess 
of deaths in patients receiving torcetrapib with atorvastatin as compared to those 
receiving atorvastatin alone, mainly related to cardiovascular events.15 In 
addition, the RADIANCE and ILLUSTRATE trials revealed no therapeutic 
benefit of combining torcetrapib with atorvastatin with respect to 
atherosclerosis progression as assessed by coronary intima-media thickness 
(IMT) and intravascular ultrasonography (IVUS) measurements.11-13 
The effect of torcetrapib alone on atherosclerosis, however, has not yet been 
evaluated in humans, and the mechanism underlying the increased death rate 
associated with torcetrapib treatment has not been elucidated as yet. Therefore, 
we now examined the effect of torcetrapib with or without atorvastatin on 
atherosclerosis development in humanized APOE*3-Leiden.CETP (E3L.CETP) 
transgenic mice.16 E3L mice show a human-like response to lipid-lowering 
therapies.17 Cross-breeding with CETP transgenic mice, which express human 
CETP under control of its natural flanking regions, resulted in E3L.CETP mice 
that also respond to HDL-modulating intervention.18,19 
 
Methods 
 
Animals 
Human CETP transgenic mice which express CETP under control of its natural 
flanking regions (strain 5203)20 were obtained from Jackson laboratories (Bar 
Harbor, MC) and crossbred with E3L mice21 to obtain E3L.CETP mice.16 All 
mice used in this study were heterozygous E3L.CETP transgenic females on a 
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C57Bl/6 background. Mice were housed under standard conditions with a 12 h 
light-dark cycle and had free access to food and water unless indicated 
otherwise. Mice were fed regular chow (Ssniff, Soest, Germany) or a diet with 
15% (w/w) cacao butter (diet T, Hope Farms, Woerden, the Netherlands) 
supplemented with 0.1% or 0.25% (w/w) cholesterol (Sigma) with or without 
torcetrapib (2R,4S)-4-[[[3,5bis(trifluoromethyl) phenyl]methyl]-
(methoxycarbonyl)amino]-2-ethyl-3,4-dihydro-6-trifluoromethyl)-3-phenyl-
1(2H)-quinolinecarboxylic acid, ethyl ester (C26H25N2O4F9), (kindly provided 
by Roche, Basel, Switzerland) and/or atorvastatin ([R-(R*,R*)]-2-(4-
fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-
4[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (C33H24FN2O5) 
(Lipitor). Unless indicated otherwise, blood was drawn after 4 h fasting in 
EDTA-containing cups by tail bleeding and plasma was isolated. All animal 
experiments were approved by the institutional ethical committee on animal 
care and experimentation. 
 
Single Torcetrapib Treatment 
To verify that torcetrapib inhibits CETP activity in E3L.CETP mice in vivo, 
mice on a chow diet were given a single intragastric gavage of torcetrapib (0, 1, 
3 and 10 mg/kg) in approx. 200 µL of ethanol: solutol: saline 10:10:80 (v:v:v). 
Blood was drawn before gavage and at 1, 2, 4, 6, 8 and 24 h after gavage. 
During the first 8 h after the gavage mice were fasted. Plasma was assayed for 
total CETP activity as described below. Alternatively, mice were fed a diet 
containing 15% cacao butter with 0.1% or 0.25% cholesterol, and the effect of 
10 mg/kg torcetrapib was determined on plasma CETP activity at 2 h after 
gavage. 
 
Total Plasma CETP Activity, Endogenous CETP Activity and CETP Mass 
Total plasma CETP activity was measured as the transfer of [3H]cholesteryl 
oleate (CO) from LDL to HDL.16 Briefly, 5 µL (diluted) mouse plasma was 
incubated with human [3H]CO-labeled LDL and HDL in sodium phosphate 
buffer containing 5,5′-dithio-bis(2-nitrobenzoic acid) to inhibit lecithin-
cholesterol acyltransferase (LCAT) activity. After overnight incubation, LDL 
was precipitated. The supernatant containing [3H]CO-HDL was counted for 3H 
activity. CETP activity was calculated as nmol CE transfer/ mL plasma/ h. 
Endogenous CETP activity was determined by a fluorescent method using 
donor liposomes enriched with nitrobenzoxadiazole (NBD)-labeled cholesteryl 
esters (RB-CETP, Roar Biomedical, NY, USA), as described.22 CETP mass was 
determined using the DAIICHI CETP ELISA kit according to manufacturer’s 
instructions (Daiichi, Tokyo, Japan). 
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Long-term Torcetrapib Treatment 
To determine the effect of torcetrapib without and with atorvastatin on 
atherosclerosis development and plasma cholesterol, E3L.CETP mice were fed 
a diet containing 0.25% cholesterol to increase plasma cholesterol levels to ~16 
mM. After 4 weeks, mice were randomized into four groups according to their 
plasma cholesterol levels. Mice were fed a control diet, a diet with atorvastatin 
(0.0023% ~ 2.8 mg/kg/day), torcetrapib (0.01% ~ 12 mg/kg/day) or both. Blood 
was drawn one week before randomization and at week 6, 9 and 14 of drug 
treatment, and was assayed for lipids, CETP mass and activity. After 14 weeks, 
mice were euthanized and atherosclerosis development was assessed as 
described below.  
 
Plasma Lipids and Lipoprotein Profiles 
Plasma was assayed for cholesterol and phospholipids (PL) using commercially 
available enzymatic kits according to the manufacturer’s protocols (236691, 
Roche Molecular Biochemicals, Indianapolis IN, USA, and phospholipids B 
Wako Chemicals, Neuss, Germany, respectively). To determine the lipid 
distribution over plasma lipoproteins, lipoproteins were separated using fast 
protein liquid chromatography (FPLC). Plasma was pooled per group and 50 µL 
of each pool was injected onto a Superose 6 HR 10/30 column (Äkta System, 
Amersham Pharmacia Biotech, Piscataway, NJ, USA) and eluted at a constant 
flow rate of 50 µL/min in PBS, 1 mM EDTA, pH 7.4. Fractions of 50 µL were 
collected and assayed for cholesterol and PL as described above.  
 
Atherosclerosis Quantification 
After 14 weeks of drug intervention, mice were sacrificed by CO2 inhalation. 
Blood was drawn via cardiac puncture and hearts were isolated. Hearts were 
fixed in phosphate-buffered 4% formaldehyde, dehydrated, embedded in 
paraffin and were cross-sectioned (5 µm) throughout the aortic root area. Per 
mouse 4 sections with 50 µm intervals were used for atherosclerosis 
measurements. Sections were stained with hematoxylin-phloxin-saffron (HPS) 
for histological analysis. Lesions were categorized for severity according to the 
American Heart system adapted for mice.23,24 Various types of lesions were 
discerned: type 0 (no lesions), type 1-3 (early fatty streak-like lesions containing 
foam cells) and type 4-5 (advanced lesions containing foam cells in the media, 
presence of fibrosis, cholesterol clefts, mineralization and/or necrosis). Lesion 
area was determined using Leica Qwin image analysis software (EIS, Asbury 
NJ). AIA 31240 antiserum (1:3000, Accurate Chemical and Scientific, 
Westbury, NY) was used to quantify the macrophage area and the number of 
monocytes adhering to the endothelium. Sirius Red was used to quantify the 
collagen area, and the antibody M0851 (1:800, DAKO) against smooth muscle 
cell actin to quantify the smooth muscle cell area. Monocyte chemoattractant 
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protein-1 (MCP-1) was detected using goat anti-mouse MCP-1 (M18, 1:300; 
Santa Cruz Biotechnology, Santa Cruz, Calif). 
 
Statistical Analysis 
Data are presented as means ± SD unless indicated otherwise. Statistical 
differences were assessed using the Mann Whitney U test. For lesion typing, 
differences were assessed by the Chi Square test. SPSS 14.0 was used for 
statistical analysis. Values of P<0.05 was regarded as statistically significant.  
 
The authors had full access to and take full responsibility for the integrity of the 
data. All authors have read and agree to the manuscript as written. 
 
Results 
 
Torcetrapib Inhibits CETP Activity in E3L.CETP mice 
To verify that E3L.CETP mice appropriately respond to CETP inhibition, 
E3L.CETP mice on a chow diet received an oral garage of torcetrapib (1, 3 and 
10 mg/kg) or vehicle. As expected, torcetrapib time- and dose-dependently 
reduced plasma CETP activity, reaching a minimum at 2 h after gavage (-
59±8%, -83±4%, and -96±4%; P<0.01). At 3 and 10 mg/kg, significant 
reductions were still observed after 8 h (-45±25% and -45±17% respectively; 
P<0.01) (Fig. 1A). Because cholesterol-feeding of E3L.CETP mice increases 
plasma CETP mass and activity,16 we next measured the inhibitory capacity of 
torcetrapib on plasma CETP activity in mice fed a diet without or with 0.1% 
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Figure 1. A single dose of torcetrapib inhibits CETP in vivo. E3L.CETP mice fed a chow diet 
received the indicated amounts of torcetrapib via intragastric gavage. Blood was drawn at the 
indicated time points and plasma was assayed for CETP activity (A). E3L.CETP mice, fed a 
chow diet or a diet containing 0.1% and 0.25% cholesterol, received torcetrapib (10 mg/kg) 
by intragastric gavage and total CETP activity was measured 2 h after gavage (B). Values are 
means ± SD (n=4-6); *P<0.05, **P<0.01, ***P<0.001 as compared to the control group. 
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(w/w) or 0.25% (w/w) cholesterol, which increased plasma CETP activities 
(3.4-fold and 4.3- fold, respectively). Despite the increase in plasma CETP 
activity, an oral gavage of torcetrapib (10 mg/kg) still profoundly decreased 
CETP activity in the presence of 0.1% (-64±11%; P<0.05) and 0.25% (-
59±13%; P<0.05) cholesterol in the diet (Fig. 1B). 
 
Torcetrapib Reduces Plasma Cholesterol Levels to a Lesser Extent than 
Atorvastatin 
To determine the effect of torcetrapib on plasma lipid levels in the absence or 
presence of atorvastatin, E3L.CETP mice were fed a diet containing 0.25% (w/ 
w) cholesterol without or with torcetrapib and/or atorvastatin. Addition of 
torcetrapib, atorvastatin or both to the diet did not affect food intake or body 
weights of E3L.CETP mice (not shown). The cholesterol-rich diet resulted in a 
plasma cholesterol level of 16.1±3.5 mM in the control group. Torcetrapib 
decreased plasma cholesterol (-20%; P<0.01) to a lesser extent as compared to 
atorvastatin (-42%; P<0.001). The combination of torcetrapib and atorvastatin 
did not decrease plasma cholesterol further as compared to atorvastatin alone (-
40% vs -42%) (Fig. 2A). Since torcetrapib and atorvastatin consistently lowered 
plasma cholesterol throughout the study, they similarly decreased total 
cholesterol exposure (Fig. 2B). Thus, torcetrapib alone reduced total cholesterol 
exposure to a lower extent as compared to atorvastatin and combination therapy 
(Fig. 2B). 
Figure 2. Torcetrapib reduces plasma cholesterol to a lesser extent than atorvastatin. Mice 
were fed a diet containing 0.25% cholesterol without or with torcetrapib (0.01%), atorvastatin 
(0.0023%) or both. After 9 weeks of drug intervention, blood was drawn and plasma was 
assayed for cholesterol (A). Blood was drawn at additional time points (0, 6, 9, and 14 
weeks) and TC was measured. Total cholesterol exposure during the study was calculated 
(B). Values are means ± SD (n=14-15); *P<0.05, **P<0.01, ***P<0.001 as compared to the 
control group. 
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To determine the distribution of lipids over lipoproteins, lipoproteins were 
fractionated by FPLC and cholesterol and PL were measured in the individual 
fractions (Fig. 3). Torcetrapib reduced (V)LDL-C (-26%) (Fig. 3A) to a lesser 
extent than atorvastatin (-42%) (Fig. 3A and 3B), and torcetrapib did not 
enhance the (V)LDL-C reducing effect of atorvastatin (Fig. 3B). In addition, 
torcetrapib increased plasma HDL-C levels by +30% in the absence of 
atorvastatin (Fig. 3A) and by +34% in the presence of atorvastatin, as judged 
from the cholesterol content of the FPLC fractions 17-22 (Fig. 3B). This 
torcetrapib-induced increase in HDL-C was paralleled by an increase in PL in 
the HDL fractions (Fig. 3C and 3D). Despite these increased HDL-C levels, 
apoAI levels were not altered by torcetrapib treatment (not shown). 
Figure 3. Torcetrapib reduces plasma VLDL and increases HDL levels. Mice were fed a diet 
containing 0.25% cholesterol without or with torcetrapib (0.01%), atorvastatin (0.0023%) or 
both. After 14 weeks of drug intervention, blood was drawn and plasma was pooled per 
treatment group (n=14-15). Pooled plasma was fractionated using FPLC on a Superose 6 
column and the individual fractions were assayed for total cholesterol (A, B) and 
phospholipid (C, D). 
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Torcetrapib Reduces CETP Activity and Increases CETP Mass Whereas 
Atorvastatin Decreases Both CETP Activity and Mass  
Torcetrapib decreased CETP activity efficiently both in the absence (-73%; 
P<0.001) and presence of atorvastatin (-74%; P<0.001) (Fig. 4A). Atorvastatin 
alone also decreased CETP activity, but to a lesser extent (-32%; P<0.001). 
Despite the decreased CETP activity, torcetrapib treatment increased CETP 
mass (+33%; P<0.001). On the contrary, atorvastatin decreased CETP mass (-
24%; P<0.001), whereas the combination therapy did not significantly affect 
CETP mass as compared to untreated mice (Fig. 4B). These data are in line with 
previous observations that torcetrapib increases CETP mass in humans despite 
the decrease in CETP activity25 and that atorvastatin decreases CETP levels26,27 
by decreasing CETP expression.19 
 
Torcetrapib Reduces Atherosclerotic Lesion Severity and Lesion Area but Does 
Not Enhance the Anti-Atherogenic Effect of Atorvastatin 
To determine the effect of torcetrapib on atherosclerosis development in the 
absence or in the presence of atorvastatin, the 4 groups of mice were euthanized 
after 14 weeks and atherosclerosis severity and lesion size were measured in the 
aortic root. Representative pictures of each group are shown in Fig. 5A. As 
compared to the control group, mice treated with torcetrapib, atorvastatin or 
both had more lesion-free sections and fewer severe lesions of type 4 to 5. Thus, 
torcetrapib, atorvastatin and the combination of both reduced lesion severity 
similarly (Fig. 5B). Accordingly, torcetrapib and atorvastatin alone induced a 
similar reduction in lesion area (-43% and -46% respectively; P<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Torcetrapib reduces plasma CETP activity and increases CETP mass. Mice were 
fed a diet containing 0.25% cholesterol without or with torcetrapib (0.01%), atorvastatin 
(0.0023%) or both. After 9 weeks of drug intervention, blood was drawn and plasma was 
assayed endogenous CETP activity (A) and CETP mass (B). Values are means ± SD (n=14-
15); *P<0.05, ***P<0.001 vs the control group. 
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Combination treatment also reduced atherosclerosis as compared to the control 
group (-60%; P<0.001), but did not significantly enhance the atherosclerosis-
reducing potency of atorvastatin alone (Fig. 5C). 
 
Torcetrapib Induces Monocyte Recruitment and Results in a More Pro-
Inflammatory Lesion Phenotype as Compared to Atorvastatin 
We next evaluated the effect of torcetrapib, atorvastatin and the combination of 
both on monocyte recruitment and lesion composition with respect to the 
macrophage area, smooth muscle cell area and collagen area. Torcetrapib alone 
and in combination with atorvastatin increased the adherence of monocytes to 
the vessel wall as compared to the control and atorvastatin-treated group (Fig 
6A). Although torcetrapib did not significantly raise MCP-1 as compared to the 
control group, torcetrapib significantly increased MCP-1 as compared to 
Figure 5. Torcetrapib reduces 
atherosclerosis development but does not 
enhance the atherosclerosis reducing 
effect of atorvastatin. Mice were fed a 
diet containing 0.25% cholesterol without 
or with torcetrapib (0.01%), atorvastatin 
(0.0023%) or both. After 14 weeks of 
drug intervention, hearts were isolated, 
fixed, dehydrated and embedded in 
paraffin and representative HPS stained 
pictures of each group are shown (A). 
Four sections per mouse with 50 µm 
intervals were typed and categorized 
according to lesion severity (B), and total 
lesion area was calculated (C). Values are 
means ± SEM (n=14-15) *P<0.05, 
**P<0.01, ***P<0.001 as compared to 
the control group 
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atorvastatin (+99%; P<0.05) (Fig. 6B). The increase in adhering monocytes as 
induced by torcetrapib was accompanied by an increased area of macrophages 
in the intima (Fig. 6C). Although torcetrapib did not appear to affect the smooth 
muscle cell content (Fig. 6D), torcetrapib alone and in combination with 
Figure 6. Torcetrapib unfavorably 
alters plaque composition as compared 
to atorvastatin. In the sections obtained 
as described in Figure 5, the adhesion 
of monocytes to the lesions was 
determined (A), as well as the MCP-1 
content (B) and macrophage content 
(C) of the lesions. In addition, the SMC 
content (D) and collagen content (E) of 
the lesions were quantified. Values are 
means ± SEM (n=14-15); *P<0.05, 
**P<0.01 as compared to the control 
group. 
 
0
2
4
6
8
10
12
14
A
dh
er
in
g 
m
on
oc
yt
es
(#
/s
eg
m
en
t) *
*
A
-
+
atorvastatin
torcetrapib
+
-
+
+
-
-
0
2
4
6
8
M
C
P
-1
 (
%
 o
f 
to
ta
l 
pl
aq
ue
 a
re
a)
-
+
atorvastatin
torcetrapib
+
-
+
+
-
-
B
*
0
2
4
6
8
S
m
oo
th
 m
us
cl
e 
ce
ll
 a
re
a 
(%
 o
f 
to
ta
l 
pl
aq
ue
 a
re
a)
D
-
+
atorvastatin
torcetrapib
+
-
+
+
-
-
-
+
atorvastatin
torcetrapib
+
-
+
+
-
-
0
5
10
15
20
25
30
35
M
ac
ro
ph
ag
e 
ar
ea
 
(%
 o
f 
to
ta
l 
pl
aq
ue
 a
re
a)
C
* **
**
0
5
10
15
20
25
C
ol
la
ge
n 
ar
ea
 
(%
 o
f 
to
ta
l 
pl
aq
ue
 a
re
a)
E
-
+
atorvastatin
torcetrapib
+
-
+
+
-
-
A
dh
er
in
g 
m
on
oc
yt
es
(#
/s
eg
m
en
t)
M
C
P
-1
 (
%
 o
f 
to
ta
l 
pl
aq
ue
 a
re
a)
S
m
oo
th
 m
us
cl
e 
ce
ll
 a
re
a 
(%
 o
f 
to
ta
l 
pl
aq
ue
 a
re
a)
M
ac
ro
ph
ag
e 
ar
ea
 
(%
 o
f 
to
ta
l 
pl
aq
ue
 a
re
a)
C
ol
la
ge
n 
ar
ea
 
(%
 o
f 
to
ta
l 
pl
aq
ue
 a
re
a)
Chapter 5 
 110 
atorvastatin tended to decrease the area of collagen (P=0.14 and P=0.13, resp.) 
(Fig. 6E). Thus, whereas atorvastatin reduces lesion size without affecting 
lesion composition as compared to untreated mice, torcetrapib reduces lesion 
size accompanied by a more pro-inflammatory lesion phenotype, reflected by an 
increased macrophage-to-collagen ratio, as compared to control-treated mice 
(+75%) and atorvastatin-treated mice (+67%). 
 
Discussion 
 
Torcetrapib has been shown to markedly raise HDL-C and was, therefore, 
expected to reduce atherosclerosis in humans. Despite this, the recent 
RADIANCE, ILLUSTRATE AND ILLUMINATE trials have concluded that 
torcetrapib was ineffective in reducing atherosclerosis11-13 and increased clinical 
event rate.15 However, it should be realized that the effectiveness of torcetrapib 
has only been assessed in dyslipidemic patients who also received atorvastatin. 
Therefore, in the present study we examined the effect of torcetrapib per se on 
atherosclerosis development. In our study we show that torcetrapib alone 
reduces the progression of atherosclerosis, but does not enhance the anti-
atherosclerotic potency of atorvastatin and that torcetrapib results in a more pro-
inflammatory lesion phenotype as compared to atorvastatin. 
Torcetrapib reduced total cholesterol exposure to a lesser extent (-17%) as 
compared to atorvastatin (-41%), whereas torcetrapib and atorvastatin equally 
reduced atherosclerotic lesion size (both ~-45%). Previous diet-induced 
atherosclerosis studies in mice have consistently demonstrated that 
atherosclerotic lesion area could generally be reliably predicted from cholesterol 
exposure (H.M.G. Princen PhD and P.C.N. Rensen PhD, unpublished data, 
2007). Therefore, torcetrapib decreased atherosclerosis development more 
drastically than could be expected based merely on the observed reduction in 
cholesterol exposure. Since torcetrapib treatment results in increased HDL 
levels, it is likely that HDL is involved in the atheroprotective effect of 
torcetrapib. In line with this hypothesis, we have observed previously that 
E3L.CETP mice show a 7-fold increased atherosclerotic lesion area as 
compared to E3L only mice, which was much more than could be expected 
based on a modest increase in total plasma cholesterol per se. In fact, we 
showed that plasma from E3L.CETP mice was less effective in mediating SR-
BI-dependent cholesterol efflux than plasma from E3L mice, as accompanied by 
a large reduction in HDL-1.16 In the present study, we did not detect an effect of 
torcetrapib on either SR-BI or ABCA1-mediated cholesterol efflux (not shown), 
possibly related to the relatively mild effect of torcetrapib on the HDL level as 
compared to total CETP deficiency. We therefore speculate that effects of 
torcetrapib on other properties of HDL, including its anti-inflammatory, anti-
oxidative and/or anti-thrombotic properties may have resulted in the more 
Torcetrapib induces pro-inflammatory lesions 
 111 
prominent reduction in atherosclerotic lesion size than could be expected merely 
on the basis of a reduction in total cholesterol. 
The fact that torcetrapib alone reduced atherosclerosis development is in line 
with a previous study showing that torcetrapib treatment alone reduces 
atherosclerosis in rabbits.28 However, we also show that torcetrapib did not 
significantly enhance the anti-atherogenic potential of atorvastatin. We have 
evaluated the effects of torcetrapib and atorvastatin in E3L.CETP mice with a 
relatively high plasma cholesterol level of approx. 16 mM, to avoid the 
possibility that the combined cholesterol-lowering actions of atorvastatin and 
torcetrapib would result in a plasma cholesterol level below that required for 
atherosclerosis development in E3L.CETP mice (i.e. 6-8 mM). Despite this 
limitation, torcetrapib per se (i.e. without concomitant administration of 
atorvastatin) may thus have an anti-atherosclerotic effect in humans as well.  
From the recent clinical trials, it has become clear that torcetrapib has several 
adverse effects. The ILLUMINATE trial showed that torcetrapib elevated blood 
pressure, increased cardiovascular events and increased death rate, mainly 
related to cardiovascular causes.15 However, the mechanisms underlying these 
unexpected adverse effects have not completely been elucidated yet. In the 
present study, we did not detect a significant effect of torcetrapib on blood 
pressure, probably because of small experimental groups (data not shown). 
However, compared with atorvastatin, torcetrapib enhanced monocyte 
adherence to the vessel wall, enhanced vascular MCP-1 expression, and 
increased the macrophage area within the lesions. Torcetrapib thus appears to 
enhance the recruitment of monocytes to the endothelium and transmigration of 
the monocytes into the intima resulting in an enhanced macrophage content of 
the plaque, compared with similarly sized lesions resulting from atorvastatin 
treatment. The observation that torcetrapib tended to reduce the collagen 
content of the plaque independent of the smooth muscle cell content can be 
explained by induction of collagen breakdown by macrophages, (e.g., via 
secretion of metalloproteinases). Although plaque rupture is a rare phenomenon 
in mice, such inflammatory lesions with a high macrophage to collagen ratio are 
more unstable and may well have caused an increased incidence of plaque 
rupture in humans, thereby explaining increased cardiovascular death. It would 
be interesting to evaluate in future studies whether these effects of torcetrapib 
are compound-specific or related to its effect on lipoprotein metabolism, by 
comparison with other CETP inhibitors that are currently under development 
(e.g. JTT-705 and anacetrapib). 
Interestingly, recent data from the ILLUMINATE trial indicate that torcetrapib 
increased plasma aldosterone levels via an as yet unknown mechanism.15 In 
addition to increasing blood pressure,29 aldosterone increases atherosclerosis 
development in mice.30-32 This is related to its pro-inflammatory properties 
including increased MCP-1 expression, increased monocyte infiltration into the 
coronary artery, increased lipid loading of macrophages, and increased 
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expression of matrix metalloproteinases.29,30 Preliminary data on aldosterone 
levels in pooled plasma of the various mouse groups indicated that the average 
aldosterone level is higher in the torcetrapib-treated group (+15%) and 
combination-treated group (+48%) than in the atorvastatin-treated group. This 
suggests that the torcetrapib-induced increase in aldosterone levels may causally 
increase the inflammatory plaque phenotype in mice. 
In conclusion, torcetrapib inhibits the progression of atherosclerosis, but does 
not enhance the anti-atherosclerotic potency of atorvastatin. In addition, as 
compared to atorvastatin, torcetrapib causes a more pro-inflammatory and 
unstable lesion phenotype. 
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Abstract 
 
Pregnane X receptor (PXR) agonism has been shown to affect multiple steps in 
both the synthesis and catabolism of HDL, but its integrated effect on HDL 
metabolism in vivo remains unclear. The aim of this study was to evaluate the 
net effect of PXR agonism on HDL metabolism in APOE*3-Leiden (E3L) and 
E3L.CETP mice, well-established models for human-like lipoprotein 
metabolism. Female mice were fed a diet with increasing amounts of the potent 
PXR agonist 5-pregnen-3β-ol-20-one-16α-carbonitrile (PCN). In E3L and 
E3L.CETP mice, PCN increased liver lipids as well as plasma cholesterol and 
triglycerides. However, whereas PCN increased cholesterol contained in large 
HDL-1 particles in E3L mice, it dose-dependently decreased HDL-cholesterol 
in E3L.CETP mice, indicating that CETP expression dominates the effect of 
PCN on HDL metabolism. Analysis of the hepatic expression of genes involved 
in HDL metabolism showed that PCN decreased expression of genes involved 
in HDL synthesis (Abca1, Apoa1), maturation (Lcat, Pltp) and clearance (Sr-
b1). The HDL-increasing effect of PCN, observed in E3L mice, is likely caused 
by a marked decrease in hepatic SR-BI protein expression, and completely 
reversed by CETP expression. We conclude that chronic PXR agonism dose-
dependently reduces plasma HDL-cholesterol in the presence of CETP. 
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Introduction  
 
Since low HDL-cholesterol is a strong and independent risk factor for 
cardiovascular disease,1 pharmacological approaches aimed at raising HDL are 
generally seen as a novel therapeutic strategy to reduce atherosclerosis. 
However, the recent large phase III trials assessing the effect of the CETP 
inhibitor torcetrapib in combination with atorvastatin failed, despite achieving a 
60% increase in HDL-cholesterol.2-4 Torcetrapib not only failed to reduce 
atherosclerosis, as assessed by coronary intima-media thickness (IMT) and 
intravascular ultrasonography (IVUS) measurements,2-4 but also increased the 
risk of cardiovascular events and death rate.5 Although these data question the 
therapeutic significance of raising HDL, the adverse effects of torcetrapib may 
well be compound-specific and related to increased inflammation.6 Therefore, 
the search for additional strategies aimed at raising HDL, e.g. via increasing the 
expression of apoAI, is warranted. 
The pregnane X receptor (PXR) may be a novel suitable target to raise HDL. 
PXR agonism has been shown to increase plasma apoAI and HDL-cholesterol 
in wild-type mice, but not in PXR-knockout mice, suggesting that PXR agonism 
may be a new strategy to increase HDL by enhancing apoAI expression.7 In 
addition, PXR expression in mice antagonizes the cholic acid-mediated 
downregulation of plasma HDL-cholesterol and apoAI.8 PXR activation may 
also increase HDL formation by the intestine by increasing ABCA1 and 
ABCG1 expression and protein levels in intestinal cells, which results in an 
increased cholesterol efflux from intestinal cells to apoAI and HDL in vitro.9 
PXR activation also decreased SR-BI expression in HepG2 cells and primary rat 
hepatocytes in vitro,10 which may add to a potential HDL-increasing effect in 
vivo. 
However, some data indicate that PXR agonism may also negatively affect 
HDL levels. For example, PXR activation decreases the expression of ABCA1 
in hepatocytes in vitro,10 which would reduce HDL formation in an in vivo 
setting. PXR also increases lipogenesis in the liver leading to an increased 
hepatic triglyceride (TG) content and increased plasma VLDL-TG levels,11,12 
which may result in reduced HDL-cholesterol levels via CETP-mediated 
exchange of neutral lipids. An increased hepatic lipid content may increase 
CETP expression, and increased VLDL-TG will result in a higher rate of 
cholesteryl ester transfer from HDL to VLDL with a higher reciprocal rate of 
TG transfer from VLDL to HDL, resulting in a relatively TG-rich HDL that is 
more rapidly remodeled and cleared via hepatic lipase.13 
In this study we aimed to examine the integrated effect of PXR agonism by the 
established PXR agonist PCN14,15 on HDL metabolism in vivo. Hereto, we used 
the APOE*3-Leiden (E3L) mouse, a well-established model for human-like 
lipoprotein metabolism.16 In addition, we used the E3L.CETP mouse6,17-19 to 
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assess the specific contribution of CETP in the PXR-mediated effects on HDL 
metabolism. 
 
Materials and Methods 
 
Animals and diets 
Female APOE*3-Leiden (E3L) and E3L.CETP transgenic mice that express 
human CETP under control of its natural flanking regions17 were housed under 
standard conditions with access to water and food ad libitum. Mice were fed a 
diet enriched with 15% cacao butter (Diet T; AB Diet Services, Woerden, The 
Netherlands) for 3 weeks to increase plasma cholesterol levels from 2 mM to ~6 
mM. Blood was collected after a 4 h fast from the tail vein into EDTA-
containing cups, and both E3L and E3L.CETP mice were randomized according 
to their plasma total cholesterol, TG and HDL-cholesterol. Subsequently, mice 
were fed control diet (diet T) or the same diet with 5-pregnen-3β-ol-20-one-
16α-carbonitrile (PCN; Sigma) at increasing doses of 0.01%, 0.03% and 0.1% 
(corresponding with 11, 33 and 110 mg/kg/day) for three weeks each. After 
each treatment period, blood was drawn after 4 h of fasting into EDTA-
containing cups via tail bleeding. After the last treatment period with the highest 
dosage, mice were sacrificed and livers were isolated. All experiments were 
approved by the Institutional Committee on Animal Care and Experimentation. 
 
Plasma lipids and lipoprotein profiles 
Plasma total cholesterol and triglycerides (TG) were measured using 
commercially available enzymatic kits (236691 and 1488872, respectively, 
Roche Molecular Biochemicals, Indianapolis IN, USA) according to the 
manufacturer’s instructions. Phospholipids were determined using an enzymatic 
Phospholipids kit (Spinreact, Sant Esteve de Bas, Spain). To determine the lipid 
distribution over plasma lipoproteins, lipoproteins were separated using FPLC. 
Plasma was pooled per group, and 50 µL of each pool was injected onto a 
Superose 6 HR 10/30 column (Äkta System, Amersham Pharmacia Biotech, 
Piscataway, NJ, USA) and eluted at a constant flow rate of 50 µL/min in PBS, 1 
mM EDTA, pH 7.4. Fractions of 50 µL were collected and assayed for 
cholesterol as described above. In E3L.CETP mice, plasma HDL-cholesterol 
was measured after precipitation of the apoB-containing lipoproteins from 20 
µL EDTA plasma by adding 10 µL heparin (LEO Pharma, The Netherlands; 
500 U/mL) and 10 µL 0.2 M MnCl2. Mixtures were incubated during 20 min at 
room temperature and centrifuged for 15 min at 13,000 rpm at 4°C. In the 
supernatant HDL-C was measured. 
 
Hepatic lipid levels 
Liver samples (~50 mg) were vigorously shaken (20 sec at 4800 rpm) in ice-
cold methanol (10 µL/mg tissue) using a Mini Bead Beater (BioSpec Products, 
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Bartlesville, USA). Tissue homogenates (45 µL~4.5 mg tissue) were diluted 
with ice-cold methanol (450 µL) and ice-cold chloroform (1350 µL), and 
further shaken (20 sec at 4800 rpm) to extract lipids from the tissue samples. 
Mixtures were centrifuged (15 min at 14,000 rpm; 4°C) and supernatant was 
transferred into a new tube, dried under nitrogen gas. Lipids were dissolved in 
100 µL 2% Triton-X100. Total cholesterol, TG and phospholipid levels were 
assayed as described above.  
 
Plasma CETP activity 
Total (lipoprotein-independent) CETP activity was measured as the transfer of 
[3H]cholesteryl oleate (CO) from LDL to HD,20 exactly as described.6 
Endogenous (lipoprotein-dependent) CETP activity was determined by a 
fluorescent method using donor liposomes enriched with nitrobenzoxadiazole-
labeled cholesteryl esters (RB-CETP, Roar Biomedical, New York),6 as 
described.21 
 
Table 1. Primers used for rtPCR 
Gene Forward primer Reverse primer 
Abca1 CCCAGAGCAAAAAGCGACTC GGTCATCATCACTTTGGTCCTTG 
Apoa1 GGAGCTGCAAGGGAGACTGT TGCGCAGAGAGTCTACGTGTGT 
CETP CAGATCAGCCACTTGTCCAT CAGCTGTGTGTTGATCTGGA 
Cyp3A11 CTTTCCTTCACCCTGCATTCC CTCATCCTGCAGTTTTTTCTGGAT 
Cyp7a1 CAGGGAGATGCTCTGTGTTCA AGGCATACATCCCTTCCGTGA 
Gapdh TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
Hl CAGCCTGGGAGCGCAC CAATCTTGTTCTTCCCGTCCA 
Hprt TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 
Lcat GGCAAGACCGAATCTGTTGAG ACCAGATTCTGCACCAGTGTGT 
Cyclo CAAATGCTGGACCAAACACAA GCCATCCAGCCATTCAGTCT 
Pltp TCAGTCTGCGCTGGAGTCTCT AAGGCATCACTCCGATTTGC 
Sr-b1 GTTGGTCACCATGGGCCA CGTAGCCCCACAGGATCTCA 
 
Abca1, ATP-binding cassette transporter A1; Apoa1, apolipoprotein AI; CETP, human 
cholesteryl ester transfer protein; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Hl, 
hepatic lipase; Hprt, hypoxanthine-guanine phosphoribosyl transferase; Lcat, lecithin: 
cholesterol acyltransferase; Cyclo, cyclophilin; Pltp, phospholipid transfer protein; Sr-b1, 
scavenger receptor class B type I. 
 
Hepatic mRNA expression 
Total mRNA extraction from liver tissue samples was performed using TRIzol 
(Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions. 
mRNA quality was confirmed with lab-on-a-chip (Bio-Rad Laboratories, 
Hercules, CA, USA), and mRNA was converted to single-stranded cDNA using 
the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Ontario, Canada). 
RT-PCR was performed using the IQ5 multicolor real-time PCR detection 
system using the SYBR Green RT-PCR mix (Bio-Rad Laboratories, Hercules, 
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CA, USA). mRNA levels were normalized to mRNA levels of hypoxanthine-
guanine phosphoribosyl transferase (HPRT), cyclophilin and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Primers are listed in Table 1.  
 
HDL apolipoprotein composition 
Plasma was pooled per group and lipoproteins were separated using FPLC. 
HDL fractions (7.5 µL) were run on a 4-20% SDS-PAGE gel (Bio-Rad 
Laboratories, Hercules CA, USA). Gels were stained with Coomassie brilliant 
blue. 
 
Hepatic ABCA1 and SR-BI protein 
Immunoblot analysis of hepatic ABCA1 and SR-BI was performed as 
described.22 In short, liver samples were lysed, cell debris was removed, and 
protein concentration was determined. Equal amounts of protein (20 µg) were 
separated on 7.5% SDS-PAGE gels and transferred to nitrocellulose membrane. 
Loading of equal amounts of cell protein was confirmed with Ponceau S 
staining of the resulting blots. Immunolabeling was performed using murine 
monoclonal αABCA1 (AC-10) or rabbit polyclonal αSRBI (anti-BI495) as 
primary antibody and goat-anti-mouse IgG and goat-anti-rabbit IgG, 
respectively, as secondary antibodies. Immunolabeling was detected by 
enhanced chemiluminescence. 
 
Statistical analysis 
Data are presented as means ± SD. Statistical differences were assessed using 
the Student T Test (hepatic mRNA expression) or the Mann Whitney U test (all 
other analyses). SPSS 14.0 was used for statistical analysis and p<0.05 was 
regarded as statistically significant.  
 
Results 
 
PXR agonism affects plasma lipid levels 
E3L and E3L.CETP mice were fed a control diet or a diet with increasing doses 
of the PXR agonist PCN (0, 0.01, 0.03 and 0.1%), and plasma TG and 
cholesterol were determined (Fig. 1). PCN dose-dependently increased plasma 
TG in both E3L mice (up to + 218%; p<0.01) (Fig. 1A) and E3L.CETP mice 
(up to + 185%; p<0.05) (Fig. 1B), indicating that the effect of PCN on plasma 
TG is independent of CETP expression. However, whereas PCN significantly 
increased plasma cholesterol in E3L mice (up to +19%; p<0.01) (Fig. 1C), PCN 
only tended to increase plasma cholesterol in E3L.CETP mice (Fig. 1D). 
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Figure 1. PXR agonism dose-dependently increases plasma cholesterol and triglycerides. 
APOE*3-Leiden (E3L) mice (A, C) and E3L.CETP mice (B, D) were fed a control diet 
(time-matched control group) or a diet with increasing doses of 5-pregnen-3β-ol-20-one-16α-
carbonitrile (PCN) (0, 0.01, 0.03, and 0.10%) for three weeks each. Before treatment and at 
the end of the 3 week periods, blood was drawn from both PCN-treated and time-matched 
control mice and plasma was assayed for triglycerides (A, B) and cholesterol (C, D). Values 
are means ± SD (n= 6-7 per group); * p<0.05, ** p<0.01 versus control group. 
 
PXR agonism increases hepatic lipid levels  
Since the effects of the PXR agonist on plasma lipids may be caused by an 
altered hepatic lipid homeostasis, the effect of PCN on hepatic lipid 
composition was determined (Fig. 2). In E3L mice, PCN increased the levels of 
TG (+342%; p<0.01), total cholesterol (+159%; p<0.01) and phospholipids 
(+100%; p<0.01) (Fig. 2A). Similar effects of PCN were observed in 
E3L.CETP mice (Fig. 2B), indicating that the effect of PCN on hepatic lipid 
levels is also independent from CETP expression.  
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Figure 2. PXR agonism increases hepatic lipid levels. E3L mice (A) and E3L.CETP mice (B) 
were fed a control diet (time-matched control group) or a diet with increasing doses of PCN 
for three weeks each. After the last treatment period (0.10% PCN and time-matched control), 
mice were sacrificed and livers were isolated. Liver were homogenized, lipids were extracted, 
and triglycerides (TG), total cholesterol (TC) and phospholipids (PL) were quantified. Values 
are means ± SD (n= 6-7 per group); ** p<0.01 versus control group. 
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Figure 3. PXR agonism oppositely affects 
plasma HDL in E3L and E3L.CETP mice. 
E3L mice (A, C) and E3L.CETP mice (B) 
were fed a control diet (time-matched 
control group) or a diet with increasing 
doses of PCN for three weeks each. Plasma 
obtained after the last treatment period 
(0.10% PCN and time-matched control) was 
pooled per group and lipoproteins were 
separated using FPLC. Fractions were 
collected and assayed for total cholesterol 
(A, B) and apolipoprotein composition (C). 
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PXR agonism decreases plasma HDL levels in presence of CETP 
We next investigated the effect of PCN on the cholesterol distribution over 
lipoproteins after separation by FPLC (Fig. 3). In both E3L and E3L.CETP 
mice, PCN increased the amount of cholesterol in VLDL. HDL-cholesterol 
contained in large HDL particles increased in E3L mice (Fig. 3A). On the other 
hand, HDL-cholesterol of all sizes was markedly decreased in E3L.CETP mice 
upon PCN treatment (Fig. 3B). Analysis of the apolipoprotein composition of 
FPLC fractions 16 and 20 of plasma from E3L mice, showed that PCN induces 
the appearance of large apoE-rich HDL-1 as apparent from a high ratio of apoE 
to apoAI (fraction 16), and that PCN treatment reduced the amount of apoAI in 
HDL of regular size (fraction 20) (Fig. 3C). Analysis of HDL-cholesterol in 
plasma after precipitation of apoB-containing lipoproteins showed that the 
HDL-decreasing effect of PCN in E3L.CETP mice was dose-dependent (Fig. 4). 
Figure 4. PXR agonism dose-
dependently decreases plasma HDL in 
E3L.CETP mice. E3L.CETP mice were 
fed a control diet (time-matched control 
group) or a diet with increasing doses of 
PCN for 3 weeks each. After the last 
treatment period (0.10% PCN and time-
matched control), blood was drawn and 
plasma was assayed for HDL-cholesterol 
after precipitation of apoB-containing 
lipoproteins. Values are means ± SD (n= 
6-7 per group); ** p<0.01 versus control 
group. 
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Figure 5. PXR agonism does not affect plasma CETP activity in E3L.CETP mice. 
E3L.CETP mice were fed a control diet (time-matched control group) or a diet with 
increasing doses of PCN for three weeks each. After the last treatment period (0.10% PCN 
and time-matched control), blood was drawn and plasma was assayed for total CETP activity 
(A) and endogenous CETP activity (B). Values are means ± SD (n= 6-7 per group); * 
p<0.05, ** p<0.01 versus control group. 
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PXR agonism does not affect plasma CETP activity 
We have previously observed that a decrease in the hepatic cholesterol content 
of E3L.CETP mice e.g. by treatment with fenofibrate 18 or atorvastatin 19 
decreases both the hepatic expression of CETP and the activity of CETP in 
plasma. Since PXR agonism strongly increases hepatic cholesterol content, we 
questioned whether the reduction in plasma HDL in E3L.CETP mice may be 
related to increased plasma CETP activity. Therefore, the effect of PCN was 
determined on hepatic CETP expression as well as on total and endogenous 
CETP activity in plasma of E3L.CETP mice (Fig. 5). Albeit that a small effect 
was observed on total plasma CETP activity at the highest dose, PCN in general 
did not affect either the total CETP activity (Fig. 5A) or endogenous (Fig. 5B) 
CETP activity, which is in line with an unaltered hepatic gene expression (Table 
1). The reduction of HDL in E3L.CETP mice can thus not be explained by 
increased CETP activity. 
 
Table 2. PXR agonism affects hepatic gene expression. 
 
A. PXR targets 
  E3L E3L.CETP 
  control  PCN control  PCN 
Cyp3a11 1.00 ± 0.35 12.74 ± 5.05*** 1.00 ± 0.38 13.37 ± 2.76*** 
Cyp7a1 1.00 ± 0.53 0.32 ± 0.15** 1.00 ± 0.41 0.59 ± 0.34 
 
B. HDL metabolism 
  E3L E3L.CETP 
  Control  PCN control  PCN 
Abca1 1.00 ± 0.24 0.76 ± 0.23 1.00 ± 0.16 0.81 ± 0.31 
Apoa1 1.00 ± 0.33 0.60 ± 0.20* 1.00 ± 0.38 0.50 ± 0.10* 
Hl 1.00 ± 0.17 0.67 ± 0.16** 1.00 ± 0.28 0.73 ± 0.17 
Lcat 1.00 ± 0.48 0.80 ± 0.18 1.00 ± 0.23 0.68 ± 0.13* 
Pltp 1.00 ± 0.22 0.45 ± 0.12*** 1.00 ± 0.29 0.54 ± 0.18** 
Sr-b1 1.00 ± 0.16 0.45 ± 0.09*** 1.00 ± 0.28 0.61 ± 0.16* 
CETP n.d. n.d. 1.00 ± 0.53 1.77 ± 0.80 
 
E3L and E3L.CETP mice were fed a control diet or a diet with increasing doses of PCN. 
After the last treatment period (0.10% PCN or time-matched control), mice were sacrificed 
and livers were isolated. mRNA was isolated and mRNA expression of the indicated genes 
was quantified by RT-PCR. Genes are grouped as established PXR targets (A) and genes 
involved in HDL metabolism (B). Data are calculated as fold difference as compared to the 
control group. Values are means ± SD (n= 6-7 per group). * p<0.05, ** p<0.01, *** p<0.001 
versus control group. N.d., not detected. 
 
PXR agonism affects hepatic expression of genes involved in HDL metabolism 
To get further insight into the mechanism(s) underlying the effects of PCN on 
HDL metabolism, we evaluated the hepatic expression of genes involved in 
HDL metabolism (Table 2). 
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As a control for PXR agonism, we determined the effects of PCN on the 
expression of Cyp3a11, which is an important target gene of PXR,23,24 and 
Cyp7a1, which is negatively regulated by PXR.25 PCN strongly upregulated 
Cyp3a11 (13-14-fold) and down-regulated Cyp7a1 (-60 -70%) in E3L mice and 
E3L.CETP mice, which confirms that PCN is a potent PXR agonist in these 
mouse models. 
PCN had similar effects on the hepatic expression of the various genes involved 
in HDL metabolism in E3L and E3L.CETP mice. PCN decreased proteins 
involved in HDL assembly including Abca1 (~20%, n.s.) and Apoa1 (~40-50%; 
p<0.05). In addition, PCN decreased the expression of genes involved in HDL 
maturation such as Lcat (~20-30%), Hl (~30%) and Pltp (~50%), as well as the 
gene involved in hepatic clearance of HDL-cholesterol, Sr-b1 (~40-50%). 
 
PXR agonism decreases hepatic SR-BI protein levels 
Since a decrease in SR-BI can explain the increase in HDL-cholesterol 
contained in large HDL-1 particles in E3L mice, we determined whether the 
relatively large effect of PCN on the hepatic expression of Sr-b1 was reflected 
by reduced hepatic protein levels. Western blot analysis of hepatic homogenates 
of E3L.CETP mice indicated that PCN did not substantially reduce hepatic 
ABCA1 protein (-21%, n.s.), which is in line with Abca1 expression analysis, 
but substantially reduced SR-BI protein (-77%, p<0.05) (Fig. 6). Similar results 
were obtained for E3L mice (data not shown). 
 
Discussion 
 
Studies on the effect of PXR activation on HDL metabolism have generated 
conflicting data with respect to their net effect on HDL levels. However, these 
data have been derived either from in vitro studies of from in vivo studies in 
wild-type mice that naturally have very low (V)LDL and high HDL levels, and 
do not express CETP. Therefore, we have evaluated the effect of PXR agonism 
 
B. SR-BI
A. ABCA1
PCN
Control
PCN
Control
Figure 6. PXR agonism reduces hepatic SR-BI 
protein. E3L.CETP mice were fed a control 
diet (time-matched control group) or a diet 
with increasing doses of PCN for three weeks 
each. After the last treatment period (0.10% 
PCN and time-matched control), mice were 
sacrificed and livers were isolated. Livers were 
homogenized and equal amounts of hepatic 
proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membrane. 
ABCA1 (A) and SR-BI (B) were visualized by 
immunolabeling. Results of 4 individual mice 
per group are shown.  
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on HDL metabolism in E3L mice, which have a more favorable ratio of 
(V)LDL to HDL and is a well-established model for human-like lipoprotein 
metabolism, as well as E3L.CETP mice. 
We have demonstrated that E3L and E3L.CETP mice respond well to PXR 
agonism. PCN not only considerably increased hepatic Cyp3a11 expression and 
reduced Cyp7a1 expression, but also induced fatty livers as judged from an 
increased liver weight, increased levels of hepatic TG, total cholesterol and 
phospholipid, as well as formation of lipid droplets (not shown). Hepatic 
steatosis appears to be a common effect of PXR agonism, since 1) expression of 
activated PXR in the livers of transgenic mice increases hepatic TG levels,12 2) 
PXR agonism in mice expressing the human PXR gene increases hepatic TG 
levels,12 and 3) PCN increases hepatic TG levels in wild-type mice, but not in 
PXR knockout mice.11 
We showed that PCN markedly increased plasma TG accompanied by a modest 
increase in plasma cholesterol, as reflected by increased (V)LDL levels. This is 
most probably a consequence of the increased hepatic lipid levels, which may 
result in an increased substrate-driven hepatic VLDL production.  
The effect of PXR agonism on plasma HDL levels appeared more complex. In 
E3L mice, PCN increased cholesterol contained in large HDL-1. Accumulation 
of apoE-rich large HDL-1 is a common characteristic of SR-BI deficient mice, 
since SR-BI appears solely responsible for the selective clearance of HDL-
cholesteryl esters in mice.26 Indeed, we observed that PCN largely decreased the 
hepatic expression of Sr-b1 as well as hepatic SR-BI protein in both E3L and 
E3L.CETP mice. This strongly suggests that the decrease in hepatic SR-BI may 
be a causal factor for the increase in large HDL. Based on these data we 
speculate that a decrease in hepatic SR-BI may also contribute to the increase in 
HDL-cholesterol and apoAI in wild-type mice as previously observed by 
Bachman et al.7 In contrast, PXR agonism by PCN failed to increase cholesterol 
within large HDL-1 in E3L.CETP mice. This can be explained by the fact that 
large HDL-1 is a preferred substrate for CETP, since CETP expression in SR-
BI-deficient mice normalized both the particle size and plasma levels of HDL.27 
PXR agonism not only failed to increase the HDL particle size in E3L.CETP 
mice as compared to E3L mice, but even dose-dependently decreased the HDL-
cholesterol level. We have previously shown that fenofibrate18 and atorvastatin19 
increase HDL-cholesterol levels by decreasing hepatic CETP expression related 
to lower liver lipid levels, suggesting that the PXR-induced increased liver lipid 
levels may conversely reduce HDL levels by increased CETP expression. 
However, PCN did not affect hepatic CETP expression or total CETP activity in 
plasma in E3L.CETP mice. One could argue that the PCN-induced increase in 
VLDL-TG levels may result in a substrate-driven increase in CETP activity, 
resulting in a relatively TG-rich HDL that would be more rapidly remodeled 
and cleared via hepatic lipase.13 However, such a mechanism is less plausible 
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since we were also unable to detect an increase in the endogenous (lipoprotein-
dependent) CETP activity. 
Albeit that CETP expression per se seems to be the main contributor to the 
PXR-induced decrease in HDL-cholesterol in E3L.CETP mice, other players 
involved in HDL metabolism may contribute as well. Previous studies showed 
that PXR agonism decreased ABCA1 expression in hepatocytes,10 but we only 
observed a tendency towards reduced hepatic Abca1 mRNA (~20%) and protein 
(~20%). However, PCN markedly reduced hepatic Apoa1 mRNA (~40-50%). 
Given the fact that both apoAI and ABCA1 are important for the generation of 
discoidal HDL precursors (i.e. apoAI) and their subsequent lipidation (i.e. 
ABCA1), genetic deficiency for either apoAI28 or ABCA129 dramatically 
decreases HDL levels. Therefore, a potential modest reduction of ABCA1 
accompanied by the large reduction in apoAI may well have synergistically 
contributed to the dose-dependent marked decrease in HDL in our in vivo study 
in mice, but only in the mice that express CETP. In addition, PCN decreased the 
expression of genes involved in HDL maturation such as Hl (~30%), Lcat (~20-
30%) and Pltp (~50%). Although HL-deficiency mildly increases HDL,30 
LCAT-deficiency31 and PLTP-deficiency32 both reduce plasma HDL levels. 
Therefore, the effects of PXR agonism on the hepatic expression of Lcat and 
Pltp, but not Hl, may also have contributed to some extent to the observed 
reduction in HDL.  
Together, our data show that PXR agonism increases cholesterol contained in 
large HDL-1 particles in E3L mice, as related to decreased hepatic SR-BI 
levels, and decreases HDL-cholesterol in E3L.CETP mice primarily resulting 
from CETP expression per se. Since the E3L.CETP mouse has proven a 
valuable model to predict drug-induced responses in humans with respect to 
HDL metabolism6,18,19 we anticipate that PXR agonism is not a valid strategy to 
raise HDL. 
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Abstract 
 
Apolipoprotein CI (apoCI) has been suggested to influence HDL metabolism by 
activation of LCAT and inhibition of HL and CETP. However, the effect of 
apoCI on scavenger receptor BI (SR-BI)-mediated uptake of HDL-cholesteryl 
esters (CE), as well as the net effect of apoCI on HDL metabolism in vivo is 
unknown. Therefore, we evaluated the effect of apoCI on the SR-BI-mediated 
uptake of HDL-CE in vitro and determined the net effect of apoCI on HDL 
metabolism in mice. Enrichment of HDL with apoCI dose-dependently 
decreased the SR-BI-dependent association of [3H]CE-labeled HDL with 
primary murine hepatocytes, similar to the established SR-BI-inhibitors apoCIII 
and oxLDL. ApoCI-deficiency in mice gene dose-dependently decreased HDL-
cholesterol levels. Adenovirus-mediated expression of human apoCI in mice 
increased HDL levels at a low dose and increased the HDL particle size at 
higher doses. We conclude that apoCI is a novel inhibitor of SR-BI in vitro and 
increases HDL levels in vivo. 
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Introduction 
 
Apolipoprotein CI (ApoCI) is a 6.6 kDa protein that is mainly synthesized by 
the liver, and also by other tissues such as lung, spleen, intestine, brain and 
adipose tissue. After secretion by the liver, apoCI associates with chylomicrons, 
VLDL and HDL and is exchangeable between these lipoproteins.1 ApoCI is 
highly positively charged, and is present in a relatively high plasma 
concentration of about 10 mg/dL.1 
Several functions of apoCI in lipoprotein metabolism have been described. 
ApoCI affects the metabolism of apoB-containing lipoproteins. Using apoCI-
deficient and apoCI-overexpressing mice, it has been shown that apoCI 
attenuates the clearance of VLDL by inhibition of the lipolytic conversion of 
VLDL by lipoprotein lipase (LPL), either directly2 or indirectly via product 
inhibition due to its fatty acid-binding properties.3 In addition, apoCI decreases 
the clearance of VLDL by inhibition of the binding and uptake of VLDL by the 
classical apoE-recognizing receptors, including the LDL receptor (LDLr)4 and 
LDLr-related protein (LRP)5 on the liver, as well as the VLDL receptor 
(VLDLr)6 that is mainly present on peripheral tissues. ApoCI has also been 
shown to increase the production of VLDL.7 By these combined actions, apoCI 
thus increases the plasma levels of VLDL-associated triglyceride (TG) and 
cholesterol (C) in mice.1,2 
ApoCI has also been suggested to be involved in HDL metabolism, although 
such a role has only been derived from in vitro observations. ApoCI is involved 
in HDL remodeling by activation of lecithin: cholesterol acyltransferase 
(LCAT) that esterifies cholesterol in HDL and, therefore, increases HDL-C 
levels and HDL particle size,8,9 and by inhibition of hepatic lipase (HL) that 
lipolyzes TG and phospholipids (PL) in HDL.10,11 However, the in vivo 
relevance of these actions of apoCI is unknown, but it is conceivable that apoCI 
increases the plasma levels and/or the particle size of HDL. ApoCI has also 
been identified as an inhibitor of the activity of cholesteryl ester (CE) transfer 
protein (CETP),12 which may add to a potential HDL-raising effect of apoCI, at 
least in CETP-expressing species. 
ApoCI may also affect the uptake of HDL-CE via SR-BI, as two homologues of 
apoCI (i.e. apoCII and apoCIII) have recently been demonstrated to inhibit SR-
BI.13 Although such an effect of apoCI has not been reported before, SR-BI 
inhibition would add to a potential HDL-raising effect of apoCI in vivo, since 
SR-BI is solely responsible for the selective hepatic uptake of HDL-CE in 
mice.14 
Therefore, in the present study we evaluated whether apoCI would represent a 
novel modulator of SR-BI by evaluating the effect of apoCI on the uptake of 
HDL-CE by freshly isolated mouse hepatocytes. In addition, we examined the 
in vivo relevance of the combined effects of apoCI on HDL metabolism using 
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apoCI-deficient mice and mice that overexpress apoCI using adenoviral 
expression.  
 
Methods 
 
Mice 
Heterozygous apoCI knockout (apoc1-/-) mice15 were crossbred to obtain wild-
type (WT), apoc1+/- and apoc1-/- littermates (C57Bl/6 background). 
Overexpression of apoCI was achieved via injection of a recombinant 
adenovirus that expresses human apoCI as described.16 
MX1Cre:LRPlox/lox.LDLr-/-.VLDLr-/- mice (C57Bl/6 background), that are 
deficient for the LDLr, VLDLr and hepatic LRP after three intraperitoneal 
injections of polyinosinic: polycytidylic ribonucleic acid (pI:pC), have been 
generated as described previously.17 Mice had access to regular chow and water 
ad libitum. When indicated, blood was drawn via the tail vein into paraoxon-
coated capillaries after 4 h fasting at 13.00 h and plasma was collected after 
centrifugation. 
 
Radiolabeling of HDL 
HDL was isolated from human plasma by density gradient ultracentrifugation 
and labeled with [3H]cholesteryl oleoyl ether (COEth) as described previously.18 
 
In vitro hepatocyte studies 
Hepatocytes were isolated from anesthetized WT and LRP-.LDLr-/-.VLDLr-/- 
mice by perfusion of the liver with collagenase.19 Freshly isolated cells 
(1x106/mL) were incubated (3h at 37°C) in DMEM + 2% BSA with 
[3H]COEth-labeled HDL (20 µg protein/mL) in the absence or presence of 
apoCI (Protein Chemistry Technology Center, Dallas TX, USA), apoCIII 
(Biodesign International, Saco, ME, USA), or oxidized (oxLDL) (100 µg 
protein/mL) under gentle shaking. After incubation, cells were pelleted by 
centrifugation and unbound label was removed by repeated washing with Tris-
buffered saline. The pellet was lysed in 0.1 M NaOH and cell-associated 
radioactivity and protein content were measured. [3H]COEth association was 
calculated as dpm/mg cell protein.  
 
Biochemical analysis 
Plasma cholesterol levels were measured with a commercially available 
enzymatic kit (236691, Roche Molecular Biochemicals, Indianapolis IN, USA). 
Plasma apoCI was measured by ELISA2 and apoAI was measured by western 
blotting.20 Lipoproteins were fractionated using fast performance liquid 
chromatography (FPLC). Hereto, plasma was pooled per group and 50 µL of 
each pool was injected onto a Superose 6 HR 10/30 column (Äkta System, 
Amersham Pharmacia Biotech, Piscataway, NJ, USA) and eluted at a constant 
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flow rate of 50 µL/min in PBS, 1 mM EDTA, pH 7.4. Fractions of 50 µL were 
collected and assayed for cholesterol as described above. 
 
Statistical analysis 
Data were analyzed using the Mann-Whitney nonparametric test. Analyses were 
performed with SPSS 14.0 (SPSS inc, Chicago, USA).  
 
Results 
 
ApoCI inhibits the association of [
3
H]COEth-labeled HDL with hepatocytes 
To examine whether apoCI affects the SR-BI-mediated uptake of HDL-CE, we 
evaluated the effect of apoCI on the association [3H]COEth-labeled HDL with 
primary hepatocytes from WT mice. Enrichment of HDL (20 µg protein/mL) 
Figure 1. ApoCI dose dependently inhibits SR-BI in vitro. Primary hepatocytes were isolated 
from WT mice (A, B) and LRP-.LDLr-/-.VLDLr-/- mice (C, D) and incubated (3 h at 37°C) 
with [3H]COEth-HDL (20 µg/mL) enriched with apoCIII (20 µg/mL) or apoCI (20 µg/mL) 
(A, C). In a separate experiment, cells were incubated with apoCI (5 and 20 µg/mL) or 
oxLDL (100 µg/mL) (B, D). Cell-associated radioactivity was expressed as dpm/mg cell 
protein. Values represent means ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. 
C
el
l 
as
so
ci
at
io
n 
(%
 o
f 
co
nt
ro
l)
D
C
el
l
as
so
ci
at
io
n
(%
 o
f 
co
nt
ro
l)
**
*** ***
C
B
A
**
ap
oC
III
***
ap
oC
I
co
nt
ro
l
ap
oC
I (
5 µ
g/
m
L)
ap
oC
I (
20
 µ
g/
m
L)
ox
LD
L
co
nt
ro
l
***
ap
oC
III
***
ap
oC
I
co
nt
ro
l
ap
oC
I (
5 µ
g/
m
L)
ap
oC
I (
20
 µ
g/
m
L)
ox
LD
L
co
nt
ro
l
LRP-.LDLr-/-.VLDLr-/-Wild-type
Wild-type LRP-.LDLr-/-.VLDLr-/-
0
100
*
***
***50
150
0
100
50
150
0
100
50
150
0
100
50
150
C
el
l 
as
so
ci
at
io
n 
(%
 o
f 
co
nt
ro
l)
C
el
l
as
so
ci
at
io
n
(%
 o
f 
co
nt
ro
l)
C
el
l 
as
so
ci
at
io
n 
(%
 o
f 
co
nt
ro
l)
C
el
l
as
so
ci
at
io
n
(%
 o
f 
co
nt
ro
l)
Chapter 7 
 
 136 
with the established SR-BI inhibitor apoCIII (20 µg/mL) inhibited HDL-CE 
association with WT hepatocytes (-37%; P<0.001), which is in line with the 
findings of Huard et al.13 ApoCI, at the same concentration, inhibited HDL-CE 
association even more effic iently than apoCIII (-57%; P<0.001) (Fig. 1A). In a 
second experiment, we showed that the inhibition of HDL-CE association by 
apoCI is dose-dependent (-19% at 5 µg/mL; P<0.05 and -53% at 20 µg/mL; 
P<0.001), and that the highest apoCI concentration was equally effective as the 
established SR-BI inhibitor oxLDL (-57% at 100 µg/mL; P<0.001) (Fig. 1B). 
As apoCI is also an inhibitor of the classical apoE recognizing receptors (i.e. 
LRP, LDLr and VLDLr), we repeated this experiment with hepatocytes from 
LRP, LDLr and VLDLr triple-knockout mice. ApoCI affected the association of 
HDL-CE with LRP-.LDLr-/-.VLDLr-/- hepatocytes (Fig. 1C and D) similarly as 
with WT cells (Fig. 1A and B). This shows that the inhibitory effect of apoCI 
on HDL-CE association with hepatocytes is independent of the apoE-
recognizing receptors, and confirms that HDL-CE association with hepatocytes 
is strictly dependent on SR-BI.14 
 
ApoCI deficiency decreases plasma HDL levels in mice 
Previous in vitro studies have demonstrated that apoCI activates LCAT8,9 and 
inhibits HL 10,11 and we thus now show that apoCI additionally inhibits SR-BI. 
To evaluate the consequences of these combined effects for HDL-C metabolism 
in vivo, we first examined the effect of genetic apoCI-deficiency in mice on 
HDL-C levels. Hereto, blood was drawn from 4 hours fasted WT, apoc1+/- and 
apoc1-/- littermates. ApoCI-deficiency resulted in a gene dose-dependent 
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Figure 2. ApoCI deficiency in mice decreases HDL in vivo. Blood was drawn from WT, 
apoc1+/- and apoc1-/- littermate mice after 4 h fasting, and plasma was assayed for total 
cholesterol (A). Values represent means ± SD (n=12). **P<0.01. Plasma was pooled per 
group (n=12), lipoproteins were fractionated by FPLC and cholesterol in fractions was 
measured (B).  
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decrease in plasma cholesterol up to -32% (P<0.01) upon homozygous apoCI 
deficiency (Fig. 2A). Separation of the various lipoprotein fractions from 
plasma by FPLC showed that the decrease in plasma cholesterol was mainly 
confined to the HDL fraction. A gene dose-dependent decrease in HDL-C was 
observed up to -29% in apoc1-/- mice (Fig. 2B). In contrast, apoCI deficiency 
did not affect plasma apoAI levels (not shown). 
 
ApoCI overexpression increases plasma HDL levels and enlarges HDL 
To examine the effect of apoCI overexpression on HDL-C levels and HDL size, 
WT mice were injected with a recombinant adenovirus expressing human apoCI 
(0.1, 0.3, 1, and 3.3 x109 pfu/mouse).16 This resulted in a virus dose-dependent 
increase in plasma levels of apoCI (0, 12, 23 and 33 mg/dL) and cholesterol (up 
to +48%; P<0.001) (Fig. 3A). Fractionation of lipoproteins by FPLC indicated 
that overexpression of apoCI led to a dose-dependent increase in VLDL, which 
is explained by the well-known attenuation of the catabolism of apoB-
containing lipoproteins. Interestingly, overexpression of a low dose of apoCI led 
to an increase of the normal sized HDL (+15%), whereas higher doses rather led 
to an increase of HDL particle size as shown by the appearance of HDL-1 (Fig. 
3B).  
 
Discussion 
 
The aim of our study was to determine the effect of apoCI on HDL metabolism, 
by addressing the effect of apoCI on the hepatic HDL receptor SR-BI in vitro 
Figure 3. ApoCI overexpression in mice increases HDL in vivo. WT mice were injected with 
a recombinant adenovirus expressing human apoCI to dose-dependently increase apoCI 
plasma levels. After 5 days, blood was drawn after a 4 h fast, and plasma total cholesterol 
was measured (A). Values represent means ± SD (n=5). *P<0.05, **P<0.01, ***P<0.001. 
Plasma was pooled per group (n=5), lipoproteins were fractionated by FPLC and cholesterol 
in fractions was measured (B). 
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and by evaluating the net effect of apoCI on plasma HDL in vivo. We showed 
that apoCI inhibits the SR-BI-mediated association of HDL-CE with primary 
murine hepatocytes. Furthermore, we showed in mice that apoCI-deficiency 
reduces HDL levels and, conversely, that modest and high apoCI 
overexpression increases and enlarges HDL, respectively. 
Previous in vitro studies have suggested that apoCI may be involved in HDL 
metabolism by stimulation of LCAT,8,9 inhibition of HL10,11 and inhibition of 
CETP,12 which are all involved in the remodeling of HDL in the circulation. 
Based on the structural homology of apoCI with apoCII and apoCIII, which 
have been shown to inhibit the of SR-BI-mediated selective uptake of HDL-CE 
by HepG2 cells,13 we postulated that apoCI may also inhibit SR-BI. Indeed, 
apoCI appeared even more effective in inhibiting the SR-BI-mediated uptake of 
HDL-CE by primary mouse hepatocytes than apoCIII. 
It is interesting to speculate how apoCI affects SR-BI function. As compared to 
apoCII and apoCIII, apoCI is unusually rich in positively-charged lysine 
residues, which is important for both its lipopolysaccharide-binding21 and 
CETP-inhibiting22 properties. The fact that apoCI, apoCII and apoCIII all 
inhibit SR-BI suggests that the high positive charge of apoCI is not essential for 
this effect. The mechanism by which apoCII and apoCIII inhibit SR-BI, has not 
yet been resolved.13 SR-BI binds HDL via multiple binding sites23 and 
subsequently mediates selective CE uptake from this particle.24 Therefore, 
apoCI, apoCII and apoCIII may interfere with this process by 1) modifying 
HDL particles in a way that binding of SR-BI to HDL is reduced, 2) stabilizing 
HDL particles in a way that CE can not easily be removed, and/or 3) interacting 
directly with SR-BI, thereby preventing binding to HDL.  
Interestingly, the effects of apoCI on the various HDL-modulating proteins, 
including activation of LCAT, inhibition of HL, and inhibition of SR-BI, should 
theoretically all lead to an increase in HDL levels and/or particle size. First, 
overexpression of LCAT, an HDL-associated plasma enzyme that is responsible 
for cholesterol esterification in HDL,25-27 increases both HDL-C and HDL 
size.28 Second, homozygous deficiency for HL, a plasma enzyme that degrades 
TG and PL within HDL,29 does not have a large impact on HDL-C, but does 
result in accumulation of large HDL-1 particles.30 Third, heterozygous SR-BI 
deficiency primarily results in an increase in HDL-C, whereas homozygous SR-
BI deficiency leads to accumulation of large HDL-1.31 Therefore, we postulated 
that apoCI expression would positively correlate with HDL-C levels and HDL 
size. Indeed, we showed that apoCI deficiency reduced HDL-C. Conversely, 
overexpression of increasing amounts of apoCI increased HDL-C at moderate 
expression and gradually increased the formation of large HDL-1 at higher 
apoCI expression levels. These effects are thus all consistent with the expected 
effects of apoCI on LCAT, HL and SR-BI, albeit that it is not feasible to 
quantify the relative contribution of the individual pathways. 
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Regarding the current interest in raising HDL as a novel strategy to reduce 
cardiovascular risk, apoCI may be an exciting new lead. It is interesting to note 
that, in addition to its effect on LCAT, HL and SR-BI, apoCI is also the main 
endogenous protein inhibitor of CETP.12 CETP  is absent in mice but present in 
plasma of humans and may therefore also add to the HDL-raising effect of 
apoCI in humans. Although a causal effect of apoCI on determining HDL levels 
in humans would be difficult to study, more than 90% of plasma apoCI appears 
to be associated with HDL in normolipidemic subjects32 and we recently 
demonstrated a positive correlation between plasma apoCI and HDL.33 Of 
course, since levels of HDL do not always reflect the atheroprotective properties 
of HDL (i.e. its role in reverse cholesterol transport, its anti-inflammatory and 
antioxidative properties), studies on the effect of apoCI on HDL functionality 
are still warranted. 
A drawback of apoCI as a lead in HDL-raising therapy would be that apoCI not 
only increases HDL levels, but also increases VLDL levels mainly by inhibition 
of LPL activity.2 This appeared the predominant reason why apoCI 
overexpression on a hyperlipidemic apoE-deficient background aggravated 
atherosclerosis,11 whereas apoCI-deficiency attenuated atherosclerosis.34 
Furthermore, SR-BI has recently been described to facilitate the hepatic uptake 
of VLDL and chylomicrons.35,36 These effects may thus add to some extent to 
the VLDL-raising effect of apoCI. Therefore, it would be interesting to perform 
in vitro structure-and-function studies to determine the minimal domain of 
apoCI that targets subsets of HDL-modulating proteins, including preferentially 
LCAT, HL and CETP, without adversely affecting VLDL metabolism via LPL 
and potentially SR-BI. 
In conclusion, we have demonstrated that apoCI is a novel inhibitor of the SR-
BI-mediated uptake of HDL-CE by hepatocytes, and that apoCI is a determinant 
for the plasma levels and size of HDL in vivo.  
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Abstract 
 
Apolipoprotein CI (apoCI) is a highly positively charged plasma apolipoprotein 
of 57 amino acids and has a dual role in plasma lipoprotein metabolism and 
atherosclerosis. On one hand, apoCI inhibits the cholesteryl ester transfer 
protein (CETP), which increases the plasma level of anti-atherogenic high 
density lipoproteins (HDL). On the other hand, apoCI inhibits lipoprotein lipase 
(LPL), which increases proatherogenic (very) low density lipoproteins 
((V)LDL). In this study, we show that the CETP-inhibitory function of apoCI 
resides in the C-terminal domain, whereas the C terminus of apoCI is not 
sufficient for the LPL-inhibitory function of apoCI. The C-terminal peptide 
apoCI32-57 potently inhibited CETP activity, mainly caused by positively 
charged amino acids, with a negligible effect on LPL activity. Therefore, 
apoCI32-57 may be an interesting lead in the search for novel CETP inhibitors as 
a new strategy to increase HDL thereby reducing cardiovascular risk. 
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Introduction 
 
Apolipoprotein CI (apoCI) is the smallest known apolipoprotein. ApoCI 
consists of only 57 amino acids, arranged in two amphipathic helices connected 
by a flexible hinge region, and is unusually rich in positively charged lysine (K) 
and arginine (R) residues (21 mol%). ApoCI is mainly produced by hepatocytes 
and secreted into plasma, where it associates with predominantly anti-
atherogenic high density lipoproteins (HDL), but also with atherogenic very 
low density lipoproteins (VLDL).
1
  
ApoCI has various functions in lipoprotein metabolism. ApoCI has been 
identified as the main endogenous HDL-associated inhibitor of cholesteryl ester 
transfer protein (CETP) activity,
2
 probably because of its large amount of 
positively charged amino acids,
3
 which is regarded as an anti-atherogenic 
property. CETP is responsible for the transfer of cholesteryl esters (CE) from 
HDL to low density lipoproteins (LDL) and VLDL in plasma. In this way, 
CETP lowers HDL-cholesterol (C) and at the same time increases (V)LDL-C, 
thereby unfavourably modifying two risk factors for atherosclerosis. CETP 
inhibition is generally regarded as an effective new therapeutic strategy to 
increase HDL-C levels and reduce cardiovascular disease (CVD) risk.
4,5
 In fact, 
apoCI-deficiency in human CETP transgenic mice increases CETP activity and 
lowers HDL-C levels.
6
 Conversely, human apoCI overexpressing (APOC1) 
transgenic mice have reduced specific CETP activity.
7
 ApoCI could therefore 
be an interesting lead for a new generation of CETP inhibitors. 
However, apoCI is also a major inhibitor of lipoprotein lipase (LPL),
8
 which is 
a pro-atherogenic property. LPL hydrolyses triglycerides (TG) within TG-rich 
lipoproteins such as VLDL, resulting in the liberation of fatty acids (FA) that 
can be stored in adipose tissue or used as energy supply for skeletal muscle and 
heart. Therefore, apoCI-deficient mice on a hyperlipidemic apoE-deficient 
background have decreased VLDL levels
9
 and decreased atherosclerosis.
10
 
Conversely, APOC1 transgenic mice have severely increased plasma VLDL 
levels,
8
 and APOC1 mice on a hyperlipidemic apoE-deficient background have 
increased atherosclerosis.
11,12
 Because of apoCI-induced LPL inhibition, human 
apoCI overexpression in CETP transgenic mice not only reduces specific CETP 
activity, but also largely increases VLDL levels. The increase in VLDL levels 
consequently increases hepatic CETP gene expression, which precludes an 
increase in HDL-C resulting from CETP inhibition only.
7
  
To investigate whether apoCI may represent a suitable lead for novel CETP 
inhibitors, we aimed in this study to identify by structure-function analysis the 
minimal CETP-inhibitory domain of apoCI without LPL-inhibitory activity. 
Studies in baboons with high HDL have identified the N-terminal domain 
apoCI1-38 as the CETP inhibitor,
13,14
 whereas studies on the interaction of human 
apoCI with human CETP indicated that the C-terminal domain apoCI34-54, rather 
than the N-terminal domain apoCI4-25, inhibited CETP.
3
 Therefore, we 
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generated full-length apoCI as well as an array of N-terminal and C-terminal 
apoCI-derived peptides by solid-phase synthesis, and determined their effect on 
the activity of CETP as well as of LPL. To get more insight into the mechanism 
by which apoCI inhibits CETP activity, we also evaluated the contribution of 
the positively charged amino acids by replacing K and R residues by 
electroneutral alanine (A) residues. 
 
Materials and Methods 
 
ApoCI and apoCI peptides. 
Full-length human apoCI (apoCI1-57; purity >95%) was synthesized by the 
Protein Chemistry Technology Center (UT Southwestern Medical Center, 
Dallas, TX). ApoCI-derived peptides, without or with replacement of positively 
charged K and R by electroneutral A, were synthesized by the Peptide Synthesis 
Facility of the Department of Immunohematology and Blood Transfusion at the 
Leiden University Medical Center (Leiden, The Netherlands) by solid phase 
peptide synthesis on a TentagelS-AC (Rap, Tübingen, Germany) using 9-
fluorenylmethoxycarbonyl/t-Bu chemistry, benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate/N-methylmorpholine for 
activation and 20% piperidine in N-methylpyrrolidone for 
fluorenylmethoxycarbonyl removal.
15
 The peptides were cleaved from the resin, 
deprotected with trifluoroacetic acid/water, and purified on Vydac C18. The 
purified peptides were analyzed by reverse-phase HPLC and their molecular 
masses were confirmed by MALDI-TOF mass spectrometry (purity >95%). The 
primary sequences of apoCI and apoCI-derived peptides are shown in Table 1. 
 
 
Table 1. Primary sequences and isoelectric points (pI) of full-length human apoCI (apoCI1-57) 
and apoCI-derived peptides. 
ApoCI 
peptides 
pI Primary sequence 
1-57 7.93 TPDVSSALDKLKEFGNTLEDKARELISRIKQSELSAKMREWFSETFQKVKEKLKIDS 
1-20 4.27 TPDVSSALDKLKEFGNTLED 
1-23 4.86 TPDVSSALDKLKEFGNTLEDKAR 
1-30 5.98 TPDVSSALDKLKEFGNTLEDKARELISRIK 
1-38 6.02 TPDVSSALDKLKEFGNTLEDKARELISRIKQSELSAKM 
46-57 9.53 FQKVKEKLKIDS 
35-57 9.40 SAKMREWFSETFQKVKEKLKIDS 
32-57 8.11 SELSAKMREWFSETFQKVKEKLKIDS 
32-57 A 5.00 SELSAAMAEWFSETFQKVKEKLKIDS 
32-57 B 4.25 SELSAKMREWFSETFQAVAEALAIDS 
32-57 C 3.45 SELSAAMAEWFSETFQAVAEALAIDS 
 
The positively charged basic amino acids Lys (K) and Arg (R) are represented in boldface. 
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CETP activity.  
The effect of apoCI and apoCI-derived peptides on the CETP-mediated transfer 
of [
3
H]cholesteryl oleate (CO) from LDL to HDL was determined essentially as 
described.
16
 HDL, LDL and lipoprotein deficient serum (LPDS) were isolated 
from human plasma by ultracentrifugation, and  LDL was radiolabelled by 
incubation with [
3
H]CO (Amersham Biosciences, Buckinghamshire, UK)-
containing phosphatidylcholine vesicles in the presence of LPDS exactly as 
described.
16
 ApoCI and apoCI-derived peptides were incubated (6 h at 37°C) 
with [
3
H]CO-LDL (31.25 nmol total cholesterol) and HDL (12.5 nmol total 
cholesterol) in a total volume of 175 µL 0.1 M phosphate buffer, pH 7.4, in the 
presence of the 10 µL LPDS as CETP source and 8 mM of the lecithin-
cholesterol acyltransferase (LCAT) inhibitor 5,5'-dithiobis-(2-nitrobenzoic acid) 
(DTNB) (Sigma). After incubation, LDL was precipitated with 75 µL 0.1 M 
phosphate buffer and 25 µL 0.167 mM manganese chloride, and the supernatant 
was counted for HDL-associated [
3
H]CO in Ultima Gold (Perkin Elmer, 
Boston, MA, USA). CETP activity was calculated as nmol CE transfer/ mL/ 
min and expressed as % of control.  
 
LPL activity assay. 
The effect of apoCI and apoCI peptides on the triacylglycerol hydrolase activity 
of LPL was assessed by determining their effect on the LPL-mediated 
hydrolysis of TG within VLDL-like
 
emulsion particles,
8
 using either soluble 
LPL as described
17
 or heparan sulfate proteoglycan (HSPG)-bound LPL. 
Hereto, 0.25 µg/well HSPG (Sigma) was bound to 96-wells plates by overnight 
incubation at 4°C. Wells were blocked (1 h at 37°C) with 1% BSA in 0.1 M 
Tris.HCl pH 8.5, Bovine LPL (0.2 U/well; Sigma) was attached to HSPG by 
incubation (2 h at 37°C) in 12% BSA in 0.1 M Tris.HCl, pH 8.5. After washing, 
[
3
H]TO-labelled VLDL-like emulsion particles (0.5 mg TG/mL), pre-incubated 
with apoCI
 
(30 min at 37°C), were added in the presence of essentially fatty
 
acid-free BSA (60 mg/mL, Sigma) and the LPL-cofactor apoCII (2.5 µg/mL) in 
0.1 M Tris.HCl, pH 8.5. After incubation (20 min at 37°C) the reaction was 
stopped by placing plates on ice and 20 µL
 
sample was added
 
to 1.5 mL of 
methanol: chloroform: hexane: oleic acid (1,410: 1,250: 1,000: 1,
 
v/v/v/v) and 
0.5 mL of 0.1 N NaOH was added. To quantify the [
3
H]oleate generated, 0.5
 
mL 
of the aqueous phase obtained after vigorous mixing (15 sec)
 
and centrifugation 
(15 min at 3,600 rpm) was counted in Ultima Gold. 
 
Statistical analysis. Data were analyzed using the Mann-Whitney 
nonparametric test. Analyses were performed with SPSS 14.0 (SPSS Inc, 
Chicago, USA).  
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Results 
 
ApoCI dose-dependently inhibits CETP activity. 
To confirm the previously reported CETP-inhibitory effect of full-length human 
apoCI, we determined the dose-dependent effect of apoCI1-57 on the transfer of 
[
3
H]CO from human LDL to human HDL in the presence of LPDS as source of 
CETP (Fig. 1). Indeed, apoCI dose-dependently inhibited CETP activity, with 
an IC50 of approx. 4 µM, and nearly completely inhibited CETP activity at 16 
µM (-91%; P<0.05).  
 
The CETP-inhibitory property of apoCI is confined to its C-terminal domain.  
Since the CETP-inhibitory effect of apoCI has been attributed to either its N-
terminus
13,14
 or C-terminus,
3
 we generated an array of N-terminal and C-
terminal apoCI-derived peptides by solid-phase synthesis (shown in Table 1), 
and determined their effect on CETP activity (Fig. 2). The N-terminal peptides 
apoCI1-20 to apoCI1-38 did not affect CETP activity at 16 µM, and only 
marginally decreased CETP activity at 64 µM in a length-dependent way (-19% 
for apoCI1-38; P<0.05) (Fig. 2A). In contrast, the C-terminal peptides apoCI35-57 
and apoCI32-57 already affected CETP at 16 µM (-37% for apoCI32-57; P<0.05), 
and largely decreased CETP activity at 64 µM, again in a length-dependent way 
(-100% for apoCI32-57; P<0.05) (Fig. 2B). 
 
The CETP-inhibitory property of apoCI32-57 depends on positively charged 
amino acids. 
It has been shown that the ability of apoCI to inhibit CETP activity could be 
explained by reduction of the electronegative surface charge of HDL.
3
 Since 
apoCI is unusually rich in electropositive K and R residues, we thus determined 
the contribution of these residues to the CETP-inhibitory effect of apoCI32-57 by 
site-specific replacement into A residues that are electroneutral and do not 
affect the overall peptide structure (Fig. 3). At a concentration of 16 µM, 
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Figure 1. ApoCI dose-dependently 
inhibits CETP activity. Full-length 
apoCI (apoCI1-57; 0-16 µM) was 
incubated (6 h at 37°C) with [3H]CO-
LDL and HDL in PBS in the presence 
of LPDS as source of CETP. The 
amount of [
3
H]CO transferred from 
LDL to HDL was determined by 
counting [
3
H]CO-HDL after 
precipitation of LDL. CETP activity 
was calculated relatively to control 
incubations without apoCI. Values 
are means ±SD, n=3, * P<0.05, as 
compared to control without peptides 
added.  
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wild-type apoCI32-57 decreased CETP activity appreciably (-37%; P<0.05). 
Neutralization of positively charged residues, within either the KMR cluster at 
the N-terminal end or within the KVKEKLK cluster at the C-terminal end, 
reduced CETP inhibition partially (-22% and -21%; P<0.05), whereas 
neutralization of all positively charged amino acids completely abolished the 
CETP-inhibitory property of apoCI32-57. A similar pattern was observed at 64 
µM, albeit that the peptide in which all K and R residues have been replaced by 
A still inhibit CETP activity to some extent (-31%; P<0.05). 
Figure 2. The CETP-inhibitory property of apoCI is confined to its C-terminal domain. 
ApoCI peptides derived from the N-terminal domain (A) or C-terminal domain (B) were 
incubated (6 h at 37°C) at concentrations of 16 µM and 64 µM with [
3
H]CO-LDL and HDL 
in PBS in the presence of LPDS as source of CETP. CETP activity was calculated relatively 
to control incubations without apoCI. Values are means ±SD, n=3, * P<0.05, as compared to 
control without peptides added.  
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ApoCI32-57 does not inhibit LPL activity as compared to full-length apoCI1-57. 
ApoCI32-57, which is the minimal apoCI peptide that results in maximum CETP 
inhibition, may have therapeutic value provided that it selectively inhibits the 
activity of CETP as compared to LPL. Therefore, we next determined the effect 
of full-length apoCI1-57 and of apoCI32-57 on LPL activity by incubation with 
glycerol tri[
3
H]oleate-labeled VLDL-like emulsion particles and HSPG-bound 
LPL (Fig. 4). Indeed, whereas apoCI1-57 dose-dependently decreased LPL 
activity (-90% at 16 µM; P<0.05), LPL activity was not significantly affected 
by apoCI32-57.  
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Figure 3. The CETP-inhibitory property of apoCI32-57 depends on positively charged amino 
acids. ApoCI32-57 or apoCI32-57 in which positively charged K and R are replaced at the N-
terminal end (A), C-terminal end (B), or both ends (C) were incubated (6 h at 37°C) at 
concentrations of 16 µM and 64 µM with [
3
H]CO-LDL and HDL in PBS in the presence of 
LPDS as source of CETP. CETP activity was calculated relatively to control incubations 
without apoCI. Values are means ±SD, n=3, * P<0.05, as compared to control without 
peptides added.  
Figure 4. Full-length apoCI, but not 
apoCI32-57, inhibits LPL activity. 
ApoCI1-57 (A) and apoCI32-57 (B) 
were incubated (20 min at 37°C) at 
concentrations of 4 µM and 16 µM 
with glycerol tri[
3
H]oleate-labeled 
VLDL-like emulsion particles and 
HSPG-bound LPL. Generated 
[
3
H]oleate was separated from 
glycerol tri[3H]oleate by extraction 
and quantified. LPL activity was 
determined as the percentage of 
fatty acids (FA) generated per 
minute. Values are means ±SD, n=3, 
* P<0.05, as compared to control 
without peptides added. 
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Discussion 
 
Using an array of apoCI-derived peptides, we demonstrated that the CETP-
inhibitory property of apoCI is restricted to the C-terminal domain of apoCI. 
We identified apoCI32-57 as a minimal CETP inhibitory sequence that does not 
inhibit LPL activity, and showed that the positively charged amino acids K and 
R are largely responsible for the CETP-inhibitory effect. 
First, we thus demonstrated that the CETP-inhibitory property of apoCI resides 
in its C-terminal domain. This observation is consistent with a previous study 
comparing the CETP-inhibitory effect of apoCI34-54 and apoCI4-25.
3
 By direct 
comparison, we showed that apoCI32-57 is more effective in CETP inhibition 
than apoCI34-54 (not shown). However, our data contradict earlier findings in a 
strain of baboons with high HDL in which apoCI1-38 was identified as the 
naturally occurring CETP inhibitor in plasma.
13
 Notably, human apoCI1-38 also 
inhibits baboon CETP.
14
 It is therefore likely that the discrepancy between the 
various studies is explained by species differences on the level of CETP: the N-
terminus of apoCI affects baboon CETP whereas the C-terminus of apoCI 
affects human CETP. It should be noted that we did show a modest effect of 
apoCI1-38 on CETP activity (Fig. 2A), and the studies on baboon CETP did not 
compare apoCI1-38 with a C-terminal peptide.
14
 Therefore, it is still possible that 
the baboon CETP activity assay is more sensitive than the human CETP activity 
assay, and thus detects a larger CETP-inhibitory effect of apoCI1-38, without 
ruling out that apoCI32-57 is even more effective.  
It has been shown that the ability of apoCI to inhibit CETP activity could be 
explained by reduction of the electronegative surface charge of HDL,
3
 thereby 
inhibiting the physical association of CETP with HDL. Therefore, we evaluated 
the contribution of the positively charged amino acids within apoCI32-57 to its 
CETP-inhibitory effect by replacement of K and R residues in the KMR cluster 
at the N-terminal end or within the KVKEKLK cluster at the C-terminal end by 
electroneutral A. This is a small amino acid that does not affect the overall 
peptide structure as predicted from secondary structure analysis using Peptide 
Companion software (not shown). We demonstrated that replacement of 
positively charged amino acids in either the KMR or KVKEKLK motif both 
reduced the CETP inhibitory effect of apoCI32-57. In addition, despite the 
presence of positively charged amino acids in both the N-terminus and C-
terminus of apoCI, the C-terminal peptide apoCI32-57 had a higher isoelectric 
point (pI = 8.11) than apoCI1-38 (pI = 6.02). These observations thus confirm the 
hypothesis that the CETP-inhibitory property of apoCI is dependent on its 
overall positive charge rather than on specific electropositive residues. 
In addition to electropositive charge, other structural properties of apoCI likely 
contribute to inhibition of CETP activity. First, apoCI32-57 appeared to be a 
stronger CETP inhibitor than apoCI35-57 whereas there is no difference in the 
amount of positively charged residues. Second, apoCI46-57 has a higher 
isoelectric point (pI = 9.53) as compared to apoCI32-57 (pI = 8.11), but is a less 
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efficient CETP inhibitor. Third, replacement of all K and R residues in apoCI32-
57 did not completely abrogate its CETP-inhibitory effect. It is thus conceivable 
that, in addition to the importance of the peptide charge, the peptide length 
positively influences the α-helical conformation of the peptides and the binding 
affinity of the peptide for HDL. 
Whereas full-length apoCI is an effective inhibitor of LPL activity, apoCI32-57 
did not affect LPL activity. In fact, none of the applied apoCI-derived peptides 
were able to inhibit LPL activity (not shown). The mechanism by which apoCI 
inhibits LPL activity has not been fully elucidated. ApoCI may directly interact 
with LPL and/or interfere with other apolipoproteins that modulate LPL activity 
such as the LPL co-activator apoCII or apoCIII or apoAV.
8
 Alternatively, apoCI 
may affect LPL activity by product inhibition, since apoCI effectively binds 
free fatty acids.
18
 The lack of an LPL-inhibiting effect of the truncated apoCI 
peptides could thus result from reduced interference with any of these three 
processes. The fact that C-terminal peptides inhibit the activity of CETP, but 
not that of LPL, suggests that these peptides may still bind avidly with HDL 
(thereby interfering with CETP activity), but weakly with VLDL (thereby 
precluding interference with LPL activity). Since the anti-apoCI antibody that 
we used in our ELISA does not react with apoCI-peptides even after minimal 
truncation of apoCI, such a hypothesis is difficult to test by routine techniques. 
In our study, we focused on the most prominent features of apoCI in lipid 
metabolism, i.e. CETP inhibition and LPL inhibition. ApoCI  has also been 
described to stimulate LCAT,
19,20
 inhibit HL
11,12
 and inhibit the HDL receptor 
scavenger receptor class B type I (SR-BI),
21
 which may contribute to HDL 
increase. In addition, apoCI inhibits (V)LDL clearance via apoE-recognizing 
receptors,
22,23
 which may contribute to hyperlipidemia. Therefore, in vivo 
studies using CETP transgenic mice and wild-type mice are needed to evaluate 
whether apoCI32-57 is capable to increase HDL without inducing hyperlipidemia 
and whether such an effect can be ascribed to CETP inhibition only. 
The fact that apoCI32-57 inhibits CETP activity without affecting LPL activity 
suggests that apoCI32-57 is a valuable lead for a new anti-atherogenic therapy, as 
raising HDL by inhibiting CETP is generally seen as a protective lipoprotein in 
atherosclerosis development. This is especially relevant considering the recent 
clinical failure of the CETP inhibitor torcetrapib.
24
 Despite evoking a large 
increase in HDL-cholesterol levels, torcetrapib did not potentiate the anti-
atherogenic potency of atorvastatin as judged from coronary intima-media 
thickness (IMT) and intravascular ultrasonography (IVUS) measurements.
25-27
 
In fact, torcetrapib increased overall mortality and the amount of non fatal 
cardiovascular events.
24
 These disappointing results are probably explained by 
compound-specific off target toxic effects of torcetrapib, including hypertension 
and hyperaldosteronism.
28
 Being derived from an endogenous protein, apoCI32-
57 is not expected to induce such side effects. Also, whereas torcetrapib forms 
an inactive complex between HDL and CETP, thereby resulting in an 
accumulation of CETP protein in plasma,
29
 apoCI is not expected to result in 
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accumulated CETP in plasma as its proposed working mechanism (i.e. 
reduction of the interaction between HDL and CETP) is different from that of 
torcetrapib. 
In conclusion, we identified apoCI32-57 as the minimal domain in apoCI that 
inhibits CETP activity without affecting LPL activity. Therefore, future studies 
are warranted to evaluate whether apoCI32-57 will raise HDL without inducing 
hyperlipidemia and may be a valuable lead in the search for new CETP 
inhibitors that aim at raising HDL and reducing atherosclerosis.  
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Cardiovascular disease (CVD) is a major cause of morbidity and mortality in 
the western world, and is mainly caused by atherosclerosis. In the Netherlands, 
about one third of all deaths are due to CVD. Dyslipidemia (i.e. high plasma 
(V)LDL-cholesterol (C), high triglycerides and low HDL-C) is a major risk 
factor for atherosclerosis development and cardiovascular disease. Patients with 
dyslipidemia are usually treated with cholesterol lowering drugs including 
statins
1
 and fibrates.
2
 These drugs lower plasma cholesterol very efficiently (up 
to 40%),
1,2
 however, they prevent only a fraction (about 30%) of cardiovascular 
events. Therefore new therapeutic strategies to reduce CVD risk more 
efficiently are necessary. Since HDL is clearly inversely correlated with CVD 
risk, and has been attributed multiple protective effects in atherosclerosis by its 
role in reverse cholesterol transport (RCT) and its anti-inflammatory, anti-
oxidative and anti-thrombotic properties, HDL-raising therapy is currently 
considered as a promising strategy to further reduce CVD risk.
3,4
 
The research described in this thesis was performed to elucidate the mechanisms 
underlying the HDL-C raising effects of classic lipid-lowering drugs 
(fenofibrate, atorvastatin, niacin) as well as an experimental HDL-raising 
compound (torcetrapib), and to evaluate the HDL-raising potential of novel 
strategies (PXR agonism, apoCI). The major conclusions and implications of 
our findings and future perspectives will be discussed here.  
 
HDL modulation by classical lipid lowering drugs 
 
The classical lipid-lowering drugs statins, fibrates and niacin have been shown 
to modestly raise HDL-C levels in humans up to 10, 15, and 30%, respectively.
5
 
Interestingly, these drugs failed to show human-like HDL-increasing effects in 
either normolipidemic or classical hyperlipidemic mice (i.e. LDL receptor-
knockout and apoE-knockout mice). Although fenofibrate has been shown to 
increase HDL in wild-type mice, the raised HDL had an increased particle size, 
as opposed to the raised HDL in humans. Likewise, although these drugs did 
evoke human-like lipid-lowering effects in ApoE*3Leiden transgenic (E3L) 
mice
6
 with respect to dose-dependent decreases of (V)LDL-C and triglycerides, 
they generally failed to raise HDL-C in E3L mice.
7
  
As mice naturally lack the cholesteryl ester transfer protein (CETP), which is an 
important determinant of HDL metabolism in humans, we reasoned that the 
HDL-raising effect of the classical lipid-lowering drugs may relate to the 
presence of CETP. Therefore, we crossbred E3L mice with CETP mice to 
generate the novel E3L.CETP mouse model.
8
 In this thesis we show that 
E3L.CETP mice indeed respond with an increase in HDL besides a decrease in 
(V)LDL to both a fibrate (fenofibrate; chapter 2), a statin (atorvastatin; chapter 
3) and niacin (chapter 4). This indicates not only that the E3L.CETP mouse is a 
valuable model to study the effect of HDL modulating drugs on lipid 
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metabolism, but also that CETP plays an essential role in the HDL increase 
observed with these drugs. 
It is interesting to note that these various classes of drugs have a similar HDL-
increasing effect, as dependent on CETP expression, whereas they evoke their 
lipid-lowering effects through different mechanisms. Statins, fibrates and niacin 
reduce plasma lipids by primarily by inhibition of the de novo hepatic 
cholesterol synthesis,
9,10
 stimulation of triglyceride hydrolysis in plasma,
11-13
 
and inhibition of lipolysis in adipocytes,
14
 respectively. Despite these different 
primary actions on lipid metabolism, our studies demonstrated that they all 
reduce the activity and mass of CETP in plasma. In fact, we showed that 
atorvastatin, fenofibrate and niacin all reduced the hepatic mRNA expression of 
CETP, which is likely the main causal factor for the reduction in plasma CETP. 
In line with this hypothesis, increasing the hepatic cholesterol content of CETP 
transgenic mice by cholesterol feeding increases hepatic CETP expression via 
LXR-dependent mechanisms as well as plasma CETP mass.
15,16
 The three 
classes of lipid-lowering drugs not only decrease CETP expression, but also 
decrease (V)LDL levels. Since (V)LDL is an acceptor of HDL-derived 
cholesteryl esters and, therefore, also a driving force for CETP activity, the 
decrease in (V)LDL adds to the drug-induced reduction in CETP activity.  
Based on our observations, we speculate that lipid-lowering drugs in general 
will thus all increase HDL-C to a certain extent by reducing plasma CETP 
activity, as a result of a reduction in both hepatic CETP expression and plasma 
(V)LDL. In fact, observations in human subjects indeed showed that statins and 
fibrates both reduce CETP mass and activity.
17-21
 The effect of niacin on plasma 
CETP in humans has not been reported as yet, but niacin will thus probably also 
reduce CETP mass and activity. Interestingly, hyperlipidemic patients carrying 
the CETP TaqIB1 polymorphism, who have therefore higher plasma CETP 
levels than people with the TaqIB2 variant, benefit more from statin treatment 
with respect to the development of coronary atherosclerosis, 
22
 suggesting that 
the reduction of CETP activity is indeed a relevant contributor to the protective 
effects of lipid-lowering drugs in atherosclerosis. 
The apparent robust causal relation between hepatic lipid content and hepatic 
CETP expression raises the question whether the pathological condition of 
hepatic steatosis would be a causal factor for reducing HDL-levels by increasing 
CETP expression. Interestingly, a recent study in obese subjects showed that 
liver fat indeed inversely correlated with HDL levels.
23
 However, since (V)LDL 
levels are also increased in patients with a fatty liver,
23
 more research is needed 
to confirm the hypothesis that hepatic steatosis results in increased plasma 
CETP levels thereby decreasing HDL.  
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HDL modulation by CETP inhibition 
 
CETP inhibition has been regarded as a novel promising HDL-C raising 
strategy to reduce atherosclerosis and cardiovascular disease. Large clinical 
studies with the CETP inhibitor torcetrapib have been performed to evaluate 
whether CETP inhibition is able to increase HDL levels and reduce 
atherosclerosis. Torcetrapib indeed increased HDL-C to a marked extent (+60% 
at 60 mg/day), but did not reduce atherosclerosis as measured by Intima Media 
Thickness (IMT) and Intravascular Ultrasound (IVUS)
24-26
 and had unwanted 
effects including increased overall mortality as well as fatal and non fatal 
cardiovascular events.
27
 
There are several possible explanations for the disappointing results of the 
torcetrapib studies, related to 1) inclusion criteria of the patients, 2) combination 
therapy with atorvastatin, 3) properties of the newly formed HDL, or 4) 
compound specific effects.  
First, in the torcetrapib studies, patients were included who had undergone 
cardiac catheterization
26
 or have (familial)
 
dyslipidemia.
24,25
 These broad 
inclusion criteria led to the inclusion of a very heterogeneous patient group that 
may not all benefit from CETP inhibition, as the metabolic context, including 
baseline CETP activity, HDL-C levels and TG levels, is likely to be an 
important determinant of the effect of CETP inhibition on atherosclerosis 
development and CVD risk. The view that the metabolic context is important in 
the effect of CETP inhibition on atherosclerosis is supported by mouse studies, 
which in general show that CETP expression is atheroprotective in mice with 
increased HDL levels while CETP expression is atherogenic in mice with 
elevated (V)LDL levels. CETP expression in mice with high HDL because of 
LCAT overexpression or SR-BI deficiency reduces atherosclerosis.
28,29
 In line 
with these mouse data, it has been shown that subjects with highly elevated 
HDL-C levels which were mainly associated with CETP mutations, have higher 
prevalence of ischemic ECG changes.
30
 CETP inhibition in subjects who have 
already high HDL may, therefore, not lead to protection against atherosclerosis 
and CVD. These findings may also suggest that HDL elevation by CETP 
inhibition is only protective when this normalizes or elevates HDL mildly 
compared to normolipidemic subjects and CETP inhibitors should not be used 
to further increase HDL in subjects who have cardiovascular risk factors but 
normal or elevated HDL levels. In contrast, CETP is a clear atherogenic factor 
in hyperlipidemic mouse models with impaired (V)LDL clearance, including 
apoE knockout,
31
 LDL receptor knockout
31
 and E3L mice.
8
 When translated to 
humans, dyslipidemic subjects with high plasma TG may therefore benefit from 
CETP inhibition since CETP transfers HDL-CE to (V)LDL that is inefficiently 
cleared from plasma as indicated by high TG. This suggests that CETP 
inhibition could be particularly promising in those dyslipidemic patients, who 
besides elevated (V)LDL also have low HDL and/or high CETP activity. 
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Further subgroup analyses should be performed in the recent torcetrapib studies 
to study whether patients with low HDL, high CETP activity and/or high TG at 
baseline benefit from torcetrapib with respect to atherosclerosis development. 
Second, the clinical studies with torcetrapib were all performed in combination 
with atorvastatin,
24-26
 which by itself reduces CETP activity in plasma.
17-20,32,33
 
By investigating the effect of torcetrapib on atherosclerosis development in 
E3L.CETP mice, either in combination with atorvastatin or alone (chapter 5), 
we showed that torcetrapib per se did in fact reduce atherosclerosis while 
torcetrapib did not reduce atherosclerosis in mice that were also treated with 
atorvastatin, indicating that combination treatment with atorvastatin and other 
lipid lowering drugs may attenuate or mask the effect of torcetrapib on 
atherosclerosis. 
Third, it is not clear whether the increased HDL as induced by CETP inhibition 
by torcetrapib is atheroprotective or not. HDL is thought to be protective in 
atherosclerosis via mediating RCT and by its proposed anti-inflammatory, anti-
oxidative and anti-thrombotic properties. Torcetrapib alters HDL by increasing 
its size, by the formation of a torcetrapib/CETP complex that associates with 
HDL, and torcetrapib may alter the protein composition of HDL which may 
alter HDL functionality. In addition, torcetrapib may reduce HDL-CE clearance 
as it has been described that in humans, the majority of HDL-CE reaches the 
liver via (V)LDL after CETP-mediated transfer of HDL-CE from HDL to 
(V)LDL, and this pathway is blocked by torcetrapib.
34,35
 
Fourth, torcetrapib may have had compound-specific adverse side effects with 
respect to increased mortality and increased cardiovascular events, and 
compound-specific side effects may explain why torcetrapib did not add to the 
atherosclerosis-reducing effect of atorvastatin. Torcetrapib has been found to 
increase blood pressure by approx. 5 mm Hg,
24-26,36
 which is not observed with 
novel CETP inhibitors including anacetrapib and JTT-705. This mild increase in 
blood pressure is unlikely to completely have counteracted potential protective 
effects of the HDL increase and is unlikely to have caused increased mortality, 
but it may be indicative for other underlying adverse effects. Analysis of plasma 
samples from patients treated with torcetrapib showed an increase in sodium, 
bicarbonate and aldosterone levels.
27
 Torcetrapib also increased plasma plasma 
aldosterone in E3L.CETP mice (chapter 5). The raise in aldosterone may not 
only explain the increase in blood pressure, but animal studies have also shown 
that aldosterone causally increases atherosclerosis, inflammation and oxidative 
stress,
37-40
 indicating that the increase in aldosterone may have counteracted 
potentially atheroprotective effects of the torcetrapib-induced increase in HDL. 
We have demonstrated that torcetrapib increases the macrophage to collagen 
ratio within atherosclerotic plaques in E3L.CETP mice (chapter 5). Whereas 
plaques of mice do not easily rupture spontaneously, such a phenotype is 
considered more prone to spontaneous rupture in humans. Extrapolation of our 
data to humans may thus suggest that the increase in cardiovascular events and 
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death may have been caused, at least partly, by increased incidence of plaque 
rupture. As aldosterone is associated with more inflammation and increased 
activity of matrix metalloproteinases (MMP),
39,41
 which cause breakdown of 
collagen, it can be reasoned that the increased aldosterone levels may have 
contributed to the plaque phenotype. However, this hypothesis should be 
underscored by experimental studies. The effects of torcetrapib on aldosterone 
and blood pressure are compound-specific and independent of CETP, as 
torcetrapib induced these effects in both humans, CETP transgenic mice and 
non-transgenic mice.
42
 In contrast, anacetrapib does not increase blood pressure 
and aldosterone levels.
42,43
 The effect of novel CETP inhibitors on plaque 
composition and cardiovascular events is thus eagerly awaited. 
 
In addition to chemical CETP inhibitors, endogenous CETP inhibitors have also 
been described. Whereas the lipid transfer inhibitor protein (LTIP) as present on 
LDL inhibits CETP activity,
44
 apoCI is the major endogenous CETP inhibitor 
present on HDL.
45
 being an endogenous protein, apoCI may be a lead for novel 
safe CETP inhibitors. However, apoCI is also an inhibitor of LPL.
46
 Because of 
apoCI-induced LPL inhibition, human apoCI overexpression in CETP 
transgenic mice not only reduces specific CETP activity, but also largely 
increases VLDL levels. The increase in VLDL levels consequently increases 
hepatic CETP gene expression, which precludes an increase in HDL-C resulting 
from CETP inhibition only.
47
  
To find an apoCI derived CETP inhibitor without LPL inhibitory properties, we 
performed structure-function analysis using an array of apoCI derived peptides. 
ApoCI32-57 was the most efficient CETP inhibitory peptide tested, and this 
peptide had only minimal effects on LPL. Therefore we expect that this peptide 
should be able to increase HDL without inducing hyperlipidemia. Pilot 
experiments showed that intravenous injections with apoCI and apoCI32-57 were 
unable to modulate lipid levels in vivo in CETP transgenic mice (unpublished 
data), which may relate to dosing and/or adverse pharmacokinetics of the 
peptides. Short-term elevation of plasma levels of apoCI and apoCI32-57, e.g. by 
using recombinant adenoviruses that induce a relatively high hepatic protein 
expression of apoCI and apoCI32-57 in CETP expressing mice could therefore be 
useful as a tool to show the potential of apoCI32-57 to increase HDL levels 
without affecting plasma TG. If so, apoCI32-57 mimicking agents could be 
developed that can be used orally. 
In addition to CETP, apoCI also affects other HDL modifying enzymes, 
including LCAT
48,49
 HL
50,51
 and SR-BI (chapter 7). These combined actions 
increase HDL in naturally CETP-deficient wild-type mice (chapter 7), but 
functionality of the increased HDL is unknown. It is also unknown how 
apoCI32-57 would act on these various proteins involved in HDL metabolism. 
Therefore, additional in vitro and in vivo experiments in wild-type mice should 
be performed to show whether potential HDL-increasing effects of apoCI32-57 
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are CETP dependent. In addition, studies in E3L.CETP mice will be useful to 
reveal whether apoCI32-57 will reduce atherosclerosis. It would be interesting to 
study the effect of apoCI32-57 on the plaque phenotype as well as to evaluate 
whether the effect of torcetrapib on plaque composition was indeed compound 
specific, especially because apoCI has a different mechanism to inhibit CETP as 
compared to torcetrapib, i.e. reduction of affinity of CETP with HDL
52
 versus 
formation of an inactive HDL/CETP complex.
53
 
 
Novel strategies to reduce cardiovascular disease 
 
Cholesterol lowering is a proven effective strategy to reduce cardiovascular 
disease. Therefore a large number of new drugs to reduce plasma lipid levels is 
under development, including microsomal triglyceride transfer protein (MTP) 
inhibitors, squalene synthase inhibitors, and apoB expression inhibitors that are 
all aimed at reducing lipid production by the liver.
54-58
 However, as statins 
already efficiently reduce plasma (V)LDL-C levels without severe side effects, 
and additional safe (V)LDL-C lowering agents to treat patients that do not 
respond well to statins are available (e.g. cholesterol binding resins) it will be 
difficult to develop novel lipid lowering drugs that lead to more clinical benefit 
with respect to protection against cardiovascular disease.  
After the disappointing results from the torcetrapib studies, it is difficult to 
predict whether novel HDL raising agents will prevent CVD in the future. 
Despite that there is no direct evidence for the protective effect of HDL in 
atherosclerosis, HDL is thought to play a role in RCT, and is thought to be anti-
inflammatory, anti-oxidative and anti-thrombotic. HDL raising my be achieved 
by 1) reducing HDL clearance, 2) increasing HDL maturation and modification 
of HDL metabolism or 3) enhancing HDL production. 
In mice, clearance of HDL-C is almost exclusively mediated via SR-BI. In 
humans, Cla-1 (i.e. the human orthologue of SR-BI) is thought to play a less 
important role, since HDL-CE is mainly cleared from plasma after CETP-
mediated transfer to (V)LDL.
34
 Albeit that raising HDL by reducing its 
clearance may increase the anti-inflammatory and anti-oxidative properties of 
HDL, the role of HDL in RCT (i.e. transfer of cholesterol to the liver, followed 
by excretion via the feces) is possibly the most important protective function of 
HDL. Together with the fact that SR-BI-deficiency in mice aggravates 
atherosclerosis, reducing HDL clearance may probably not be the most valid 
HDL-raising strategy.  
LCAT plays an important role in the maturation of HDL as this enzyme 
esterifies HDL-associated cholesterol into CE. Mutations in LCAT which lower 
LCAT activity reduce HDL-C levels and mildly enhance atherosclerosis 
development (as measured by IMT).
59
 However, since overexpression of LCAT 
in mice increases atherosclerosis, LCAT-targeted interventions to raise HDL 
should be pursued with care. As niacin increases HDL via CETP reduction 
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(chapter 4) niacin can also be considered as a compound that increases HDL via 
HDL modulation. Niacin is however not well tolerated because it induces severe 
flushing. A recent study shows that addition of the prostaglandin D2 receptor 1 
blocker laropiprant reduces niacin mediated flushing which may increase niacin 
use.
60
 In addition novel compounds targeting the niacin receptor GRP109A are 
under development.
61
 However, it is uncertain whether the protective effects of 
niacin on IMT progression and mortality are mediated via its HDL raising or via 
its (V)LDL reducing properties 
62,63
 
HDL production is presumably mainly initiated by the synthesis and secretion 
of apoAI by the liver and intestine, and lipidation of apoAI in plasma via 
ABCA1. Indeed, apoAI-deficiency and ABCA1-deficiency in mice largely 
decrease HDL-C. Interestingly, humans carrying mutations in ABCAI and 
apoAI
59
 have a more severe increase in atherosclerosis (as measured by IMT) as 
compared to carriers of CETP or LCAT mutations, suggesting that enhancing 
HDL production would be the most promising strategy in the prevention of 
atherosclerosis and CVD. Upregulation of ABCA1 in macrophages can be 
achieved with compounds like LXR agonists.
64
 However, these compounds will 
also induce the expression of lipogenic genes in the liver which counteract 
potential protective effects of ABCAI upregulation in atherosclerosis. In 
addition, LXR activation will result in upregulation of multiple proteins 
involved in cholesterol efflux, including apoE, which hampers evaluation of the 
effect of upregulation of ABCA1 only. Therefore, compounds that specifically 
upregulate ABCA1 expression in macrophages, preferably in the atherosclerotic 
vessel wall, should be developed. Increase of apoAI can be achieved via 
administration of apoAI or apoAI mimicking compounds, or via upregulation of 
apoAI expression. ApoAI, infused either as a lipid-free protein or contained in 
recombinant HDL, increases HDL levels. Clinical studies show that short-term 
apoAI infusion lead to a quick reduction of atheroma volumes in patients with 
acute coronary syndrome.
65
 However, a drawback of apoAI infusion is that 
treatment is invasive and very expensive, and that long term effects are still 
unknown.
66
 Alternatively, apoAI mimicking agents have been developed which 
can be given orally.
67
 Agents that increase apoAI production would also be 
promising to increase endogenous HDL production. It has been suggested from 
studies in wild-type mice that PXR agonism would increase apoAI production 
and raise HDL levels.
68
 However, we observed in our more human-like 
E3L.CETP mice that PXR agonists reduced HDL of all sizes concomitant with 
a reduction (rather than an increase) in apoAI expression (chapter 6). This study 
thus indicates that PXR agonism is likely also unable to raise apoAI and HDL in 
humans. Recently, rvx-208 has been developed to induce apoAI expression and 
raise HDL levels, as shown in mice and non-human primates. Provided that this 
compound is specific for apoAI, it would be promising new lead in the ongoing 
search for HDL-raising strategies to prevent CVD.
69
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Concluding remarks 
 
Besides a large number of new lipid-lowering agents, drugs that are aimed to 
specifically raise HDL are currently under development. The therapeutic value 
of such HDL-raising therapies, however, is still unclear, especially since the 
first HDL-raising strategy by torcetrapib failed in large human trials. The 
question whether raising HDL will add to the atheroprotective effect of lipid-
lowering therapy is thus still unanswered. Albeit that high HDL-C is clearly 
associated with reduced CVD risk, high HDL-C is also associated with low 
(V)LDL-C and TG, a balance that is probably dictated by bidirectional transfer 
of neutral lipids by CETP. Therefore, it is difficult to predict the importance of 
HDL independent of other risk factors, and virtually no direct evidence is 
currently available to show that HDL per se is protective in atherosclerosis 
development. Therefore, other therapeutic strategies such as inhibition of 
inflammation, which besides dyslipidemia is also a driving force for 
atherosclerosis, should not be overlooked.  
The torcetrapib trials taught us that care should be taken in selecting appropriate 
subjects in human studies that are expected to benefit most from a novel 
experimental approach to reduce CVD. Future studies will show which of these 
new strategies will eventually be used in the future therapy of those patients that 
are prone to develop CVD. Moreover, our studies indicate the importance of 
testing effects of experimental drugs on lipid metabolism, atherosclerosis and 
plaque composition in appropriate animal models. We expect that our newly 
developed E3L.CETP mouse model with a human-like lipoprotein metabolism 
will largely contribute to the development of such compounds by reliably 
predicting human responses to experimental drugs and revealing underlying 
mechanisms.  
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Summary  
 
Cardiovascular disease (CVD) is a major cause of mortality and morbidity in 
the Western world. CVD is mainly caused by atherosclerosis, for which 
dyslipidemia, characterized by high a plasma level of (very) low density 
lipoprotein ((V)LDL) and a low plasma level of high density lipoprotein (HDL), 
is a major risk factor. To reduce the risk to develop CVD, drugs aimed at 
correcting dyslipidemia by lowering (V)LDL are currently the first choice of 
treatment. Albeit that these drugs lower (V)LDL-C very efficiently (up to 
~40%), and generally result in a slight increase in HDL-C, they only prevent a 
fraction of all cardiovascular events (~30%). Therefore new therapeutic 
strategies to reduce cardiovascular events more efficiently are necessary. Since 
HDL is has been attributed multiple protective effects in atherosclerosis by its 
role in reverse cholesterol transport and its anti-inflammatory and anti-oxidative 
properties, HDL-raising therapy is currently considered as a promising strategy 
to further reduce CVD risk. In this thesis, the mechanisms underlying the HDL-
raising effects of the classical lipid-lowering drugs fenofibrate, atorvastatin and 
niacin were elucidated. Furthermore, the effects of potential novel HDL-raising 
strategies, including torcetrapib, PXR agonism and apoCI, on HDL metabolism 
were addressed. For these studies, we used the APOE*3-Leiden.CETP 
(E3L.CETP) transgenic mouse, a valuable model for human-like lipoprotein 
metabolism. 
 
The lipid-lowering drugs fibrates and statins efficiently reduce plasma 
cholesterol and triglycerides (TG) in dyslipidemic subjects. In addition, they 
also increase HDL-C to some extent (~5-15%), but the mechanism underlying 
the increase in HDL-C was unclear. Since both fibrates and statins 1) reduce the 
concentration of cholesteryl ester transfer protein (CETP) in human plasma, and 
2) do not increase HDL-C in naturally CETP-deficient mice, we reasoned that 
CETP plays a dominant role in the HDL-increasing effect of both fibrates and 
statins. To evaluate the role of CETP in the HDL-C increase as seen in humans, 
we used E3L mice that have been shown to respond in a human-like manner 
with respect to the lipid-lowering effects of fibrates and statins, and E3L.CETP 
littermates. In chapter 2, E3L and E3L.CETP mice were fed a Western-type 
diet with or without fenofibrate. Fenofibrate decreased (V)LDL-TG and 
(V)LDL-C in both E3L and E3L.CETP mice, but fenofibrate increased HDL-C 
only in E3L.CETP mice. Fenofibrate did not affect the turnover of HDL-CE, 
indicating that fenofibrate causes a higher steady-state HDL-C level without 
altering the HDL-C flux through plasma. Analysis of the hepatic gene 
expression profile showed that fenofibrate did not differentially affect the main 
players in HDL metabolism, including phospholipid transfer protein (Pltp), 
ATP-binding cassette transporter A1 (Abca1), scavenger receptor class B type I 
(Sr-b1), and apolipoprotein AI (Apoa1), in E3L.CETP mice as compared to E3L 
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mice. However, in E3L.CETP mice, fenofibrate reduced hepatic CETP mRNA 
as well as the CE transfer activity in plasma. In chapter 3, a similar approach 
was used to evaluate whether atorvastatin increases HDL-C via CETP 
modulation. Atorvastatin reduced plasma cholesterol in both E3L and 
E3L.CETP mice, which was specific for (V)LDL, but atorvastatin increased 
HDL-C only in E3L.CETP mice. Hepatic mRNA expression levels of genes 
involved in HDL metabolism, including Pltp, Abca1, Sr-b1 and Apoa1, were 
not differently affected by atorvastatin in E3L.CETP mice as compared to E3L 
mice. However, in E3L.CETP mice, atorvastatin down-regulated the hepatic 
CETP mRNA expression as well as the total CETP level and cholesteryl ester 
(CE) transfer activity in plasma. Therefore, we concluded that both fenofibrate 
and atorvastatin increase HDL-C by reducing the CETP-dependent transfer of 
cholesterol from HDL to (V)LDL, as related to lower hepatic CETP expression 
and a reduced plasma (V)LDL pool. 
The most potent HDL-raising drug currently available is niacin, but the 
mechanism underlying the effects of niacin on HDL metabolism is still 
unknown. In chapter 4, E3L and E3L.CETP mice on a western-type diet were 
treated with niacin. In E3L.CETP mice, niacin dose-dependently decreased 
plasma cholesterol and TG and dose-dependently increased HDL-C, plasma 
apoAI as well as the HDL particle size. In E3L mice, niacin also reduced 
plasma cholesterol and TG, but had no effect on HDL. In E3L.CETP mice, 
niacin dose-dependently decreased the hepatic expression of CETP as well as 
plasma CETP mass and CETP activity. Additionally, niacin dose-dependently 
decreased the clearance of apoAI from plasma and reduced the uptake of apoAI 
by the kidneys. Therefore, we concluded that niacin markedly increases HDL-C 
in E3L.CETP mice by reducing CETP activity, as related to lower hepatic 
CETP expression and a reduced plasma (V)LDL pool, and increases HDL-
apoAI by decreasing the clearance of apoAI from plasma. 
 
Torcetrapib is the first compound designed specifically to increase HDL-C 
levels via inhibition of CETP activity. In large clinical trials, torcetrapib 
increases HDL-C by about 60%, but did not potentiate the effect of atorvastatin 
on atherosclerosis, as determined by measurement of intima-media thickness 
(IMT) and intravascular ultrasound (IVUS). The effect of torcetrapib alone is 
unknown. Moreover, torcetrapib treatment led to adverse effects including an 
increase in cardiovascular events and increased death rate. In chapter 5 we 
aimed to study the effects of torcetrapib with and without atorvastatin on the 
development of atherosclerosis and to study the adverse effects of torcetrapib. 
E3L.CETP mice on a western-type diet were treated with torcetrapib, 
atorvastatin or both, and atherosclerosis development was determined in the 
aortic root. Torcetrapib decreased plasma cholesterol, albeit to a lesser extent 
than atorvastatin or the combination of torcetrapib and atorvastatin. Torcetrapib 
increased HDL-C in the absence and presence of atorvastatin. Torcetrapib and 
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atorvastatin alone both reduced atherosclerotic lesion size to a similar extent, 
but combination therapy did not reduce atherosclerosis as compared to 
atorvastatin alone. Remarkably, as compared to atorvastatin, torcetrapib induced 
enhanced monocyte recruitment and expression of monocyte chemoattractant 
protein-1 (MCP-1) and resulted in lesions of a more inflammatory phenotype, as 
reflected by an increased macrophage content and reduced collagen content. We 
thus concluded that CETP inhibition by torcetrapib per se reduces 
atherosclerotic lesion size but does not enhance the anti-atherogenic potential of 
atorvastatin. In addition, as compared to atorvastatin, torcetrapib introduces 
lesions of a less stable phenotype. 
 
Pregnane X receptor (PXR) agonism has been suggested to increase HDL levels 
in wild-type mice, but its effect on integrated HDL metabolism in a model with 
human-like lipoprotein metabolism was still unknown. In chapter 6, we treated 
E3L and E3L.CETP mice with the PXR agonist pregnenolone-16α-carbonitrile 
(PCN). In E3L and E3L.CETP mice, PCN increased liver lipids as well as 
plasma cholesterol and TG. Whereas PCN increased HDL-C, especially within 
large HDL-1 particles in E3L mice, it dose-dependently decreased HDL-C in 
E3L.CETP mice. PCN decreased expression of genes involved in HDL 
synthesis (Abca1, Apoa1), maturation (lecithin: cholesterol acyltransferase 
(Lcat), Pltp) and clearance (Sr-b1). The HDL-increasing effect of PCN, 
observed in E3L mice, is likely caused by a marked decrease in hepatic SR-BI 
protein expression, and is completely reversed by CETP expression. We 
concluded, therefore, that chronic PXR agonism dose-dependently reduces 
plasma HDL-C in the presence of CETP and is thus not a relevant target for the 
development of HDL raising therapy. 
 
Apolipoprotein CI (apoCI) has been suggested to influence HDL metabolism by 
activation of LCAT and inhibition of HL and CETP. However, the effect of 
apoCI on SR-BI, as well as the net effect of apoCI on HDL metabolism in vivo 
is unknown. Therefore, we evaluated in chapter 7 the effect of apoCI on the 
SR-BI-mediated uptake of HDL-CE in vitro and determined the net effect of 
apoCI on HDL metabolism in mice. We demonstrated that apoCI dose-
dependently decreased the SR-BI-dependent association of HDL-CE with 
primary murine hepatocytes in vitro. Subsequent in vivo studies showed that 
apoCI-deficiency in mice gene dose-dependently decreased HDL-C levels, and 
adenovirus-mediated expression of human apoCI in mice increased HDL levels 
at a low dose and increased the HDL particle size at higher doses. Therefore, we 
concluded that apoCI is a novel inhibitor of SR-BI in vitro and increases HDL 
levels in vivo. 
Since apoCI is the main endogenous HDL-associated CETP inhibitor, it can be 
a lead for the development of a new generation CETP inhibitors aimed at 
increasing HDL levels and reducing CVD risk. However, apoCI also inhibits 
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LPL activity which leads to hypertriglyceridemia, a risk factor for CVD. 
Therefore, in chapter 8 we aimed to identify the minimal CETP-inhibitory 
domain of apoCI without LPL-inhibitory activity. We show that the CETP-
inhibitory function of apoCI resides in the C-terminal helix, whereas the C 
terminus is not sufficient for the LPL-inhibitory function of apoCI. The C-
terminal peptide apoCI32-57 potently inhibited CETP activity, mainly caused by 
positively charged amino acids, with a negligible effect on LPL activity. 
Therefore, we concluded that apoCI32-57 may be an interesting lead in the search 
for novel CETP inhibitors as a new strategy to increase HDL thereby reducing 
cardiovascular risk. 
 
Taken together, the studies described in this thesis contribute to the 
understanding of the mechanisms underlying HDL-modulating strategies. We 
demonstrated that the HDL-raising effect of classical lipid-lowering drugs 
depends on the presence of CETP. We also showed that CETP inhibition may 
still be a potential atherogenic strategy, provided that CETP inhibitors do not 
adversely affect lesion composition. In addition, we identified the minimal 
CETP-inhibitory domain within apoCI that may provide a lead towards a new 
generation of safe CETP inhibitors.  
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Samenvatting  
 
Hart- en vaatziekten vormen een belangrijke oorzaak van mortaliteit en 
morbiditeit in de westerse wereld, en worden voornamelijk veroorzaakt door 
atherosclerose. Een belangrijke risicofactor voor atherosclerose is dyslipidemie, 
die gekarakteriseerd wordt door een hoog plasmaniveau van het lage dichtheids 
lipoproteïne ((V)LDL) en een laag plasmaniveau van het hoge dichtheid 
lipoproteïne (HDL). Dyslipidemie wordt voornamelijk behandeld met 
lipidenverlagende medicijnen. Deze medicijnen verlagen de plasmaniveaus van 
(V)LDL-C zeer efficiënt (~40%) en geven tevens een milde verhoging van 
HDL, maar desondanks voorkomen zij slechts een fractie van alle hart- en 
vaatziekten (~30%). Daarom zijn nieuwe therapeutische strategieën om hart- en 
vaatziekten verder terug te dingen noodzakelijk. Omdat HDL op verschillende 
manieren kan beschermen tegen atherosclerose, namelijk door zijn rol in het 
reverse cholesterol transport en/of door middel zijn van anti-inflammatoire en 
anti-oxidatieve eigenschappen, wordt HDL verhoging gezien als een 
veelbelovende nieuwe manier om hart- en vaatziekten te voorkomen. In dit 
proefschrift werden de mechanismen onderzocht die aan de HDL-verhogende 
werking van de klassieke lipidenverlagende middelen atorvastatine, fenofibraat 
en niacine ten grondslag liggen. Daarnaast werden de effecten van potentiële 
nieuwe HDL verhogende strategieën, inclusief het experimentele geneesmiddel 
torcetrapib, en de lichaamseigen eiwitten pregnaan X receptor (PXR) en 
apolipoproteïne CI (apoCI), op het HDL metabolisme onderzocht. Voor deze 
studies maakten we gebruik van APOE*3-Leiden.CETP (E3L.CETP) transgene 
muizen, een waardevol nieuw muismodel voor het menselijke lipoproteïnen 
metabolisme.  
 
Fibraten en statines verlagen plasmaniveaus van cholesterol en triglyceriden 
efficiënt in dyslipidemische patiënten. Daarnaast laten deze middelen een milde 
verhoging van het cholesterol in HDL (5-15%) zien terwijl het mechanisme dat 
hieraan ten grondslag ligt onduidelijk is. Omdat fibraten en statines de 
concentratie van het cholesteryl ester transfer proteïne (CETP) in het plasma 
verlagen, en omdat fibraten en statines HDL niet verhogen in muizen die van 
nature geen CETP tot expressie brengen, onderzochten wij de hypothese dat 
CETP een essentiële rol speelt bij het HDL-verhogende effect van zowel 
fibraten als statines. Hiervoor werd gebruik gemaakt van E3L en E3L.CETP 
transgene muizen die hetzelfde als de mens reageren op klassieke 
lipidenverlagende medicijnen zoals statines en fibrates met betrekking tot 
verlaging van lipiden in het plasma. In hoofdstuk 2 werden E3L en E3L.CETP 
muizen gevoed met een vetrijk dieet in aan- en afwezigheid van fenofibraat. 
Fenofibraat verlaagde plasma (V)LDL-cholesterol (C) en (V)LDL-triglyceriden 
(TG) in zowel E3L als E3L.CETP muizen, maar verhoogde HDL-C alleen in 
E3L.CETP muizen. Fenofibraat beïnvloedde de klaring van HDL-cholesteryl 
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esters (CE) uit het plasma niet, wat erop wijst dat fenofibraat een hoger 
plasmaniveau van HDL-C veroorzaakt zonder de flux van het HDL-C te 
veranderen. Analyse van de expressie van genen in de lever die betrokken zijn 
bij het HDL metabolisme toonde aan dat fenofibraat de belangrijkste spelers in 
het HDL metabolisme, waaronder het fosfolipiden transport proteïne (Pltp), de 
ATP-bindende cassette transporter A1 (Abca1), de scavenger receptor B type I 
(SR-B1), en het apolipoproteïne AI (Apoa1)) niet verschillend beïnvloedde in 
E3L.CETP en E3L muizen. In E3L.CETP muizen verminderde fenofibraat wel 
de genexpressie van CETP evenals de overdracht van CE tussen lipoproteïnen 
in plasma. In hoofdstuk 3 gebruikten we een vergelijkbare aanpak om te 
evalueren of atorvastatine HDL-C ook zou verhogen via CETP modulatie. 
Atorvastatine verlaagde plasma (V)LDL-C niveaus in zowel E3L als E3L.CETP 
muizen, maar verhoogde HDL-C uitsluitend in E3L.CETP muizen. Expressie 
van genen in de lever die betrokken zijn bij het HDL metabolisme (Pltp, Abca1, 
Sr-b1 en Apoa1) werden niet verschillend beïnvloed door atorvastatine in 
E3L.CETP en E3L muizen. In E3L.CETP muizen verlaagde atorvastatine echter 
wel de genexpressie van het CETP evenals het niveau van CETP en de activiteit 
van CETP in plasma. Daarom concludeerden wij dat zowel fenofibraat als 
atorvastatine HDL-C verhogen door de CETP-afhankelijke overdracht van CE 
van HDL naar (V)LDL te verlagen. Dit wordt veroorzaakt door een lagere 
hepatische CETP expressie en een lagere hoeveelheid (V)LDL in het plasma.  
Het meest krachtige medicijn wat momenteel beschikbaar is om HDL te 
verhogen is niacine. Het mechanisme dat aan de verhoging van HDL ten 
grondslag ligt is echter nog onbekend. In hoofdstuk 4 voerden wij E3L en 
E3L.CETP muizen een vet rijk dieet met of zonder niacine. In E3L.CETP 
muizen verlaagde niacine het plasma cholesterol en TG op een 
dosisafhankelijke wijze. Niacine verhoogde het HDL-C niveau ook op een 
dosisafhankelijke manier, net als het plasmaniveau van apoAI en de 
deeltjesgrootte van het HDL. In E3L muizen verlaagde niacine het 
plasmaniveau van cholesterol en TG terwijl de verhoging van HDL-C niet werd 
waargenomen. In E3L.CETP muizen verminderde niacine dosisafhankelijk de 
hepatische expressie van CETP evenals de massa en activiteit van CETP in 
plasma. Bovendien reduceerde niacine op een dosisafhankelijke manier de 
opname van apoAI vanuit het plasma door de nieren. Daarom concludeerden 
wij dat niacine het HDL-C in E3L.CETP muizen verhoogt door de CETP 
activiteit te verlagen, als gevolg van zowel een verlaagde CETP expressie als 
een verminderde hoeveelheid (V)LDL in het plasma. Daarnaast verhoogt 
niacine apoAI door de klaring van apoAI uit plasma te verminderen. 
 
Torcetrapib is het eerste medicijn dat specifiek is ontworpen om HDL te 
verhogen, namelijk door de activiteit van CETP in het plasma te remmen. In 
grote klinische studies bleek torcetrapib inderdaad in staat het HDL met 
ongeveer 60% verhogen. Ondanks deze forse HDL verhoging werd in patiënten 
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die met atorvastatine en torcetrapib werden behandeld echter geen vermindering 
van atherosclerose gevonden in vergelijking met patiënten die alleen met 
atorvastatine werden behandeld. Het effect van torcetrapib zonder atorvastatine 
was vooralsnog onbekend. Daarnaast leidde de behandeling met torcetrapib tot 
ongunstige bijwerkingen zoals een verhoging van cardiovasculaire 
gebeurtenissen en een verhoogd sterftecijfer. In hoofdstuk 5 werd het effect van 
torcetrapib met en zonder atorvastatine in muizen bestudeerd om meer inzicht te 
krijgen in de potentiële anti-atherogene werking en de bijwerkingen van 
torcetrapib. E3L.CETP muizen werden gevoerd met een vetrijk dieet waaraan 
torcetrapib, atorvastatine of beide werden toegevoegd, en de ontwikkeling van 
atherosclerose werd vervolgens na 14 weken beoordeeld in het kleppengebied 
van het hart. Torcetrapib verminderde het plasmaniveau van cholesterol, hoewel 
in mindere mate dan atorvastatine en combinatie van torcetrapib en 
atorvastatine. Daarnaast verhoogde torcetrapib het HDL-C. Zowel torcetrapib 
als atorvastatine verminderden atherosclerose, en wel in gelijke mate, maar de 
combinatie van beide middelen had geen additionele anti-atherogene werking. 
Vergeleken met atorvastatine veroorzaakte torcetrapib een verhoogde binding 
van monocyten aan het vaatendotheel, wat gepaard ging met een verhoogde 
hoeveelheid van het monocyt chemoattractant proteïne-1 (MCP-1) in de 
atherosclerotische plaques. Dit resulteerde in laesies met meer macrofagen en 
minder collageen, die in de mens minder stabiel zijn en kunnen scheuren. Wij 
concludeerden daarom dat remming van CETP door torcetrapib op zich 
atherosclerose kan verminderen. Echter, net zoals in de mens is torcetrapib niet 
in staat het anti-atherogene effect van atorvastatine te versterken. Bovendien 
introduceert torcetrapib laesies van een minder stabiel fenotype vergeleken met 
atorvastatine. 
 
Er is in de literatuur gesuggereerd dat agonisten van de pregnaan X receptor 
(PXR) het HDL kunnen verhogen. Deze suggestie hebben wij onderzocht in ons 
muismodel met een menselijk lipoproteïnen metabolisme. In hoofdstuk 6 
behandelden wij E3L en E3L.CETP muizen met de PXR agonist pregnenolon-
16α-carbonitril (PCN). In E3L en E3L.CETP muizen verhoogde PCN lipiden in 
de lever evenals cholesterol en TG in plasma, terwijl PCN in E3L muizen het 
cholesterol specifiek in HDL verhoogde, vooral in grote HDL-1 deeltjes. In 
E3L.CETP muizen gaf PCN een dosisafhankelijke verlaging van het HDL. PCN 
verminderde de expressie van genen in de lever betrokken bij de synthese 
(Abca1, Apoa1), maturatie (lecithin: cholesterol acyltransferase (Lcat), Pltp) en 
klaring (SR-B1) van het HDL. Het HDL-verhogende effect van PCN, dat in 
E3L muizen werd waargenomen, wordt waarschijnlijk veroorzaakt door een 
daling van de HDL receptor SR-BI in de lever. Deze HDL verhoging wordt 
echter door CETP expressie volledig tenietgedaan. Wij concludeerden daarom 
dat chronisch PXR agonisme in de aanwezigheid van CETP het HDL-C 
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dosisafhankelijk verlaagt en daarom geen relevante strategie is voor de 
ontwikkeling van HDL-verhogende medicijnen. 
 
Er is aangetoond dat het plasma eiwit apoCI het HDL metabolisme zou kunnen 
beïnvloeden door activatie van LCAT, en remming van HL en CETP. Het effect 
van apoCI op SR-BI en het netto effect van apoCI op HDL niveaus was echter 
nog onbekend. In hoofdstuk 7 werd daarom het effect van apoCI op de SR-BI-
gemedieerde opname van HDL-CE in vitro geëvalueerd en het netto effect van 
apoCI op het HDL metabolisme in muizen bepaald. Wij toonden aan dat apoCI 
de SR-BI-afhankelijke associatie van HDL-CE met muizenhepatocyten 
vermindert. Daarnaast verminderde apoCI-deficiëntie in muizen op een 
dosisafhankelijk wijze het HDL-C niveau. Een matige overexpressie van apoCI 
in muizen leidde tot een verhoogd HDL-C niveau, en een hogere overexpressie 
van apoCI leidde tot een vergroting van de HDL deeltjes. Daarom 
concludeerden wij dat apoCI een nieuwe remmer is van SR-BI in vitro en dat 
apoCI het HDL niveau verhoogt in vivo. 
Omdat apoCI de belangrijkste fysiologische HDL-geassocieerde CETP remmer 
is kan apoCI een basis vormen voor de ontwikkeling van nieuwe CETP 
remmers om HDL te verhogen en het risico op hart- en vaatziekten te 
verminderen. ApoCI remt echter ook de activiteit van LPL wat leidt tot 
hypertriglyceridemia, en dus een atherogene eigenschap is. Daarom was het 
doel in hoofdstuk 8 om het minimale CETP remmende domein van apoCI 
zonder LPL remmende eigenschappen te identificeren. Wij toonden aan dat de 
CETP remmende functie van apoCI zich vooral bevindt in het C-terminale 
domein van apoCI, en dat de C terminus niet voldoende is voor de LPL 
remmende functie van apoCI. ApoCI32-57 remde de activiteit van CETP krachtig, 
hoofdzakelijk gemedieerd door positief geladen aminozuren, terwijl apoCI32-57 
LPL niet remde. Daarom concludeerden wij dat apoCI32-57 een interessante basis 
kan zijn in de zoektocht naar nieuwe CETP remmers om HDL te verhogen en 
het risico op hart- en vaatziekten te verlagen. 
 
Samengenomen dragen de studies die in dit proefschrift worden beschreven bij 
tot het begrip van de mechanismen die aan HDL modulerende strategieën ten 
grondslag liggen. Wij toonden aan dat het HDL verhogende effect van klassieke 
lipidenverlagende middelen afhankelijk is van de aanwezigheid van CETP. 
Daarnaast toonden wij aan dat de remming van CETP nog steeds een potentiële 
anti-atherogene strategie kan zijn, met als voorwaarde dat nieuwe CETP 
remmers de laesie samenstelling niet ongunstig beïnvloeden. Bovendien 
identificeerden wij het minimale CETP remmende domein binnen apoCI dat een 
basis voor een nieuwe generatie van veilige CETP remmers kan vormen. 
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List of abbreviations 
 
aa   amino acid 
ABCA1/G1/G4 adenosine triphosphate-binding cassette transporter  
   A1/G1/G4      
AcLDL  acetylated LDL 
AdAPOC1  adenovirus expressing human APOC1 
AdLacZ   adenovirus expressing ß-galactosidase 
APOC1  human apoCI expressing mice 
Apo   apolipoprotein 
Bp   base pair 
BSA   bovine serum albumin 
C   cholesterol 
CE    cholesteryl ester 
CETP   cholesteryl ester transfer protein 
CM   chylomicron 
CO   cholesteryl oleate 
COEth  cholesteryl oleoyl ether 
CVD   cardiovascular disease 
DNA   deoxyribonucleic acid 
EDTA  ethylenediaminetetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
E3L   APOE*3-Leiden 
FC   free cholesterol 
FCR   fractional catabolic rate 
FFA   free fatty acids 
FPLC   fast-performance liquid chromatography 
HDL   high density lipoprotein 
HL   hepatic lipase 
HMG-CoA  3-hydroxy-3-methylglutaryl coenzyme A 
HPRT  hypoxanthine phosphoribosyltransferase 
HRP   horse radish peroxidase 
HSL   hormone sensitive triglyceride lipase 
HSPG  heparin sulfate proteoglycans 
IDL   intermediate density lipoprotein 
IMT   intima-media thickness 
IVUS   intravascular ultrasonography 
LCAT  lecithin:cholesterol acyl transferase 
LDL   low density cholesterol 
LDLr   LDL receptor 
LPL   lipoprotein lipase 
LPS   lipopolysaccharide 
LRP   LDL receptor related protein 
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LXR   liver X receptor 
MCP1  monocyte chemotactic protein-1 
MTP   microsomal triglyceride transfer protein 
mRNA  messenger RNA 
PBS   phosphate buffered phosphate 
PCN   pregnenolone-16α-carbonitrile 
PCR   polymerase chain reaction 
Pfu   plaque forming unit 
PL   phospholipid 
PLTP   phospholipid transfer protein 
PPARα  peroxisome proliferator-activated receptor α 
PPRE   peroxisome proliferator response element 
PXR   pregnane X receptor 
RCT   reverse cholesterol transport 
RNA   ribonucleic acid 
RXR   retinoid X receptor 
SD   standard deviation 
SEM   standard error of the mean 
SRA   scavenger receptor class A 
SR-BI  scavenger receptor class B type I 
TC   total cholesterol 
TG   triglyceride 
VLDL  very low density lipoprotein 
VLDLr  VLDL receptor 
WAT   white adipose tissue  
WT   wild type 
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